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Human neurodegenerative disorders are among the most difficult to study. In particular, 
the inability to readily obtain the faulty cell types most relevant to these diseases has impeded 
progress for decades. Amyotrophic lateral sclerosis is a late onset neurodegenerative disease in 
which the upper and lower motor neurons degenerate, leading to paralysis and eventually 
death. Recent advances in pluripotent stem cell technology now grant access to significant 
quantities of disease pertinent neurons both with and without predisposing mutations.  The two 
studies described in this thesis demonstrate the feasibility of using MNs, generated from 
pluripotent stem cell lines harboring known ALS mutations, to establish in-vitro models of the 
disease. Specifically, we first used gene targeting to establish genetically controlled systems, 
able to identify causal relationships between a familial ALS mutation and in vitro phenotypes. 
Next, using transcriptional profiling, we identified novel pathways altered by the mutation and 
demonstrated functional consequences of these pathways’ misregulation. Furthermore, by 
monitoring the physiology of the pluripotent stem cell derived MNs, we discovered an increased 
firing rate in the mutant MNs, and identified an FDA-approved drug, retigabine, capable of 
rescuing this defect. Lastly, to aid in the discovery of additional therapeutic compounds, we 
combined gene targeting, transcriptional profiling, and a fluorescent reporter human embryonic 
stem cell line to establish a well-controlled in vitro system capable of identifying genetic 
modifiers of the phenotypes described herein. 
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ALS as a Model Pathology for Disease Modeling Experiments  
For historical as well as methodological reasons, the application of patient-specific stem 
cells in disease modeling experiments is a particularly promising approach for ALS. First, a vast 
amount of data has been generated to describe the disorder. The clinical presentation of ALS 
has been characterized for over 100 years, as have the loss of spinal and cortical MNs, and the 
typical progression of the disease into paralysis and ultimately death
1. The disease can present 
as bulbar or limb onset, but commonly progresses to impacting the entire motor system
1.  Also 
thoroughly described are the results of post-mortem sections, which often reveal ubiquitin and 
other protienaceous inclusions in the spinal cord
1. This clinical data establishes common 
pathological findings which can be used as starting points for in vitro disease modeling 
experiments. 
Second, stem cell disease modeling experiments are a promising means for parsing the 
complex set of genetic and environmental factors that may contribute to the development of the 
disorder. While the predominant patient group develops the disease in a seemingly sporadic 
manner (sALS), 17%-23% of patients with ALS report a family history of the disorder and are 
classified as familial ALS (fALS) patients
2-4. Dominant inheritance is the most commonly 
reported transmission pattern, although recessive inheritance has been documented in some 
cases
1. Family predisposition to the disorder has led to many genetic studies of affected 
genealogies, leading to the discovery of over 20 familial ALS mutations
1.  The most common 
mutations are found in the C9orf72, SOD1, FUS, and TDP-43 genes
1.  While most mutations 
are missense amino acid changes, the C9orf72 gene was found to contain a large 
hexanucleotide expansion
5.  The diverse function of the genes which when mutated can lead to 
ALS has not enabled a clear pathway of disease to be established. Furthermore, every gene 
which has been implicated in fALS has also been found to be mutated in a smaller fraction of3 
 
 sALS cases
1.  The implication of fALS genes in sALS is further supported by pathological 
findings of TDP-43 and to a lesser degree SOD1 positive inclusion in post mortem section of 
sALS spinal motor neurons
6,7. While some of these sALS cases may have de novo mutations 
within the genes more commonly associated with fALS, it is also likely small family size, 
misdiagnosis of ALS, and incomplete penetrance has resulted in an underrepresentation of 
fALS. Further complicating the study of ALS in patients is the impact of environmental factors or 
other genetic modifying mutations which can influence the clinical representation of ALS
1. 
Supporting this conclusion is the large patient heterogeneity which is seen even between 
individuals which harbor the same fALS mutation
1,3. Patient groups with the same fALS 
mutations can present with variable disease onset, progression of the disorder, and bulbar or 
limb onset
3. A more specific example of patient heterogeneity is found in patients identified as 
carriers of the C9orf72 hexanucleotide expansion, who have been shown to present symptoms 
of ALS, Frontal Temporal Dementia (FTD), or a combination of both ALS and FTD
8. These 
findings have dispelled the notion that ALS may be a ‘many genes, one degenerative syndrome’ 
and instead implicates ALS on a spectrum of neurodegenerative disorders which is impacted by 
patient genetics and environmental factors
1. The complicated nature of patient biology has led 
many to the use of model systems for the study of ALS, in the hopes that reducing the unknown 
factors which can modulate the disease may facilitate the discovery of disease mechanisms. 
Finally, recent results from studies employing animal models of ALS have pointed 
toward the need for human models. Multiple animal models of ALS have been established, and 
mouse models have been utilized particularly extensively
9. Mice which express the human 
SOD1 gene harboring known familial mutations present many signs of ALS commonly found in 
human patients
9. Therefore, a considerable amount of work has gone into uncovering a 
multitude of phenotypes associated with the mutations at various points during disease 
progression. Some major findings have been the induction of caspase activity, formation of 
protein inclusions, a major contribution of glial cells to MN toxicity, and the early breakdown of 4 
 
the motor unit leading to de-innervation of the muscle
9-11. While the mouse models have been 
informative, they rely on extreme overexpression of the mutant SOD1 transgene, as lower 
expressing mouse models either have large phenotypic variability or do not succumb to any 
measurable defect, and thus any conclusions maintain the caveat of pathological artifacts 
possibly being driven by protein overexpression
12. Unfortunately, many drugs which have 
proven effective in the mouse model have failed in human trials, pointing toward the need for a 
human model
13. To address the desire for human models of ALS pathology, I have worked to 
establish in vitro systems using MNs derived from human pluripotent stem cells. In this chapter I 
will discuss the impediments I have encountered in using stem cells to understand 
neurodegeneration and offer strategies to surmount them.  In particular, I’ll focus on areas that I 
feel have not yet been widely discussed. For instance, while significant effort has been put forth 
to describe the potential distinctions between hiPSCs and hESCs, there has been little 
discussion concerning the ramifications that differences between any two pluripotent stem cell 
lines might have on the outcome of a disease modeling experiment. Additionally, although 
substantial resources have been invested in methods for directed differentiation of stem cells 
into specific neural types and their functional characterization at early time points, little is known 
concerning how these neurons change, or mature over time in culture. These and other sources 
of variation between pluripotent cell lines and within neuronal cultures may result in misleading 
red herring findings or could obscure real disease related discoveries and are veritable 
challenges that must be surmounted. 
 
The Opportunities of Pluripotent Stem Cells 
The opportunity to produce discrete populations of neuronal types from human 
pluripotent cell lines has inspired a new approach to the study of human neurodegeneration. 
With workable methods for stem cell differentiation in hand, it is possible to generate human 
neurons in substantial numbers for monitoring and studying disease processes
14. The last piece 5 
 
of enabling technology came in the landmark discovery of reprogramming methods using 
defined factors
15 and the subsequent derivation of the first patient specific human induced 
pluripotent stem cell (hiPSC) lines
16,17.  Now, by using hiPSCs, it has become possible to 
produce neurons carrying the precise constellation of genetic variants that caused 
neurodegeneration in a given individual
16. These neurons enable the examination of processes 
not easily observed in postmortem tissues, including important events that might occur prior to 
disease onset
18.  Continued refinement and deployment of this “neurodegeneration-in-a-dish” 
approach holds substantial promise for gathering new insights into diseases of the nervous 
system.  Indeed, many disease related phenotypes are beginning to be documented from 
patient derived hiPSCs
14,19.  For example, changes in the processing of proteins implicated in 
ALS, Parkinson’s, Huntington’s, and Alzheimer’s diseases have been found in neurons 
produced from patient derived iPSCs
20-22.  Additionally, findings reminiscent of terminal stage 
phenotypes, such as cell death, have been observed in early onset disorders including Spinal 
Muscular Atrophy and Lesch-Nyhans
23,24.  Furthermore, phenotypes implicated in behavioral 
disorders such as neural connectivity and synapse formation have been observed using hiPSCs 
derived from patients diagnosed with schizophrenia and Rett syndrome
25,26.  While these early 
studies are important demonstrations in the utilization of hiPSC technology, their success may 
be the exception rather than the rule given our current understanding of the variability 
underlying many of these experiments.  We now know of a number of obstacles that are 
routinely encountered by investigators employing these technologies, which we have come to 
realize must be carefully considered and properly overcome if accurate conclusions are to be 
drawn
27. Attention to these would-be pitfalls will help unlock the full potential of this approach to 
understanding neurological disease.  
  
From the Embryo to Patient Reprogramming 
Inspired by progress in the study of mouse stem cells, early work on human pluripotency 6 
 
enabled the establishment of favorable conditions for both the routine derivation of hESC lines 
from discarded IVF embryos and the support of their long-term self-renewal
28-30.  The hESC 
lines that resulted from those efforts, mostly derived from embryos presumed to have a normal 
health status, allowed preparations of human neurons to be produced and in turn used to 
interrogate environmental or non-cell autonomous factors implicated in disease
31,32.  While 
these “normal” hESC lines have been incredibly useful, it seemed a logical progression of this 
approach to produce hESCs that harbored disease-predisposing mutations and study neuronal 
populations generated from them
33.  Although disease-specific hESC lines were subsequently 
derived from embryos after pre-implantation genetic diagnosis (PGD), the scarcity of the 
donated material needed, and the limited number of conditions for which PGD was routinely 
performed, prevented the main-stream implementation of this approach
34,35.  Today, methods 
for transcription factor mediated reprogramming have largely circumvented the need for PGD 
embryos by allowing almost any patient tissue available to be used for the production of hiPSC 
lines
,15,35. Such readily adoptable methods for deriving stem cell lines have now been combined 
with existing approaches for neuronal differentiation in a number of early attempts to model 
neurological disease, which have been comprehensively reviewed previously
19,36.  While the 
advent of reprogramming proved to be a critical enabler, it raised significant questions 
concerning whether hiPSCs were significantly different from hESCs
37. Although the resolution of 
this question is important, it has perhaps in retrospect distracted from a larger issue with more 
significant ramifications: How different are the properties of any two hiPSC lines produced from 
the same person, or for that matter, from multiple individuals? Furthermore, are the effects of 
these idiosyncratic differences between lines greater than the effects I can reasonably hope to 
observe as a result of any disease causing DNA variant I plan to study? Although this variability 
between pluripotent cell lines is still poorly understood, it has now begun to be recognized as a 
potential confounding factor in studies
27.  As a result, movement has begun towards the 
replacement of qualitative assays for pluripotency, such as immunostaining, or teratoma 7 
 
formation with more quantitative measures of a given cell-line’s performance
38,39. 
 
Sources of Variability 
Each pluripotent stem cell-line, whether a hESC or hiPSC, has its own particular history. 
Whether a given cell line originated from an embryo or somatic cell, the method of derivation 
that was employed and the subsequent culture medias or environments to which it has been 
exposed, have all been proposed to contribute to its inherent properties
29,40,41. As a result, it is 
conceivable that these sources of variability could interfere with the comparison of any two cell 
lines in the context of disease related experiments.  Consequently, careful consideration should 
be given to the cell lines that are selected for any given study and how their quality is controlled.  
Historically, the pluripotency of a cell-line was verified by qualitative methods such 
immunostaining with antibodies recognizing antigens selectively expressed in stem cells, or by 
injection into nude mice to assess their capacity to form benign teratomas 
30,42. While these 
assays were useful for verifying whether a cell line was indeed pluripotent, they fell short of 
providing information concerning which lines were likely to be useful for a particular 
application
42.  More recently, genome wide analyses of transcription and DNA methylation in 
larger collections of pluripotent cells have begun to catalog potential sources of variation and 
attempt correlations to a given line’s differentiation propensity or functional behaviors
27,39.  
These studies have been instrumental in both motivating the reevaluation of previous metrics for 
pluripotency and the implementation of new measures. 
Many groups have now compared hiPSCs with a few well-established hESC lines and 
have suggested that differences between the two classes of cell lines in gene expression and 
methylation are present
41,43. Some studies have concluded the transcriptional distinctions 
between stem cell-types originate from epigenetic memory of the somatic cell from which the 
iPS cells were derived
41,44. However, others have suggested that this memory is rapidly lost 
after modest passage of established lines
45. When our lab examined 20 hESC lines and a 8 
 
dozen hiPSC lines, in one of the largest studies to date, we too found substantial variability in 
transcription and DNA methylation between the many hESC and iPS cell lines
39. While we found 
that on average, hESCs and hiPSCs were modestly distinguishable, there was a considerable 
amount of overlap between the two groups
39 (Figure 1.1A). Furthermore, the average difference 
between any two human hESCs or any two hiPSCs was often greater than the average 
differences between the two classes
39. As a result, we concluded that there are many iPSCs 
that are more like the average hESC then any particular hESC might be
39. In other words, 
although there has been a good deal of focus on the inherent variation between iPSC and 
hESCs, the differences that exist between any two lines selected, regardless of how they were 
made, are likely to be greater.  Although it may or may not be that variability of transcription in 
the pluripotent state leads to similar variation in differentiated neurons, it is well known that 
changes in DNA-methylation are mitotically heritable
41.  Moreover, it has been shown that cell-
line variation can impact the phenotype of differentiated cells and neurons produced from a 
given cell line
27,39.    
Recently, the Eggan lab and other groups realized that a significant component of the 
transcriptional and DNA methylation variation between cell lines is absent from male pluripotent 
cells
24,40.  Further studies suggest this variation results from a gradual erosion of dosage 
compensation leading to an increase in X-linked gene expression, which was not corrected by 
neuronal differentiation
24.  As there are dozens of X-linked genes with nervous system 
functions, modest changes in the expression of these genes could be significantly confounding 
co-variables in many assays of neuronal function. In particular, we demonstrated perturbed 
dosage compensation had a substantial impact on the study of X-linked HPRT mutations, which 
cause Lesch-Nyhan syndrome
24.  In light of these findings, it may be wise to either use male 
cells lines, or monitor the extent to which female pluripotent cell lines have retained an inactive 
X.  We find that staining cultures with antibodies identifying the inactive X, such as those 
recognizing H3-K273me proves to be an effective strategy
46. The use of assays for monitoring 9 
 
proper maintenance of X-inactivation will be particularly important when modeling X linked 
disorders.  More generally, it will be increasingly important to understand how epigenetic 
variation arises, and where any particular cell line selected for disease related studies falls 
within the range of variability. The use of increasingly established profiling assays such as 
“Pluritest” may then allow some deviant lines to be identified and discarded
38. 
On a more encouraging note, while differences in derivation method and culture history 
cause significant variation, they may not completely overcome the subtle effects of genetic 
background.  Chen et al (2009) established a large set of hES cells including a considerable 
cohort of sibling pairs and analyzed them by transcriptional profiling
29.  Hierarchal clustering of 
the resulting data grouped sibling pluripotent stem cell lines together, regardless of how the cell 
lines were derived, suggesting that changes in genetic background may be detected 
transcriptionally despite environmental sources of variability
29. However, this experiment raises 
another issue, the potential importance of genetic background when evaluating or selecting cell 
lines for disease modeling experiments. 
While a thorough study of transcriptional and epigenetic variance within stem cell lines 
has provided some insight, the catalogs of genome-wide information that have resulted will be 
most informative when they are compared with the results of quantitative assays that probe the 
actual behavior of a stem cell line and its derivatives
39.  Early quantitative studies of stem cell 
differentiation support the view that each line displays individual propensities for differentiation 
down a given lineage
27,47 (Figure 1.1B).  If not taken into account this discordant behavior could 
cause significant problems when evaluating neurological disease modeling experiments.  For 
example, it has been shown that many stem cell lines are more difficult to neuralize and 
therefore produce fewer neural progenitors and post-mitotic neurons
27,48. Therefore, if lines such 
as these were chosen within a cohort used for studies, it could lead to erroneous assignment of 
a phenotype, merely as a result of chance. One approach proposed for overcoming this 
dilemma is to select lines by simply and rapidly assessing their differentiation propensity using a 10 
 
“lineage scorecard”
39. By allowing stem cell lines to differentiate without the influence of small 
molecules or growth factors, they generate progenitor and terminally differentiated cell types in 
an unconstrained and random manner.  By then measuring transcription of a few key genes with 
expression patterns demarcated to specific lineages, a reproducible and quantitative 
representation of cell line early differentiation propensities can be obtained
39.  Impressively, it 
was found that this approach was able to very accurately predict which lines were most useful 
for producing neurons for disease related studies
27,39. It is likely that such “lineage scorecards” 
or other simple, quantitative measures of cell line behavior will become standard practice. 
These assays will allow investigators to rapidly discard cell lines that behave poorly and 
optimally select those with a similar capacity to produce neuronal-types of interest, harmonizing 
downstream assays. The only risk I can foresee from such assays is that they could in principal 
lead to the elimination of an unanticipated effect that a given genetic variant might have on early 
development. If alterations in neuronal progenitor activity or development are implicated in the 
disorder being studied, the elimination of pluripotent cell lines with poor neuronal differentiation 
propensity may mask disease specific progenitor phenotypes by preferentially excluding the 
patient derived pluripotent cell lines which would display the most severe developmental 
defects.  However, if mature neurons are to be investigated because the disorder under study is 
late onset, the benefits realized from such assays for the production of reproducible populations 
of differentiated neuronal types that could be then rigorously assessed for disease related 





Overcoming the Noise 
Several approaches have been utilized to account for the variability among human 
pluripotent stem cell lines in modeling experiments.  First, some studies have used large cohorts 
of both patient and control pluripotent stem cell lines to derive neurons
49,50 (Figure 1.1C).  By 
comparing neurons differentiated from many distinct patients and controls, plausible disease 
relevant phenotypes within a patient cohort have been reported
50.  This approach is perhaps 
most convincing when multiple groups carry out similar phenotypic assessments, providing a 
more rigorous platform for interrogating the same cell lines as has been reported
50. While 
attempting to correlate any particular finding with cases or controls in a given study can be 
informative, it cannot demonstrate that the finding in question is the direct result of the known 
causative mutation, or mutations, the disease cases in question may harbor. Such studies leave 
open the formal possibility that the findings are accidental and the result of unrelated and poorly 
understood variation such as those described above (Figure 1.1D). Another weakness of this 
approach is the potentially large, and unknowable, number of cell lines that might be necessary 
to convincingly discover small differences between patients and controls. This is a particularly 
important consideration when investigating subtle phenotypes, which require more cell lines in 
order to ensure generalizability of results. In the case of extremely subtle phenotypes, 
examining the number of cell lines necessary to reach sufficient confidence in the reliability of 
Figure 1.1 (Continued) Variability amongst cohorts of pluripotent stem cells may lead to 
erroneous conclusions in disease modeling experiments driven by atypical cell lines. (A) 
Pluripotent  stem cell lines derived from reprogrammed fibroblasts (hiPSC) or discarded embryos 
(hESC) demonstrate a range of unique methylation  and gene expression profiles. (B) Studies 
have  also demonstrated a considerable amount of variation in differentiation propensity amongst 
pluripotent cell lines. (C) Although few studies have systematically interrogated neurons derived 
from a large cohort of cell lines in phenotypic assays, it is likely that each individual cell line will 
produce neurons that fall within a broad range of the measured phenotype. (D) This variability 
necessitates the use of multiple control and patient-derived hiPSC lines in order to rule out the 
possibility that atypical cell lines are driving or masking statistically significant cell survival 
phenotypes. (E) Gene targeting techniques  allow the generation of isogenic cell lines which differ 
at only the disease-associated variant being studied. (F) The use of neurons derived from  
isogenic pluripotent cell lines will reduce much of the variability between control and patient-
derived neurons and highlight contributions of  the variant to neuronal phenotypes. (All graphs are 
hypothetical and not from actual data.) 
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group differences may become impractical and cost-prohibitive. 
One proposed solution to this problem is to utilize pluripotent stem cells from otherwise 
genetically related individuals differing in their disease related phenotype
23.  While this approach 
might successfully reduce genetic background noise, new problems could be introduced if this 
strategy were used for modeling idiopathic or sporadic forms of a disease. For instance it could 
be that undiagnosed but genetically vulnerable individuals participating in such studies could 
develop the disease after the time of iPS cell derivation, inappropriately skewing findings in a 
cohort of control cell lines.  I conclude that while comparisons between neuronal populations 
derived from cases and controls may allow preliminary identification of disease related 
phenotypes, whenever possible, they should be married with genetic complementation studies 
designed to test the direct relationship between phenotype and genotype.  In some cases, the 
use of viral or transgenic methods to overexpress or reduce the transcriptional levels of genes 
implicated in disease progression may provide substantial evidence for their role in observed 
pathology
51.  However, advances in gene targeting technology now offer more elegant 
approaches to genetic complementation studies. 
Using gene targeting technology to remove mutations from pluripotent stem cell lines 
can create isogenic cell lines that differ at only one base pair
52,53.  This approach should in 
principal eliminate variation arising from stem cell line derivation and genetic background, 
thereby producing more ideal disease and control cell lines (Figure 1.1E and F).  While many 
methods have been used in the past for gene targeting in pluripotent stem cell lines (Bacterial 
Artificial Chromosome
54, Adeno Associated Virus
55, Helper Dependent Adeno Virus
56, single 
stranded Oligonucleotides
57, nuclease driven gene targeting is rapidly becoming established as 
a dominant approach
53,58,59.  By generating site-specific nucleases, a double strand break (DSB) 
can be induced at a pre-designated locus in the genome
60.  This DSB is often repaired by 
nonhomologous end joining, an error-prone process, which can generate frame-shift 
mutations
60.  However, if a plasmid is simultaneously introduced that contains homology to the 14 
 
sequence in which the DSB is induced, the homologous sequences can be used as a template 
for repair by homologous recombination
60.   Nuclease mediated homologous recombination has 
been used successfully to both correct and introduce known disease causing mutations
61,62. 
Additionally, cDNAs can be targeted to loci resistant to transgene silencing, allowing for 
overexpression of cDNAs in an isogenic setting
63.   
The primary concern surrounding nucleus-mediated gene-targeting is that these 
nucleases may induce collateral and unanticipated mutations at “off-target” sites around the 
genome. Exome and whole genome sequencing have been used to search for such off-target 
mutations and thus far they have been found only at a relatively low frequency
64,65.  However, 
mutations induced by nuclease activity are not the only possible risk inherent in this approach. 
In fact, the mutations derived from clonal selection are likely of as much concern as off-target 
nuclease activity
65.  Because of the risks associated with clonal isolation steps, it is advisable to 
generate multiple clones during gene targeting experiments, which can be used to verify any 
subsequent phenotypes found.  While these strategies are becoming more advanced, common 
sense must still employed in their utilization.  Proper examination of transcription and 
differentiation variability should still be performed before generation of isogenic pluripotent cell 
lines to assure the parental cell line is not atypical from the start and can efficiently produce the 
cell type of interest. 
 
To Induce or Correct a Mutation, That is the Question 
            While gene targeting promises to allow the introduction of disease alleles into hES cells, 
this does not preclude the need for patient-specific iPS cells.  In fact, many experiments critical 
for identifying and understanding relationships between genetic mutations and disease 
phenotypes are likely to continue to require patient-specific iPS cell lines
26. For example, 
patient-derived iPS cells remain an interesting opportunity for modeling of neurological disorders 
with a strong genetic basis but for which specific disease-causing mutations are unknown
26.  15 
 
Such a strategy could capture the constellation of variants that cause disease in an individual 
and allow their effects to be studied in disease affected neuronal populations
14.  Detection of a 
reproducible phenotype in such individuals could implicate the presence of genetic variants 
worthy of pursuit through genome sequencing. Also, the scalability of iPS cell derivation and the 
paucity of social concerns with this approach have resulted in the accumulation of a vast 
number of iPS cell lines
14,17.  This large number of pluripotent stem cell lines may one day 
facilitate the study of discrete disease causing variants in patients of multiple ethnicities, 
allowing the influence of genetic background to be explored and eventually the efficacy of 
potential therapeutics to be most broadly evaluated
14. 
            An additional and previously un-discussed benefit of combining gene-targeting with 
patient-derived iPS cells is the knowledge that protective genetic modifiers of a disease-causing 
variant in question are unlikely to confound in vitro studies. For example, as a multitude of novel 
disease variants are uncovered by genome-wide association studies, the use of pluripotent 
stem cell disease modeling approaches will be an attractive means to establish relationships 
between these mutations and neural dysfunction. It might initially seem attractive to introduce 
these mutations into a single “normal” genetic background, for instance into an hESC line, to 
study their influence on neuronal behavior. However, protective alleles on that genetic 
background might obscure phenotypes relevant to disease biology.  Generation of isogenic 
controls by rescuing mutations found in patient-derived iPSCs would ensure that the important 
combination of modifying alleles for disease manifestation are present in the background being 
studied.   
 
Differentiation of Pluripotent Cell Lines 
After carefully establishing and evaluating pluripotent stem cell lines for use in disease 
modeling experiments, differentiation of these cell lines into the cell types of interest must next 
be pondered.  Protocols for the production of many neural and nervous system cell-types are 16 
 
either under development or have now been reported
66. However, before embarking on disease 
related studies, it will continue to be important to thoroughly evaluate a given protocol’s ability to 
generate sufficient quantities of the appropriately functional neuronal type. 
Immunocytochemistry and transcriptional profiling are often useful for rapidly assessing whether 
gene products found in particular neural types are present following stem cell differentiation
67.  
However the lack of gene expression signatures that allow for the identification of the neuronal 
type of interest remains a problem for many experiments
68.  In these cases it may be necessary, 
and in perhaps all cases desirable, to use functional assays to determine whether the 
appropriate nervous system cell types have been produced. Examples of successful 
implementation of this approach include demonstration of neuromuscular junction formation by 
spinal motor neurons
67, capsaicin responsiveness in nociceptors
69, peptide secretion by 
neurosecretory cells
70 and ultimately successful engraftment after transplantation
71. 
While confirming the presence and appropriate functionality of the central cell type of 
interest is essential, it is also important to characterize the other cells produced during the 
differentiation process.  Most protocols result in the production of a myriad of cell types, only a 
small fraction of which will be the intended neural subtype
72 (Figure 1.2A).  These 
heterogeneous cultures can cause complications in the interpretation of downstream 
experiments and should be taken into consideration when designing any disease modeling 
studies.  Many neurological disorders have non-cell autonomous contributors to the disease 
which pose obstacles and limit conclusions that can be drawn from cultures containing diverse 
neural cell types
10,73 (Figure 1.2C).  If a toxic cell type happens to also be produced during a 
given differentiation strategy, any phenotypic differences uncovered between disease and 
control neurons may need to be subsequently queried for its cell autonomy or non-cell 
autonomy.  Modifications of protocols can  
alter the neuronal subtypes produced and it may be possible to find conditions which will yield 
the cell type of interest while limiting the production of other known toxic cell types
74.  Another 17 
 
common component of cultures derived from human pluripotent stem cells are residual neural 
progenitors, which can present a substantial obstacle to detailed neuronal phenotyping, which I 
will discuss in detail below







Needles in a Haystack 
One approach to reducing phenotypic variation is the purification of neurons of a 
particular type or stage of maturation from the differentiating culture as a whole
75 (Figure 1.2A).  
Isolation of a neural type of interest will also be invaluable for pinpointing the cell-autonomous 
effects of genetic variants. One proven strategy for neuronal isolation has been the production 
of “reporter” pluripotent stem cell lines using either transgenesis or gene targeting
76,77.   In 
general these methods have relied on using promoter sequences or other regulatory elements 
to delineate the expression of fluorescent proteins (GFP or RFP for example) or cell-surface 
antigens (E.G. H2kk, CD4, etc…) specifically to the neuronal or progenitor populations of 
interest
77,78.  When these transgenic cell lines are coupled to appropriate directed differentiation 
strategies they enable the isolation of the desired neuronal populations via fluorescent activated 
cell sorting (FACS)
77 or magnetic separation
78.  Purification of particular neurons allows for the 
establishment of a defined culture and facilitates longitudinal studies while also assuring the 
exclusion of progenitor cells thereby “time stamping” postmitotic neurons with a minimum in vitro 
age
79.  Additionally, such an approach should greatly facilitate gene expression studies by 
methods including RNA sequencing.   
Given that expression of a particular gene, and by extension expression of reporter 
transgene harboring its regulatory elements, is often only sufficient to identify a broad population 
Figure 1.2 (Continued) The diversity of neuronal cultures derived from pluripotent stem cells can 
interfere with phenotypic observations. (A) Most differentiation protocols produce a heterogeneous 
population of neuronal progenitors, neurons and glial cell types. The use of reporter pluripotent 
stem cell lines enables the purification of neurons from heterogeneous populations by 
fluorescence-activated cell sorting (FACS). Heterogeneous cultures can impede experiments in 
many ways, most of which can be overcome by the purification and plating of a defined neuronal 
culture. (B) First, toxic cell types that contribute to non-cell-autonomous neuronal death may be 
produced during differentiation and may occlude mechanistic studies of cell survival phenotypes. 
(C) Second, the self-renewing neuronal progenitor cells can expand over time and greatly 
outnumber the postmitotic neurons, thus washing out possible neuron-specific disease signals. (D) 
Last, many neurodegenerative diseases are late onset and therefore may require a considerable 
time in culture for phenotypes to manifest. Thus, the introduction of newly born neurons into 
cultures by lingering progenitor cells can add considerable variability to phenotypes that depend on 




80, understanding the strengths and limitations of a given reporter will be critical 
for the proper design and interpretation of disease-related studies. For example, in Parkinson’s 
disease it is well known that dopaminergic (DA) neurons degenerate during disease 
progression
81.  The generation of a human pluripotent stem cell line that reports on dopamine 
transporter (DAT1) expression would allow for the purification of DA neurons from 
heterogeneous neural cultures, allowing precise phenotypic comparisons between DA neurons 
of distinct phenotypes.  However, in Parkinson’s disease it is generally thought that only a 
subset of DA neurons in the midbrain are most susceptible to degeneration whereas other DA 
neurons both in the substantia nigra and other locations are more resistant
81.   Therefore failing 
to characterize the subtypes of DA neurons produced by a given protocol and collecting all 
DAT1 expressing cells for analysis might obscure findings related to subtype-specific processes 
and lead to false generalizations about cellular events occurring in Parkinson’s disease.  The 
use of more specific markers for substantia nigra DA neurons which degenerate during 
Parkinson’s disease progression, such as by using PITX3
82, or carefully characterizing the 
labeled DAT1 expressing neurons produced during in vitro differentiation may, for instance, 
allow optimized systems for disease related discoveries to be established. 
Although the expression of transcription factors can allow given neuronal types to be 
uniquely distinguished within certain regions of the brain, it is often the case that their 
transcription, or uniqueness of their expression is only limited to certain time-frames of 
development, or differentiation. Expression of the transcription factor HB9 can uniquely identify 
many motor neurons in the context of the developing spinal cord and neuronal cultures that 
have been caudalized to a spinal identity. However, HB9 and reporter genes driven by its 
regulatory elements are silenced in many motor neurons as they mature
83. Therefore, the timing 
of maximal utility for such reporters must also be considered. As a case in point, I have found 
that human ES cells reporting on motor neuron differentiation with an Hb9::GFP transgene are 
very useful for purifying immature neurons, but expected silencing of this reporter occurs in 20 
 
motor neurons over time, suggesting it is of little use for monitoring their very long-term survival. 
As a result, depending on the tools at hand for monitoring the survival and long-term behavior of 
a given class of neurons, the identification of unique signatures of gene expression that persist 
through maturation of a given neuronal type, or the employment of genetic lineage tracing 
strategies, such as Cre/Lox are likely to be warranted. 
 
Development of Disease Phenotypes in Culture 
Another source of neuronal variation that could occlude disease-related phenotypes is 
disparities in the state of their functional maturation.  Progenitors represent a particularly 
significant obstacle when neurons must be cultured for long periods of time in order to allow for 
maturation of phenotypes. This is because progenitors will continue to divide in culture as 
phenotypes develop over time, and can take over a post-mitotic neuronal culture given sufficient 
time. If this occurs, progenitor-related ‘noise’ can obscure any emerging ‘signal’ from disease-
related phenotypes (Figure1. 2D). Furthermore, many of the properties that might be predicted 
to decline over time due to degenerative phenotypes, including soma size, neurite arborization, 
synapse number and aspects of physiological activity also change dramatically over the course 
of a neuron’s maturation
84,85. Thus if a given culture is composed of neurons with widely varying 
states of maturation, for instance through the action of lingering progenitors, then it may be 
difficult to distinguish young neurons that are not yet mature from older neurons which have 
begun to show signs of degeneration (Figure 1.2D). As I indicate above, purification of 
postmitotic neural types from progenitors using reporter genes to birthdate neuronal populations 
may help overcome this difficulty
72. In instances where purification of a given neural type is not 
feasible, some of these difficulties may be overcome with pulse chase labeling techniques, 
including the incorporation of BrdU into dividing cells that can illuminate any irregularities in 
progenitor activity between cell lines and determine at which stage neurons were “born” into a 
culture
86.  Also, the use of anti-mitotics can reduce the production of immature neurons by 21 
 
inhibiting progenitor cell proliferation. However, the neurons might suffer mild cytotoxic 
consequences
85. Another possibility to reduce the contributions of progenitor cells to any 
phenotype is to use neurons generated from terminal cell types
87.  Recent experiments have 
demonstrated the possibility of reprogramming terminally differentiated cell types into post 
mitotic neurons relevant to many neurological disorders.  These approaches seem to directly 
convert one terminal cell type into another, and therefore progenitor cell types are never 
introduced into the culture
87. While these new techniques may one day allow for the production 
of homogeneous cultures of single terminal cell types, at present they generally result in a 
heterogeneous population consisting of the unconverted original cell type and partially 
reprogrammed cell types along with the cell type of interest, and thus suffer from similar 
heterogeneity-related difficulties encountered in cultures derived from directed neuronal 
differentiation protocols.  Finally, it is important to remember that time in culture may not have a 
direct relationship with state of maturity of a given neuronal population
88. If a functional state is 
required to monitor a phenotype in question, supplementing culture conditions with agents that 
promote the characteristic in question, for instance astrocyte conditioned media for the induction 
of synapse formation
89, may be essential. 
Another question of significant importance, which has yet to be well addressed is: How 
long, should I expect to wait before a degenerative phenotype emerges? Certainly time to 
functional maturation may play a role in the schedule by which phenotypes might be expected to 
appear. However, there are also the more nebulous factors that influence the appearance of 
degenerative phenotypes in vivo that are associated with patient aging and are likely important 
contributors to many neurological conditions
90. Currently, there is no clear relation that can be 
made between time in culture and “age” of a neuronal type in vivo.  Some studies have 
demonstrated in-vivo transcriptional and epigenetic changes which occur during normal aging of 
the brain
91,92.  While this line of research is still in its infancy, it may one day be possible to use 
the expression of a few well-chosen genes or epigenetic alterations at specific loci to 22 
 
benchmark in-vitro derived neurons to their in-vivo counterparts.  When considering our current 
inability to quantitatively determine a neurons in-vitro age, again the action of progenitor cells 
could be detrimental to detecting any effects the age of a neuron may have on disease 
phenotypes, arguing once more that their activity should be monitored or eliminated (Figure 
1.2B). Even given a more homogeneous culture of “aging” neurons, the length of time required 
to detect disease related changes is controversial and may vary substantially from case to case.  
For example, neuronal dysfunction and death resulting from chronic cellular stress induced by 
miss-folded or misprocessed proteins is a hypothesis relevant to many neurodegenerative 
diseases 
93,94.  In order to study events that occur later in pathogenesis, such as the formation of 
large scale protein inclusions, it may be necessary to wait a sufficient length of time for mutant 
proteins to accumulate or additional poorly understood events to occur. For example, cytological 
accumulation of p62 punctate were not observed in neurons derived from Parkinson’s patients 
after 30 days in culture
21. However, after a total of seventy-five days in culture, the accumulation 
of p62 foci reminiscent to histological inclusions observed upon patient autopsy were found
21,95.  
While these findings are encouraging, they also re-raise our question concerning the precise 
nature of changes that occur during long-term culture and the relation to aging, if any, to which 
neurons cultured for different durations of time correspond.   
Another possibility is that many mutations predisposing a given neuronal type to 
degeneration may begin exerting their relevant negative effects as soon as they become 
expressed.  For instance, immunocytochemistry has uncovered disease specific processing of 
mutant protein species in iPSC derived neurons harboring predisposing mutations to ALS and 
Alzheimer’s Disease
96,97. In cases where this is relevant, careful studies of the immediate 
changes induced in the most sensitive neuronal types may provide insight with therapeutic 
value, long before end-points of degeneration such as protein inclusion formation or neuron 
death are reached. Additionally, stressors that antagonize relevant neuronal defenses may also 
unmask or accelerate disease processes enabling their study in more manageable time 23 
 
frames
22,98. In fact such techniques have been successfully utilized in several studies to 
date
22,98.  Neurons derived from familial Parkinson’s patients proved more sensitive to 
antagonists of proteasome activity, as well as inducers of oxidative and mitochondrial stress 
than controls
99.  While these results demonstrate the utility of stressors for magnifying disease 
associated phenotypes, there are some drawbacks to this approach.  Many small molecules 
used as stressors are not wholly specific for the intended target and will modulate unintended 
pathways when used at higher concentrations
100.  The use of multiple small molecules or 
genetic approaches to impact the same pathway can validate a given targets importance to 
disease pathogenesis.   
Modeling Neural Selectivity of Disease 
Cell type specificity is a hallmark of many neurological disorders
101. However, few 
attempts at revealing intrinsic differences between vulnerable and resistant neurons have been 
earnestly made
101.  The production and comparison of vulnerable and resistant neurons from 
pluripotent cell lines is an intriguing option for interrogating disease cell type selectivity (Figure 
1.3B and C).  For example, in ALS, spinal motor neurons are most sensitive to the toxic effects 
of mutant SOD1 protein
102. However, ocular motor neurons that allow blinking and eye 
movement survive much longer in patients and mouse models with the disorder
103.  Comparing 
ocular and spinal motor neurons under various conditions (oxidative stress, neurotrophic factor 
withdraw, glutamate excitotoxicity) could reveal intrinsic susceptibilities in cellular pathways that 
underlie the hallmark cell type specificity of ALS.  Additionally the use of multiple neuronal 
subtypes derived from large cohorts of patient specific pluripotent cell lines could reveal subtle 
variations in the identity of resistant and vulnerable neurons driven by distinct disease variants. 
As described above, such an approach could be useful to re-classify subgroups of patients 
previously aggregated based solely on patient diagnosis.  The C9orf72 repeat expansion has 
been implicated in comorbid Frontal Temporal Degeneration (FTD), a disease which partially 
results from degeneration of von Economo neurons, whereas SOD1 has never been implicated 24 
 
in FTD
5,104. This divergence in ALS-causing mutations could naturally pave the way for 
experiments aimed at characterizing and differentiating the pathophysiology which leads to 
degeneration of motor vs. von Economo neurons. This could be achieved by using patient-
derived neurons harboring different familial ALS mutations, including C9orf72 patient specific 
iPSCs which have comorbid FTD and SOD1 patient specific iPSCs, and characterizing their 
phenotypes in both motor and von Economo neurons. One obstacle to this type of research, 
however, is the limited availability of protocols for the differentiation of disease-resistant 
neurons. While significant effort has been devoted to the development of protocols to produce 
cells lost in disease, there has been less focus on producing cells resistant to disease 
processes. Faced with this challenge, it may be tempting to use the most convenient cell types 
for comparison based on available differentiation protocols.  For example, protocols for the 
production of ocular motor neurons have not been established, whereas efficient methods for 
the generation of sensory neurons, another subtype unaffected during ALS disease 
progression, have been published
69.  Comparisons between spinal MNs and sensory neurons 
may provide insights into the subtype selectivity of ALS (Figure 1.3). However, selecting 
comparison cell types differing as little as possible from the cell type of interest, except in the 
vulnerability to the disease process, promises to provide the clearest path to understanding 
disease selectivity by eliminating many differences particular to cell fate but not relevant to the 





Enthusiasm for the use of in vitro disease modeling has developed at a rapid pace.  The 
exciting possibilities enabled by this technology have sparked many attempts in its application.  
Initial studies which utilized pluripotent stem cell technology to model disease pathology 
generally compared one or two patient derived pluripotent cell lines to a similarly sparse group 
of control cell lines.  Results from these preliminary experiments may or may not stand the test 
of time given what I now know regarding variability amongst multiple pluripotent cell lines. As 
the black box of reprogramming and pluripotency has become illuminated, better practices in 
characterizing pluripotent cell lines have been established, allowing for quick elimination of 
atypical cell lines which could confound disease modeling results. Advances in reprogramming 
techniques have allowed for the generation of large cohorts of disease and control pluripotent 
Figure 1.3 Observation of neurons resistant to the disease being studied could allow meaningful comparisons 
between vulnerable and resistant neurons derived from control and patient pluripotent cell lines. (A) During ALS 
disease progression spinal motor neurons are lost, resulting in paralysis and eventually death of the patient. 
Sensory neurons, however, remain viable.  (B) In vitro comparisons between motor and sensory neurons 
derived from control and patient hiPSC lines may recapitulate the in vivo cell type selectivity of the disease. If 
reproducible phenotypes are uncovered, transcriptional analysis of the resistant and vulnerable neuronal  
populations may reveal mechanisms for the motor neuron specificity  of ALS. (All graphs are hypothetical and 
not from actual data.) 
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cell lines, allowing for the production of neurons from many individuals and thereby reducing the 
possibility of results being driven by aberrant cell lines. Furthermore, the rapid development of 
gene targeting techniques capable of modifying single base pairs in pluripotent stem cell lines 
now allows for comparison between isogenic stem cell derived neurons, emphasizing disease 
variant driven phenotypes. Clearly, the sophistication of disease modeling experiments has 
advanced a great deal. Screening large libraries of small molecules for their ability to alleviate 
phenotypes in neurons derived from patient specific iPSCs is being pursued by many labs 
today. A critical component to any screen is the robustness of the phenotype which any 
potential therapeutic must improve. The advances in disease modeling experiments described 
above will provide more reliable platforms for the development of large scale screens and are 
critical for the future of this line of research. Still, there is room for improvement in disease 
modeling experiments. Purification of the cell type implicated in disease pathology is not routine, 
and is often impossible when antigens specific to the degenerating neurons are unknown.  
Furthermore, the in-vitro maturation of neurons is still difficult to determine, making correlations 
with stages of patient disease pathology difficult. No doubt, as more defined disease specific 
molecular signatures are uncovered and in-vitro maturation of stem cell derived neurons 
becomes more predictable, better models capable of revealing previously unknown disease 
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Introduction  
ALS is a fatal neurological condition characterized by selective death of motor neurons 
(MNs) 
1,2. Both classical linkage studies and modern genomic approaches involving DNA 
sequencing have demonstrated that ALS can be caused by a variety of mutations in more than 
two dozen genes acting on diverse cellular functions
3,4. Mutations in superoxide dismutase 1 
(SOD1)
5 were originally identified through their autosomal dominant inheritance pattern. More 
recently, genome wide association studies, DNA sequencing efforts and linkage analysis have 
all contributed to the identification of a hexanucleotide repeat expansion at C9orf72 as a likely 
cause of ALS in a substantial fraction of both familial and sporadic cases 
6. 
Importantly, the discovery of SOD1 mutations led to a widely studied transgenic mouse 
model of ALS
7. While indisputably valuable, these animals as well as many cell-based models, 
overexpress heterologous human SOD1 at super-physiological levels
7-9. Therefore, it is 
generally accepted that findings from these animals carry the caveat that they could be artifacts 
of protein overexpression
10,11. Furthermore, there is little information on how SOD1 impacts 
human MNs, leaving open to what extent results from the SOD1 mouse model are of relevance 
to understanding disease in the human nervous system. 
In addition, identification of patient mutations in other genes, such as TDP43
12 and 
C9orf72
6 have not yet translated into the creation of animal models that are as widely accepted 
as SOD1 transgenic mice
3,13. As a result, detailed understanding of whether the many changes 
in MNs induced by overexpression of mutant, human SOD1 are also relevant to those forms of 
ALS caused by mutations in other loci, has been slow to develop. Investigations of whether 
there are shared mechanisms of MN disease are essential as they could inform the selection of 
pathways for therapeutic intervention with the greatest relevance to a broader patient 
population. 
We and others have proposed that induced pluripotent stem cells (iPSCs) from ALS 
patients
14-16 and their differentiation into spinal
17,18 could complement existing animal models, 37 
 
allowing hypotheses to be tested in human MNs expressing mutations in a variety of ALS 
causing loci, all at physiological levels
19-21. 
Here, we have combined reprogramming and stem cell differentiation approaches with 
genome engineering and RNA sequencing technologies to identify the transcriptional and 
functional changes induced by the SOD1A4V mutation in human MNs. In addition to supporting 
hypotheses concerning the actions of mutant SOD1 protein developed using transgenic mouse 
models, such as the disruption of mitochondrial function and transport, our studies identified 
novel mechanisms that may contribute to MN dysfunction. Notably, we found that mutant SOD1 
disrupts a delicate balance between ER stress and neuronal excitability that is inherent to MNs. 
Finally, studies using iPSCs derived from patients harboring C9orf72 repeat expansions indicate 
that at least a subset of the changes induced by mutant SOD1 in human MNs are relevant to 
both forms of ALS. 
  
Results   
   Generation of iPSCs and Functional Motor Neurons from SOD1
+/A4V ALS Patients. 
We derived skin fibroblasts from two female ALS patients (study participants 39 and RB9) 
carrying the same dominantly acting SOD1A4V mutation (SOD1
+/A4V), then generated iPSCs via 
retroviral transduction of OCT4, SOX2 and KLF4 (Figure 2.1). Cell lines stably exhibited typical 
human pluripotent stem cell morphology with large nuclear-to-cytoplasmic ratios and prominent 
nucleoli, growing in dense colonies with well-defined borders, and immuno-positive for human 
pluripotency markers including nuclear NANOG and the cell surface antigen TRA-1-81 (Figure 
2.1B-C). The pluripotent profile and the differentiation potential of the iPSC lines was also 




To produce MNs, we employed a 24-day differentiation protocol (Figure 2.2A) based on 
neuralization by dual SMAD inhibition
22 and MN specification through exposure to retinoic acid 
and a small molecule agonist of  sonic hedgehog signaling 
17,22. SOD1
+/A4V iPSC lines generated 
MNs  that  expressed  the  neuronal-specific  class  III  β-TUBULIN  (TUJ1)  as  well  as  the  MN-
Figure 2.1 Generation and Characterization of Patient-Specific iPS Cells. (A) Summary of patients selected for this 
study. fALS, familial ALS, O: OCT4, S: SOX2, K: KLF4, N.A: not applicable. (B) Fibroblasts derived from skin 
biopsies of ALS-SOD1+/A4V patients. (C) iPSC colonies are morphologically identical to hESC colonies, and 
express NANOG and TRA-1-80, unlike the patient fibroblasts from which they were derived (scale bar=100µm). 
(D) Scorecard analysis of pluripotency genes for iPSCs and for three germ layer differentiation after 16 days, the 
red dots indicate values for each of the two lines. (E) Gene expression for pluripotency genes, ectoderm, 
mesoderm and endoderm genes after 16 days of undirected differentiation. 
 39 
 
specific  transcription  factors  ISLET  1/2  (ISL)  and  HB9  (Figure  2.2B)
23.  These  MNs  also 
expressed  microtubule-associated  protein  2  (MAP2)  and  choline  acetyltransferase  (ChAT) 
(Figure 2.2B)
24. This differentiation strategy generated populations in which >97% of all cells 
were  TUJ1+  neurons.  Of  these  neurons,  21-38%  were  ISL+  MNs  (n=6)  (Figure  2.2C).  To 
assess their functionality, we transduced d15 MNs with a lentivirus encoding RFP under control 
of the Hb9 promoter (Hb9::RFP)
25 and performed whole-cell patch clamp recordings. RFP+ MNs 
possessed sodium and potassium currents, fired action potentials, and responded to excitatory 
and inhibitory transmitters as previously shown for other iPSC-derived MNs (Figure 2.2F-G)




Increased  Apoptosis  and  Altered  Morphometry  in  SOD1
+/A4V  Motor  Neurons. 
Having demonstrated that we could produce MNs from SOD1
+/A4V patients, we proceeded to ask 
Figure 2.2 Differentiation and Characterization of Patient-Specific iPS cell-derived Motor Neurons. (A) 
Schematic of differentiation protocol (see methods for details). (B-C) Differentiations typically yielded neurons 
that expressed TUJ1, the MN transcription factors ISL and HB9, as well as MAP2. Many ISL+ MNs were 
FOXP1high+, at 30 days post-dissociation, ISL+ MNs were ChAT positive. (D-G) Hb9::RFP positive MNs are 
electrophysiologicaly active. RFP+ cells show a 6-fold enrichment in Hb9 expression levels than the RFP 
negative fraction. In whole-cell patch clamping recordings of day 15 neurons in co-culture with glia, MNs 
exhibited initial inward sodium currents followed by outward potassium currents upon depolarization in voltage-
clamp mode, as well as repetitive action potential firing in current-clamp mode, as well as kainate and GABA 
responses (all scale bars=50µm). 41 
 
whether these neurons might manifest a phenotype distinct from controls under standard culture 
conditions. To address this, we compared SOD1
+/A4V MNs with MNs produced in parallel from 
two control iPSC lines (11a, 18a)
17, selected based on their similarity in neuronal differentiation 
capacity, iPSC reprogramming method and donor age. Differentiated preparations were plated 
on primary glial monolayers and the total number of ISL/TUJ1+ MNs was assessed after 3 and 
30 days in culture (Figure 2.3A). We found that in comparison to the number of MNs present in 
cultures made from each line at day 3, there were significantly fewer SOD1
+/A4V MNs at day 30 
(n=3, m>8000, P<0.05)(Figure 2.3B). 
Interestingly, the decline in SOD1
+/A4V cultures seemed to be specific to MNs, rather than 
reflective of an overall deficit in neurons; with no significant difference in the number of ISL-
negative,  TUJ1+,  presumptive  non-MNs  between  cases  and  controls  at  day  30  (n=3, 
m>25,000)(Figure 2.3C). 
We considered two explanations for the selective decline in MN number in SOD1
+/A4V 
cultures. We first reasoned that if MN progenitor cells remained in the cultures, and if SOD1
+/A4V 
progenitors were less abundant or functional, then the SOD1
+/A4V MN number might selectively 
decline over time. To test this, we monitored progenitor activity via long-term BrdU incorporation 
(Figure 2.3D-E, G). When we chronically administered BrdU to cultures from day 0 to day 30, 
then assessed BrdU incorporation, we observed that only 2-3% of MNs were labeled (BrdU+, 
ISL+, TUJ1+) and that this modest rate of labeling was similar in control and SOD1
+/A4V cultures 
(Figure 2.3D-E). These findings suggest that the vast majority (>97%) of MNs in our cultures 
were postmitotic prior to “day 0” and that the selective decline of MNs we observed in SOD1
+/A4V 
cultures was not due to a decrease in progenitor activity.  
The  second  hypothesis  was  that  the  selective  decline  of  MN  number  in  SOD1
+/A4V 
cultures  might  result  from  an  increased  rate  of  cell  death.  We  therefore  used  the  BrdU 
incorporation  strategy  to  specifically  quantify  only  the  MNs  born  before  day  0.  Using  this 
criterion, we again found that significantly more SOD1
+/A4V MNs were lost over the 30 days in 42 
 
culture (m=3,686, P<0.05)(Figure 2.3F). To determine whether increased apoptosis caused the 
preferential loss of postmitotic SOD1
+/A4V MNs, we performed TUNEL staining (Figure 2.3G). At 
day 21 of culture we found an increase in TUNEL+ cells in the two SOD1
+/A4V cases compared 




We also found that the pro-apoptotic phenotype we identified in SOD1
+/A4V human MNs 
was accompanied by altered morphological characteristics similar to those seen in patients and 
in  the  SOD1
G93A  mouse  model
26,27.  In  particular,  30-day  old  SOD1
+/A4V  MNs  exhibited  a 
significant reduction in relative soma size and fewer, as well as shorter processes compared to 
controls (n=3, m=88, P<0.01) (Figure 2.4A-H). Again, these effects were not observed in ISL-
negative, TUJ1+ non-MNs (n=3, m=90) (Figure 2.4D). Interestingly, further analysis suggested 
that larger MNs were most vulnerable, as MNs larger than 150µm
2 made up less than 40% of 
the total MN population in SOD1
+/A4V cases, compared to ~65% in the case of controls (Figure 
2.4E). Because we observed variability with regard to baseline soma size between experiments 
in  these  studies,  we  fit  the  cell  size  data  with  a  linear  regression  model.  We  did  find  that 
experiment number (that is, which differentiation) was an independent, significant predictor of 
absolute cell size (p=2.8x10
-9). However, despite this, the difference between SOD1A4V cases 
and  controls  was  still  highly  significant  (35.2  µm
2  (SD  5.4,  p=2.0x10
-10).  Thus  in  short,  the 
absolute  base-line  size  of  neurons  changed  from  experiment  to  experiment,  however,  the 
relative  size  distinction  was  always  conserved  with  SOD1A4V  motor  neurons  proving  to  be 
smaller than controls. Therefore, we presented the size of the ALS motor neurons normalized to 
that of control motor neurons from the same differentiation. 
Figure 2.3 (Continued) iPSC-Derived MNs from SOD1+/A4V ALS Patients Exhibit Survival Differences Relative 
to Healthy Controls (A) Neuronal cultures on glial monolayers 3 and 30 days postdifferentiation from control 
and SOD1+/A4V iPSCs. MNs costained for ISL and TUJ1 are indicated by white arrows (scale bar = 50 mm). 
(B and C) Quantifications of ISL+ MNs (n = 3, m > 8,000, ±SEM, p < 0.05) (B) and ISL- neurons (n = 3, m > 
25,000, ±SEM, p < 0.05) (C) after 30 days in culture. (D-E) Schematic of experimental strategy to evaluate the 
level of MN proliferation after dissociation; 1µM BrdU was added in plated co-cultures from days 0-30 and 
percentage of positive cells was analyzed. Between 0.2-0.8% of all MNs incorporate BrdU between days 0-3 
while 2-2.8% between days 0-30 across all the iPSC lines. Importantly the mitoticly active supporting glial cells 
were exposed to BrdU in this experiment and many are BrdU+ (large DAPI nuclei). (H) A repre-sentative image 
of BrdU incorporation after the addition of 1µM BrdU to dissociated MN cultures after 3 and 30 days. Top right 
inserts exhibit an ISL+/BrdU negative MN, bottom inserts exhibit two ISL+ MNs, with only one being postive for 
BrdU also. Single arrows indicates BrdU+/ISL+ MNs; Double arrows indicate BrdU+/ISL negative cells; 
Asterisks indicate BrdU negative/ISL+ MNs, (scale bar=30µm). (E) Quantifications of MN numbers that are 
BrdU- after 30 days in culture (n = 1, m > 3,600, ±SD, p < 0.05). (F)Differential motor  neurogenesis does not 
explain the lower numbers in SOD1+/A4V cases. (G) Quantifications of TUNEL+ nuclei of neuronal cultures 










To gain a sense of whether the survival difference we observed between SOD1 mutant 
and control motor neurons was cell autonomous, we cultured preparations of motor neurons on 
primary  glia  from  the  SOD1
G93A  mouse  model.  In  this  context,  and  as  expected  based  on 
previous  studies
28,  we  found  that  both  control  and  patient  derived  motor  neurons  survived 
significantly  more  poorly  on  SOD1
G93A  glia  than  on  control  glia.  However,  SOD1
+/A4V  MNs 
survived even more poorly than control MNs on SOD1
G93A glia (Figure 2.5B). Thus in both cases 
the iPSC-derived MNs we utilized were sensitive to well-studied models of non-cell autonomous 
toxicity involving mutant SOD1. However, SOD1
+/A4V MNs showed an additional survival deficit 
beyond  that  induced  by  the  mutant  glia,  suggesting  that  at  least  in  part,  there  was  a  cell-
autonomous contribution to the effects described above (Figure 2.3) with SOD1




Figure 2.4 (Continued) iPSC-Derived MNs from SOD1+/A4V ALS Patients Exhibit Morphometric Differences 
Relative to Healthy Controls (A) Representative images of measured soma size (white-dotted circumference) of 
control and SOD1+/A4V MNs (scale bar = 20 mm). (B) Quantifications of ISL+ MN soma size with values 
normalized to those of controls (n = 3, m = 340, ±SEM, p < 0.01). (C) MN soma size after 3, 15, and 30 days in 
culture normalized to day 3 for each cell line. Although MNs increase in size over time in all four cell lines, they 
do so to a lesser degree in SOD1+/A4V cases. (D) Quantifications of ISL-negative neuron soma size with values 
normalized to those of controls (n = 3, m = 446, ±SEM, p = n.s.). (E) Cumulative frequency graphs of MN soma 
size after 30 days in culture. Dotted lines indicate averages for control and disease. n.s., not significant; n = 
experiment; m = cell number. (F) Quantifications of MN processes, evaluated as total number of TUJ1-positive 
processes per cell showed that SOD1+/A4V MNs are less elaborate after 30 days in culture; (G) and have 





Gene Targeting and Correction of the SOD1A4V Mutation. Distinct iPSC lines can 
harbor significant variation in transcription and DNA methylation
29. This variation, in conjunction 
with a cell line’s particular genetic make-up, give it its own distinctive functional characteristics 
17, which may confound disease modeling experiments
30. Additionally, ALS patients can harbor 
more  than  one  disease-causing  genetic  variant
31,  raising  the  possibility  that  the  effects  we 
observed were not solely due to the SOD1A4V mutation. To address these issues, we used a 
two-step, zinc-finger nuclease (ZFN)-mediated gene targeting strategy to correct the SOD1A4V 
allele in iPSC line 39b (Figure 2.6A, methods). 
Gene-targeting and correction of the SOD1A4V mutation was confirmed by sequencing 
of  the  genomic  locus  (Figure  2.6B).  To  confirm  that  the  genetic  correction  had  eliminated 
expression  of  mutant  transcripts,  we  queried  the  SOD1  cDNA  from  both  cell  lines  for  the 
presence of a PshA1 Restriction Fragment Length Polymorphism (RFLP) that results from the 
missense mutation encoding the SOD1A4V variant. While this PCR-RFLP was clearly detected 
in cDNA from the 39b-SOD1
+/A4V cell line, it was eliminated by gene-correction (Figure 2.6C). 
Quantitative PCR demonstrated that the corrected 39b-SOD1
+/+cell-line did not harbor multiple 
Figure 2.5. MNs are sensitive to the toxic 




insertions of the targeting vector (Figure 2.6D). We also found that SOD1 transcript levels were 
unchanged between the parental 39b-SOD1
+/A4V cell line and its corrected derivative (Figure 
2.6E). 
Using immunoblotting we examined the SOD1 protein levels in cell extracts from the 
parental 39b-SOD1
+/A4V cell line, the intermediate heterozygous knockout line, which expresses 
only one allele of the SOD1 gene, and the corrected derivative 39b-SOD1
+/+. We found that 
while the intermediate 39b-SOD1
+/- line exhibited approximately half of the SOD1 levels of the 
parental line, correcting the mutation restored SOD1 protein levels (Figure 2.6F). As expected, 
based on the lower protein stability of the mutant SOD1A4V variant
32, correction of the SOD1 
mutant allele resulted in a modest increase in SOD1 protein levels relative to those found in 










Given that undesired genetic variations could potentially arise as result of ZFN off-target 
activity or clonal expansion, we proceeded to carefully evaluate the genomic sequence and 
genomic integrity of the parental and genome-edited cell lines. We carried out whole genome 
sequencing  (to  33.4X  and  31.1X  coverage,  for  the  39b  and  gene  corrected  cell  lines, 
respectively) and analyzed the resulting data with tools including GATK
33 and Genome STRiP
34. 
To evaluate whether large-scale copy-number alterations had arisen, we measured sequencing 
depth  of  coverage  across  the  genome  in  10kb  bins,  as  sequencing  read  depth  (when  well 
normalized) can serve as a proxy for copy number of the underlying genomic DNA
34. We found 
that sequencing read depth for the two samples closely matched each other throughout the 
genome (Figure 2.6G), excluding the possibility that deletions, duplication, or aneuploidy had 
arisen  during  passaging,  genome  editing,  or  clonal  expansion.  Furthermore,  the  top  12,000 
genomic loci with sequence similarity to the binding site of the ZFN pair described in this study 
did not deviate between the parental or gene edited cell lines, indicating highly specific nuclease 
activity. 
To  detect  other  potential  genomic  sequence  changes  in  the  corrected  cell  line,  we 
compared the fine-scale (SNP and indel) sequence calls between the parental and genome-
edited  cell  lines  across  their  genomes.    Overall,  we  found  the  corrected  cell  line  to  be 
surprisingly free of such events. However, these analyses were sufficiently sensitive to identify a 
Figure 2.6. (Continued) Genetic Correction of the SOD1A4V Mutant Allele (A) Gene targeting strategy used to 
generate the isogenic 39b-SOD1+/+ iPSC line. Nucleases targeting the SOD1 locus created a double-strand 
break upstream of Exon1; homologous recombination of the genomic locus with a targeting plasmid with control 
sequence of Exon1 coupled to PGK::Puromycin replaced the SOD1A4V mutant allele; after antibiotic selection, 
the resistance cassette was removed by Flp-mediated recombination, leaving only an FRT footprint. ZFN, 
zincfinger nuclease; FRT, Flippase Recognition Target. (B) Sequencing chromatograms of Exon1 of SOD1 in 
iPSC line 39b before and after targeting demonstrate the correction of the A4V mutation. (C) PshAI restriction 
digestion of amplified SOD1 cDNA before and after gene targeting. The mutation creates a PshAI restriction 
site that is absent in the corrected line. (D and E) qPCR of genomic SOD1 shows that there are no extra copies 
of the gene in the corrected line (D) and qRT-PCR of cDNA shows that the expression levels of SOD1 are the 
same in the corrected line (n = 3, ±SEM) (E). (F) SOD1 protein levels assessed by western blot (WB) analysis 
in parental (39b-SOD1+/A4V), targeted hemizygous knockout (39b-SOD1+/KO), and corrected (39b-SOD1+/+) 
iPSC clones. (G) To evaluate whether large-scale copy-number alterations had arisen during gene-targeting of 
the SOD1 locus, we measured sequencing depth of coverage across the genome in 10kb bins for the parental 
39b and the corrected 39b control line. Sequencing read depth for the two samples closely matched each other 
throughout the genome. 
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likely  mitotic  recombination  event  on  the  q  arm  of  chr12  (from  108Mb  to  the  end  of  the 
chromosome).  Deeper  analysis  of  this  region  demonstrated  that  the  event  had  not  induced 
novel or rare protein-coding variants. Neither had it induced coding variants associated with any 
known disease state, suggesting this event was likely to be phenotypically neutral. 
To evaluate whether either the parental cell line or the genome-edited cell line carried 
variants  associated  with  ALS,  we  analyzed  the  exonic  protein-coding  sequences  of  26 
candidate genes implicated in ALS. This analysis identified a single protein-altering sequence 
difference between the two cell lines, which corresponded to the genome edit of the A4V variant 
in SOD1. 
Following the correction of the SOD1A4V mutation, we used 39b-SOD1
+/A4V and 39b-
SOD1
+/A4V cell lines to ask whether the SOD1A4V-encoding variant was necessary for the MN 
survival and soma size phenotypes observed in the patient-control comparisons. Importantly, 
correction of the SOD1A4V mutation resulted in a significant rescue of both MN survival (n=6, 





Solubility  of  Mutant  SOD1  in  Motor  Neuron  Cultures.  SOD1  protein  variants  that 
cause ALS are prone to unfolding, misfolding and ultimately aggregation
35,36. Aggregation of 
SOD1 protein and the formation of SOD1-rich inclusions is a pathological finding in animals 
models of this disease
36, as well as at autopsy in the spinal cords of SOD1-linked cases
37 and 
some  sporadic  cases
38.  SOD1  aggregation  can  be  detected  in  spinal  cord  extracts  using 
detergent solubility assays
39. However, the relevance of SOD1 insoluble aggregates to disease 
processes is poorly understood and it remains unresolved whether SOD1 aggregation lies on 
the critical pathway to neuronal degeneration, and whether these structures are either toxic or 
protective in nature
38. 
The pair of isogenic iPSC lines we developed allowed us to address the state of SOD1 
protein  in  differentiated  human  spinal  MNs  expressing  physiological  levels  of  wild-type  and 
mutant  SOD1.  Using  immunoblotting  assays  on  detergent-soluble  (RIPA)  and  detergent-
insoluble (UREA) fractions obtained from cultures of differentiated SOD1
+/+ and SOD1
+/A4V MNs, 
we found no evidence of insoluble SOD1 protein under basal culture conditions (Figure 2.7C). In 
order to sensitize our culture system and validate the ability of our assay to detect insoluble 
SOD1 protein, we treated MN cultures with the proteasome inhibitor MG132. Treatment with 
MG132,  which  inhibits  the  proteasome  by  reducing  the  degradation  of  ubiquitin-conjugated 
proteins, increased soluble SOD1 protein levels 2-4 fold. Following MG132 treatment, SOD1 in 
SOD1
+/A4V neurons became detergent-insoluble and was found in the UREA-extracted fraction 
(Figure  2.7C).  Correcting  the  SOD1A4V  mutation  resulted  in  elimination  of  insoluble  SOD1 
protein in MN cultures following treatment with MG132. 
These  studies  suggest  that  while  it  is  possible  to  induce  accumulation  of  insoluble 
Figure 2.7. (Continued) Genetic Correction of the SOD1A4V Mutant Allele Rescues MN Survival and Soma Size 
Deficits. (A and B) Isogenic 39b-SOD1+/+ MNs exhibit increased cell survival (n = 6, m > 13,000, ±SEM, p < 
0.05) (A) and soma size (n = 3, m = 280, ±SEM, p < 0.01) (B). (C) WB analysis of SOD1 protein in 
detergentsoluble (RIPA) and detergent-insoluble (UREA) fractions in day 12 neuronal cultures. Insoluble SOD1 is 
not detected under normal conditions. After proteasome inhibition by MG132 treatment, insoluble SOD1 
selectively accumulates only in SOD1+/A4V MNs and not in the corrected line. 52 
 
mutant SOD1 protein in human MNs, insoluble protein did not accumulate to detectable levels 
under normal culture conditions. We cannot rule out the possibility that undetectable levels of 
aggregated  SOD1  protein  were  the  cause  of  the  increased  apoptosis  and  morphometric 
changes  we  found  in  SOD1
+/A4V  MNs  (Figure  2.3-2.4).  However,  our  findings  do  seem 
consistent  with  recent  claims  that  soluble  mutant  SOD1  can  have  substantial  phenotypic 
effects
35. 
RNA  Sequencing  of  Purified  SOD1
+/A4V  and  Isogenic  Control  Motor  Neurons. 
Although the changes in gene expression induced in the mouse nervous system by mutant 
SOD1 have been extensively studied, it is unknown how mutant SOD1 impacts transcript levels 
in human MNs. In order to gain insight into the molecular pathways affected by the SOD1A4V 
mutation,  we  performed  RNA  sequencing.  As  in  earlier  experiments  (Figure  2.4-2.7),  we 
differentiated 39b-SOD1
+/A4V and isogenic control stem cells then plated the resulting MNs on a 
glial monolayer (Figure 2.8A). We next transduced these cultures with an Hb9::RFP lentiviral 
reporter and used FACS to purify MNs after 15 days of additional culture. RNA and sequencing 
libraries were prepared from these MNs then subjected to sequencing. We chose day 15 for 
transcriptional studies as at this time point MNs were physiologically active, but there was only a 
trend towards reduced MN survival in SOD1
+/A4V cultures. We reasoned that at this time point 
we might identify the transcriptional changes that predisposed mature MNs to apoptosis. 
The quality of all libraries was validated using FastQC and reads were quantified after 
alignment and mapping to the reference genome hg19. We first asked whether the effects of the 
SOD1
+/A4V genotype on transcriptional patterns in spinal MNs were greater than the variability 
present  between  biological  replicates  of  our  experimental  system.  Indeed,  unsupervised 
hierarchical  clustering  segregated  samples  based  on  their  SOD1  genotype,  suggesting  that 
effects  of  the  mutant  allele  were  driving  measurable  transcriptional  differences  between 
SOD1
+/A4V  and  SOD1
+/+  MNs  (Figure  2.8B).  As  an  initial  measure  of  the  transcripts  most 
affected  by  the  SOD1A4V  mutation  we  determined  the  identity  of  the  30  transcripts  most 53 
 
increased and decreased in abundance in mutant MNs relative to controls at a false discovery 
rate (FDR) of 5% (Figure 2.8C).  Analysis of a representative subset of these transcripts by 
quantitative  RT-PCR  in  independent  experiments  validated  our  findings  (Figure  2.8D).  To 
understand whether a subset of the gene expression changes found by RNA sequencing were 
likely to be specific to MNs and not found in other cell types less affected in ALS we determined 
the expression of a subset of differentially expressed transcripts in the 39b and 39b corrected 
iPSCs (Figure 2.8E).  Of these genes only 19% (5/22) were found to be differentially expressed 
in both iPSCs and MNs.  Furthermore, we performed RNA sequencing on fibroblast cultures 
isolated from 5 healthy control individuals and the two ALS patients harboring the SOD1A4V 
mutation.  While  unsupervised  hierarchical  clustering  segregated  transcriptomes  of  MNs 
harboring the SOD1A4V variant as distinct from MNs derived from healthy controls, this was not 










Validating  the  importance  of  this  unbiased  approach,  the  vast  majority  of  genes  we 
identified to be differentially expressed between SOD1
+/A4V and control MNs had not previously 
been implicated as being modulated by mutant SOD1. These included ACOT2, an enzyme that 
hydrolyzes Coenzyme A (CoA) esters
40; the transcription factor FOSB which regulates BDNF 
expression
41,  and  NLRP2,  a  NOD-like  receptor,  pro-apoptotic  component  of  the 
inflammasome
42. Amongst the most-downregulated genes in SOD1
+/A4V MNs, we identified a 
transcript  that  encodes  the  molecular  motor  protein  DNAH9.  Transcripts  of  CXCL5,  a 
chemokine indicative of an inflammatory response previously shown to be stimulated by mutant 
SOD1  protein
42  were  similarly  increased  here.  We  also  found  that  corticotropin-releasing 
hormone (CRH), which has been implicated in other neurodegenerative diseases
43 and found to 
be expressed at lower levels in ALS patients was significantly reduced in SOD1
+/A4V MNs. 
Ontology of transcripts modulated in SOD1
+/A4V Motor Neurons. In order to probe 
the RNA sequencing data for further biological meaning we utilized two bioinformatics tools that 
query  for  enriched  gene  ontology  terms.  We  first  performed  gene-annotation  enrichment 
analysis with DAVID
44, using all the genes that were significantly altered (909 upregulated and 
580 downregulated) in SOD1
+/A4V MNs at a FDR of 5%. A total of 27 and 65 gene terms were 
enriched  when  increased  and  reduced  transcripts  were  considered  respectively  (FDR<5%). 
Transcripts  implicated  in  ‘cytoskeleton’  organization  (rank  of  significance  5,  FDR=5.84x10
-7), 
where  amongst  the  most  significantly  induced  in  SOD1
+/A4V  MNs,  consistent  with  the 
morphological alterations that we observed in these cells relative to isogenic controls (Figure 
Figure 2.8. (Continued) Transcriptional Analysis of 39b-SOD1+/A4V and Isogenic Control MNs by RNA-Seq 
Reveals Genotypic Regulatory Changes (A) Experimental outline: SOD1+/A4V and isogenic control MN cultures 
were cocultured with primary glial cells, transduced with an Hb9::RFP lentivirus, and FACS-purified on day 15 for 
RNA isolation and sequencing. (B) Dendogram demonstrating clear genotypic clustering based on transcriptional 
changes measured by RNA-seq. (C) Total number of genes and top 30 genes (based on fold change) 
misregulated in SOD1+/A4V MNs with an FDR of 5%. (D) qRT-PCR validation of misregulated genes in 
independent samples (n = 3, ±SEM). (E) qRT-PCR analysis in 39b and 39b corrected iPSCs. Genes identified as 
being differentially regulated as a result of the SOD1 mutation in Hb9::RFP MNs were evaluated in the parental 
iPSCs. 19% of the genes were found as being significantly different in iPSCs. (F) Cluster dendogram of RNA 
sequencing from SOD1A4V and healthy sex-matched fibroblast samples. The A4V fibroblasts do not segregate 
from the healthy controls. 56 
 
2.7B). Transcripts involved in ‘transcriptional regulation’ (rank of significance 13, FDR=1.7x10
-4) 
and ‘motor proteins’ (rank of significance 18, FDR=6.4x10
-3), were also induced as a result of 
the SOD1 mutation. 
Gene ontology analysis revealed that amongst the significantly decreased transcripts in 
SOD1
+/A4V  MNs,  there  was  a  very  strong  enrichment  for  genes  implicated  in  mitochondrial 
function and structure. In particular, 60% of all downregulated ontology terms were related to 
mitochondria. A total of 93 genes curated in the term ‘mitochondrion’ (rank of significance 1, 
FDR=6.3x10
-26).  In  addition,  genes  implicated  in  ‘translation’  (rank  of  significance  34, 
FDR=1.3x10
-4) were also repressed. 
As an alternative approach for querying our RNA sequencing data, we performed Gene 
Set  Enrichment  Analysis  (GSEA)
45,46.  GSEA  identified  16  gene  sets  that  were  significantly 
induced  in  SOD1
+/A4V  MNs  (NES<1.5).  Amongst  these  gene  sets,  were  the  motor  proteins 
‘kinesins’  (rank  of  significance  5;  NES=1.7).  GSEA  also  identified  100  gene  sets  to  be 
significantly  repressed  in  SOD1
+/A4V  MNs  (NES<1.5).  Notably,  gene  sets  associated  with 
mitochondrial function and translation were again amongst the most significantly suppressed. In 
particular,  gene  sets  annotated  as  being  involved  in  ‘peptide  chain  elongation’  (rank  of 
significance=2;  NES=-3.45),  ‘SRP-dependent  co-translational  protein  targeting  to  membrane’ 
(rank  of  significance=3;  NES  =-3.45),  ‘3-UTR  mediated  translational  regulation’  (rank  of 
significance  5;  NES  =-3.42),  and  ‘translation’  (rank  of  significance=8;  NES=-3.31)  were  all 
significantly suppressed. 
SOD1
+/A4V Motor Neurons Exhibit Disturbances in Mitochondrial Morphology and 
Motility.  To  determine  whether  the  transcriptional  changes  in  mitochondrial  genes  that  we 
identified by RNA-Seq in SOD1
+/A4V MNs were indicative of actual disturbances to mitochondria, 
we  performed  electron  microscopy  (EM)  studies  (Figure  2.9B).  Whereas  mitochondrial 
morphology was normal in MNs derived from a control cell line (18a), mitochondria in SOD1
+/A4V 
MNs  (39b  and  Rb9d)  were  commonly  deranged  and  more  vacuolar  in  appearance.  These 57 
 
differences  were  mostly  apparent  in  neuronal  processes.  We  concluded  that  distortion  in 
mitochondrial  morphology  was  mediated  by  expression  of  the  SOD1A4V  mutant  allele  as 
correction  of  the  mutation  eliminated  this  phenotype  (Figure  2.9B).  To  further  validate 
mitochondrial damage in SOD1
+/A4V MNs, we used immunoblotting assays to quantify the levels 
of two mitochondrial proteins, SDHA (SUCCINATE DEHYDROGENASE COMPLEX SUBUNIT A), which is 
encoded in the nucleus, and MT-COX1 (CYTOCHROME C OXIDASE  I), encoded by mitochondrial 
DNA. Consistent with mitochondrial defects mediated by expression of mutant SOD1, we found 
that correction of the SOD1A4V allele in 39b-SOD1
+/+ MNs increased the protein levels of both 
SDHA and MT-COX1, relative to the parental 39b-SOD1





As changes in mitochondrial motility have been reported previously in mouse models of 
Figure 2.9. (Continued) SOD1+/A4V MNs Exhibit Mitochondrial Defects that Are Rescued by Genetic Correction 
of the SOD1A4V Mutation (A) Experimental outline: SOD1+/A4V and isogenic control MN cultures were plated at 
low densities, transduced with an Hb9::RFP lentivirus on day 5, and analyzed on days 23–26. (B) EM analysis 
demonstrating that in contrast to control neurons (top panel), SOD1+/A4V neurons (middle panels) often 
exhibited swelling, morphological disorganization, and clustering in neurites. Mitochondria in genetically corrected 
neurons (bottom panel) exhibited normal morphological characteristics. Representative images out of three 
independent experiments are shown. Scale bar, 100 nm. (C) WB analysis of mitochondrial proteins. (D–G) 
Representative kymographs (D) of MitoTracker-stained mitochondria in MNs after live cell imaging. Distal and 
proximal orientation relative to cell body is indicated. SOD1+/A4V MNs exhibit mitochondria transportation 
deficiencies relative to controls with (E) fewer motile mitochondria, (F) less space unoccupied by mitochondria 
relative to axon length, and (G) shorter distances between stationary mitochondria (n = 4, ±SEM, p < 0.05). 59 
 
ALS we next sought to observe the movements of mitochondria within the axons of our in vitro-
derived  MNs  (Figure  2.9D-G).  MN  cultures  differentiated  from  control  and  SOD1
+/A4V  iPSCs 
were co-labeled with Hb9::RFP and MitoTracker-Green, which selectively stained mitochondria 
regardless of their membrane potential. We then carried out live cell imaging to register the 
movement of mitochondria along MN processes over the course of 5 minutes, and generated 
time/distance  kymographs  for  further  analysis  (Figure  2.9D).  We  found  that  the  SOD1A4V 
mutation resulted in a significant decrease in the number of motile mitochondria (Figure 2.9E). 
This decreased motility was coupled to an increase in mitochondrial density in processes, as 
measured by the shorter distance between stationary mitochondria and the significantly smaller 
amount of space unoccupied by mitochondria (Figure 2.9F,G). 
   SOD1
+/A4V Motor Neurons Exhibit Signatures of an Unfolded Protein Response and 
ER Stress Induction. To gain insight into how changes in individual transcripts annotated in the 
‘translation’ gene set contributed to the GSEA analysis,  we plotted their levels in SOD1
+/A4V 
relative to isogenic control  MNs (Figure 2.10A). Strikingly, we found that 93% of transcripts 
curated into this gene set were reduced in SOD1
+/A4V MNs. Amongst these there were several 
subunits of eukaryotic translation initiation factors (EIF2B3, EIF3K). Translational inhibition is 
well-established as a hallmark of ER stress and the unfolded protein responses (UPR). We 
therefore investigated whether this pathway was activated
47. 
The  UPR  is  a  signaling  cascade  that  is  activated  in  response  to  accumulation  of 
misfolded proteins and while it is thought to be initially cytoprotective, its persistent activation 
can in turn lead to apoptosis
48,49. The UPR is initiated though its proximal sensors, which include 
the proteins PERK and IRE1 (Figure 2.10B). In one of the branches of the pathway, PERK 
directly leads to an increase in the phosphorylation of eukaryotic translation initiation factor 2 
subunit a (EIF2a). 
In order to decrease the protein load of the cell, pEIF2a leads to a global attenuation of 
translation and to selective translation of the transcription factor ATF4
47. In another branch of 60 
 
the UPR, IRE1 cleaves the mRNA of XBP1, creating an active form of the transcription factor 
(sXBP1)
49.  Spliced  XBP1  along  with  ATF4  modulate  expression  of  multiple  downstream 
effectors of the UPR, including chaperone proteins. Importantly, RNA-seq analysis identified the 
heat-shock proteins DNAJC12 and HSBP1, the prefoldin subunits PFDN2 and PFDN5, as well 
as  the  chaperonin  subunits  CCT4  and  CCT7  as  being  differentially  expressed  in  SOD1
+/A4V 
MNs.  Consistent  with  the  transcriptional  changes  reflecting  an  UPR  in  our  patient-specific 
SOD1
+/A4V  MNs, ER-stress pathways and the UPR are activated in rodent ALS models and 
patient spinal cords
50-52. 
To more directly test whether the transcriptional signature we observed was caused by 
activation of the UPR in our MN cultures, we examined the levels of phopho-EIF2a. Using 
immunoblotting we found increased levels of pEIF2a in SOD1
+/A4V MNs on days 7, 9 and 12  (on 
average 1.5-fold higher than isogenic controls) (Figure 2.10C). We also found that the spliced 
XBP1 transcript was significantly elevated in SOD1
+/A4V MNs relative to isogenic controls (n=3, 
P<0.05) (Figure 2.10D), suggesting that this arm of the UPR pathway was also activated. In 
order to test if ER stress directly contributed to mutant SOD1-mediated toxicity in our cell culture 
system, we genetically manipulated the two UPR branches using siRNA knockdown of XBP1 
and ATF4 and assessed the effect on the survival of mutant and controls MNs (Figure 2.10E-F). 
Knockdown of the XBP1 transcript resulted in a modest but significant increase in the survival of 
SOD1
+/A4V MNs (Figure 2.10G). In contrast, knockdown of XBP1 in the isogenic controls did not 
lead to an increase in their survival, but instead there was a trend for a reduced MN number, 
suggesting that XBP1 might provide a protective function in this context. Knockdown of ATF4 
transcript levels depressed survival of both SOD1
+/A4V and SOD1
+/+ MNs, implying that this 
protein plays an important protective role in both contexts (Figure 2.10G). Given that reducing 
ATF4 levels was detrimental to the survival of both SOD1
+/A4V and control MNs we asked 
whether a further induction of pEIF2a would confer protection. Salubrinal is a selective inhibitor 
of phosphatases, which dephosphorylate pEIF2a
53. Furthermore Salubrinal extends the survival 61 
 
of the SOD1
G93A mouse model by reducing the UPR and increasing innervation of 
neuromuscular junction (NMJs)
52. Treatment of MN cultures with salubrinal from d15-30 led to a 
modest but significant increase in the survival of SOD1
+/A4V MNs, whereas the survival of 
controls was not affected (n=2, m>10000, P<0.05) (Figure 2.10H). 
Taken together these data clearly demonstrate that the UPR is activated in human MNs 
by  the  A4V  mutation.  Furthermore,  while  ATF4  seems  to  be  generally  protective  in  both 
contexts,  treatment  with  a  compound  that  inhibits  EIF2a  phosphatases  improves  survival  of 
SOD1
+/A4V MNs. In contrast, modulation of the XBP1 branch of the UPR pathway had a more 
complicated  effect.  Knockdown  of  XBP1  improved  SOD1
+/A4V  MN  survival  suggesting  that 










ER  Stress  is  Inherent  in  Human  Motor  Neurons  and  Spinal  Cord.  Although  the 
SOD1A4V mutation increased the levels of pEIF2a and of the spliced form of XBP1, we noted 
that, surprisingly control MNs also expressed these markers of an activated UPR, albeit at a 
lower level. This observation led us to hypothesize a novel and relatively simple explanation for 
the selective sensitivity of MNs to the effects of the A4V mutation, which is that MNs in general 
are more sensitive to unfolded proteins and ER stress because the presence of these liabilities 
is a normal and perhaps even constitutive aspect of this neuronal sub-type’s inherent biology. 
To test this hypothesis, we compared the levels of XBP1 splicing in purified, control HUES3 
Hb9::GFP+ MNs with levels found in a range of cell types including astrocytes, ES cells, neural 
progenitors, fibroblasts, Hb9::GFP-negative neurons and ES-derived anterior neurons. Of all the 
cell types examined, only the control MNs displayed detectable levels of spliced XBP1 (Figure 
2.11A). XBP1 splicing was not found at early time points but as the MNs matured in culture, it 
became evident. To test the in vivo relevance of these findings, we compared the levels of 
XBP1 splicing in RNA isolated from control human brain and control spinal cord (n=2; each 
replicate was pooled RNA from 22, non-overlapping, healthy controls). Strikingly, we saw little or 
no evidence for XBP1 splicing in the brain, while in the control spinal cord there was a marked 
and significant accumulation of the spliced transcript (Figure 2.11A). 
We wondered whether this ongoing activation of the UPR pathway was associated with 
Figure 2.10. (Continued) SOD1+/A4V MNs Exhibit Signatures of a UPR and Are Selectively Vulnerable to ER 
Stress Induction (A) GSEA of transcriptional changes in SOD1+/A4V MNs shows strong downregulation 
(normalized enrichment score: 3.31) for genes involved in translational capacity. Horizontal black bars 
represent individual genes with representative examples indicated. Blue or red represents genes that were 
upregulated or downregulated, respectively, in SOD1+/A4V relative to isogenic control MNs. Out of 139 genes 
detected that are annotated as involved in regulation of translation, 130 were downregulated, consistent with 
activation of the UPR pathway. (B) Diagram illustrating the canonical UPR. (C) WB analysis demonstrates 
increased levels of phosphorylated EIF2a, a marker for activation of the UPR pathway, in SOD1+/A4V MN 
cultures. The percentages relative to control samples for each time point are shown. (D) SOD1+/A4V MNs 
exhibit increased levels of XBP1 splicing, a marker of ER stress. RNA was isolated from purified Hb9::RFP 
MNs after 15 days in culture (n = 3, ±SEM, p < 0.05). U, unspliced; S, spliced. (E) Experimental strategy used 
to assess the contribution of XBP1 and ATF4 in the survival of SOD1+/A4V MNs.  (F) Knockdown of ATF4 and 
XBP1 in human motor neuron cultures after 30 days. (G) SOD1+/A4V MN numbers selectively increase after 
XBP1 knockdown, while ATF4 knockdown significantly decreases numbers in both control and SOD1+/A4V 
cases (n = 3, m > 9,800 and m > 8,500, ±SEM, p < 0.05). (H) Salubrinal has a modest but positive effect on 
survival of SOD1+/A4V MNs (n = 2, m > 10,000, ±SEM, p < 0.05). 
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an increased sensitivity to agents such as DTT that unfold proteins and increase levels of ER 
and oxidative stress. To test this, we prepared control MNs, fetal astrocytes and fibroblasts and 
subjected  them  to  an  acute  challenge  with  DTT.  Strikingly,  MNs  exhibited  a  greater 
susceptibility  to  DTT  administration  than  the  other  cell  types  (Figure  2.11B)  (n=3,  P<0.05). 
Given  that  the  largest  A4V  MNs  were  most  predisposed  to  cell  death  (Figure  2.3K),  we 
wondered whether these MNs would also be more sensitive to the effects of DTT. When we 
analyzed  the  area  of  the  soma  of  MNs  we  found  that  the  average  soma  size  decreased 
substantially  after  treatment  (Figure  2.11C),  which  given  the  acute  nature  of  the  treatment 
seemed most consistent with death of the largest MNs. 
These observations prompted us to investigate whether MN size correlated with basal 
ER stress levels. To address this question we generated control Hb9::RFP MNs and after 15 
days, FACS-purified them as well as separated large and small MN populations (Figure 2.11D). 
The effectiveness of this approach in separating MNs based on size was validated by re-plating 
a sub-set of the FACS-purified MNs and measuring their soma sizes (Figure 2.11E). We then 
isolated RNA from the large and small populations and examined the levels of spliced XBP1 as 
an indicator of ER stress. Larger MNs showed significantly higher levels of spliced XBP1 than 
smaller ones (Figure 2.11F) suggesting that an increased constitutive ER stress may contribute 




Hyperexcitability in Motor Neurons expressing SOD1 A4V. Previous nerve 
conduction studies evaluating axonal threshold (strength-duration time constant and recovery 
cycle times) in ALS patients demonstrated increased axonal membrane excitability
54,55, and the 
degree of hyperexcitability correlated with ALS patient survival
56. These data indicate that 
increased membrane excitability may be important as a contributor to the disease, and modeling 
suggests that either increased persistent sodium or reduced delayed-rectifier potassium 
currents could be responsible for the axonal hyperexcitability
55,57. However, whether the 
excitability results from changes in the autonomous properties of the motor neurons themselves 
Figure 2.11. (Continued) Human MNs Exhibit Increased Levels of Basal ER Stress that Are Dependent on 
Their Physiological Activity. (A) Purified Hb9::GFP control MNs show higher levels of spliced XBP1 relative 
to other human cell types. Human spinal cord RNA also shows higher levels relative to brain RNA. U, 
unspliced; S, spliced. (B and C) Control MNs are more vulnerable to acute ER stress induction (DTT, 2 mM) 
relative to fibroblasts or astrocytes (B), while (C) DTT treatment leads to a reduction in MN soma size (n = 
2, ±SD, p < 0.05). (D) Experimental strategy used to isolate MNs based on cell size. Control MN cultures 
were infected with the Hb9::RFP virus on day 5. On day 15, RFP+ MNs were FACS purified and sorted by 
size to achieve separation of small and large cells. A subset of cells (E) were replated to ensure 
confirmation of soma size by the measurement of MAP2+ cell bodies. (F) Basal levels of XBP1 splicing 
were assessed in RNA isolated from the remaining purified MNs, which showed that larger MNs had higher 
levels of spliced XBP1 than smaller ones did (n = 3, ± SEM, p < 0.05). 
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cannot be determined by this technique
58. 
To test the excitability of our stem cell derived MNs we used multi-electrode arrays 
(MEAs) to measure the firing properties of our cultures. Because substantial motor neuron 
death begins in ALS motor neurons after 15 days of neuronal maturation in our culture 
conditions, we compared MEA recordings of SOD1
+/+ and SOD1
+/A4V motor neurons after a 
shorter culture time (14 days), to avoid the possibility that increased firing might reflect either 
neuronal death or a select group of surviving hyperexcitable neurons. While the baseline spike 
rate was lower at 14 compared to 28 days, SOD1
+/A4V neurons had a far higher spontaneous 
firing rate than SOD1
+/+ neurons (p=0.01 for total rate, t-test; Figure 2.12A; average mean firing 
rate 1.30 ± 0.10 Hz for n=122 SOD1
+/+ and 1.50 ± 0.08 Hz for n=208 SOD1
+/A4V; p<0.05, t-test). 
Because the genetically corrected controls were less excitable, we conclude the 
hyperexcitability phenotype reflected the necessity of the disease-initiating mutation and 
preceded the progressive motor neuron death.  After establishing the hyperexcitability of motor 
neurons expressing the SOD1 A4V variant we wanted to evaluate the robustness of this 
phenotype in other familial forms of ALS.  To accomplish this goal we used MEAs to record the 
firing properties of MNs derived from patients with SOD1, FUS, and C9orf72 mutations as well 
as a large group of controls.  We found the spontaneous action potential firing was significantly 
increased in all mutant cases (Figure 2.12D ANOVA p < 10
-7; Tukey’s post hoc test for control 
versus SOD1 p < 0.01, control versus C9orf72 p < 0.01, control versus FUS p < 0.05)
  
demonstrating the broad nature of the increased excitability phenotype in familial ALS. 
The MEA recordings demonstrated an important physiological phenotype in MNs derived 
from ALS patient iPSCs.  We therefore wanted to probe the neuronal firing properties with patch 
clamp techniques to gain a more in depth understanding of the mutant MNs hyperexcitability. 
When we compared the motor neurons derived from the SOD1
+/A4V and their isogenic control 
cell lines in three parallel patch experiments, we observed a marked difference in the number of 
action potentials elicited during ramp depolarization (p<0.05, Mann-Whitney U test; Figure 67 
 
2.12B). There was substantial variability in the number of action potentials in motor neurons 
from the same line tested across multiple differentiations, but the increased number of action 
potentials in ALS motor neurons relative to control motor neurons was preserved. This result 
underscores the importance of performing repeated parallel differentiations in which equal 





In addition to quantifying the electrical excitability of individual neurons, patch clamp 
recording enables quantitative investigation of the specific currents that determine excitability. 
To identify the electrophysiological mechanisms responsible for the increased firing of the 
mutant motor neurons, we performed voltage-clamp experiments using HB9::RFP-positive 
motor neurons to examine different current components. As an index of excitatory and inhibitory 
voltage-dependent ion channels, we quantified the ratio of outward delayed-rectifier potassium 
current to inward transient sodium current. In four repeated differentiations of motor neurons 
from the control and SOD1
+/A4V isogenic iPSC lines, we observed that the ratio of delayed-
rectifier potassium to transient sodium current was consistently smaller in the SOD1
+/A4V motor 
neurons (p<0.001, t-test; Figure 2.12D-F). The difference appeared to be driven primarily by the 
reduced delayed-rectifier potassium channel component, as the difference in steady-state 
potassium current amplitude normalized to individual cell capacitance between SOD1
+/A4V and 
SOD1
+/+ yielded an increase in the relative steady-state delayed-rectifier potassium current 
amplitude in the SOD1
+/+ derived MNs (p<0.005, t-test; Figure 2.12D). We found a marked 
reduction in delayed-rectifier current magnitude in the SOD1
A4V/+ compared to their isogenic 
control motor neurons (p< 0.05, t-test; Figure 2.12E) but no difference in measured sodium 
Figure 2.12 (Continued) Physiological recordings reveal increased excitabiilty in SOD1A4V/+ MNs.(A) Total action 
potential ﬁring rate during 1 min of recording from MEAs cultured for 14 days on the arrays (SOD1+/+, n = 4; mean 
775 ± 712 spikes/min; 39b, n = 4; SOD1+/A4V mean 6,278 ± 1,758 spikes/min; p = 0.01, ttest). Error bars 
represent SEM. (B) Representative current clamp recordings during ramp depolarization from control and ALS 
patient-derived motor neurons. (C) Separate experiments showing average number of action potentials during 
ramp depolarization from SOD1+/+ (n=17; mean 4.1±0.5) and SOD1+/A4V (n=19; mean 6.4±0.9) motor neurons 
from three additional differentiations (p<0.05, Mann-Whitney U test). (D) Multielectrode array recordings of motor 
neurons derived from control (11a, n = 8; 15b, n = 2; 17a, n = 5; 18a, n = 7; 18b, n = 10; 20b, n = 6), SOD1 (25b, 
D90A, n = 3; 27d, G85S, n = 7; 39b, A4V, n = 3; RB9d, A4V, n = 7), C9orf72 expansion (19f, n = 2; RB8B, n = 13) 
and FUS (MGH5b, frame shift mutation at residue 511, n = 10; RB21, H517Q, n = 4) subjects cultured for 14 days. 
ANOVA, p < 10-7; Tukey’s post hoc tests for control versus SOD1 p < 0.01, control versus C9orf72 p < 0.01, 
control versus FUS p < 0.05. For subject 18, motor neurons from two different iPSC lines were recorded. Error 
bars are 95% conﬁdence interval. (E) Experiments from three separate differentiations showing averaged delayed-
rectiﬁer steady-state potassium current amplitude relative to peak sodium current  amplitude in SOD1+/+ (n=18;  
mean 0.54±0.061) and SOD1+/A4V (n = 19; mean 0.32 ± 0.036; p < 0.005,  ttest). (F) Direct measurement of 
delayed-rectiﬁer voltage-gated potassium current isolated by holding at 30mV, stepping to a test-potential of 
+40mV for 2s and normalizing steady state current amplitude to cell capacitance in SOD1+/+ (n=19; mean 42.6 ± 
4.3 pA/pF) and SOD1+/A4V (n=18; mean 30.3 ± 3.1 pA/pF; p<0.05, ttest) derived motor neurons using cells from 
two additional separate differentiations. (G) Peak sodium current amplitude normalized to cell capacitance in 
SOD1+/+ (n=16; mean 400.4 ± 44.7 pA/pF) and SOD1+/A4V (n=15; mean 387.1 ± 50.5 pA/pF; p=0.8, ttest) 
derived motor neurons. Error bars represent SEM. 69 
 
current peak amplitudes between the motor neurons (p=0.8, t-test; Figure 2.12F). Since voltage-
gated potassium channels repolarize the membrane potential back to negative values after an 
action potential, a decrease in such currents likely contributes to the observed increased action 
potential firing in the ALS motor neurons. 
Thus, correction of the deficit in delayed-rectifier potassium current in SOD1
+/+ motor 
neurons may enable repolarization of the membrane potential back to normal hyperpolarized 
values and a reduction of the excitability to levels found in wild-type motor neurons. 
Like most mammalian neurons, motor neurons express many different types of voltage-
activated potassium channels and pharmacological dissection and quantification into distinct 
components is challenging. Regardless of which currents are altered to produce 
hyperexcitability in the diseased motor neurons, Kv7 (KCNQ) channels are particularly attractive 
targets for correcting the hyperexcitability, because of their activation at subthreshold voltages 
and subsequent powerful control of excitability
59. Given this consideration and our finding of 
reduced delayed-rectifier potassium currents in the ALS-derived motor neurons, we 
hypothesized that retigabine, a specific activator of subthreshold Kv7 currents that is an 
effective, clinically-approved anticonvulsant
60, might block hyperexcitability in the SOD1
+/A4V 
motor neurons. In whole-cell patch clamp, we found that retigabine significantly increased the 
minimal current step necessary for action potential generation (rheobase) by 3.6 ± 2.4 pA 
(p<0.05, Wilcoxon signed rank test; Figure 2.13A). Retigabine also stopped the spontaneous 
firing of HB9::RFP-positive motor neurons and hyperpolarized the resting membrane potential 
by 6.0 ± 2.2 mV (p=0.001, t-test; Figure 2.13B). Because these experiments were performed in 
the presence of blockers of glutamatergic, GABAergic, and glycinergic receptors, the reduction 
in excitability caused by retigabine likely resulted from a direct effect on motor neurons. We 
used MEA recordings to determine a dose-response curve for inhibition of spontaneous firing by 
retigabine of SOD1
+/A4V ALS-derived neurons. Retigabine suppressed spontaneous firing in ALS 
neurons with an EC50 of 1.5 µM (Figure 2.13C), a concentration consistent with its 70 
 
pharmacological activity as an anti-epileptic agent in patients and similar to its EC50 for Kv7 
channels
61. In line with this finding, analysis of the RNA-Seq data from the FACS-sorted motor 
neurons confirmed expression of Kv7 channels. 
   
 
 
The efficacy of retigabine allowed us to evaluate the possibility that hyperexcitability is a 
causal factor or upstream modulator of motor neuron degeneration in ALS. We tested the effect 
of retigabine on the survival of control and SOD1
+/A4V motor neurons over the course of 30 days 
in culture. As observed under basal conditions, the loss of SOD1
+/A4V motor neurons was 
Figure 2.13. Retigabine Reduces Motor Neuron Excitability and Increases Survival. (A) Rheobase 
measurements in a 39b Hb9::RFP-positive ALS-derived motor neuron in whole-cell patch clamp before (left) 
and after (right) the application of 10mM retigabine (base line rheobase 4.8 ± 1.5 pA versus post-retigabine 
rheobase 8.4 ± 2.2 pA; n = 11; p < 0.05, Wilcoxon signed rank test). (B) Representative current clamp recording 
showing effect of 10mM retigabine on membrane voltage and spontaneous ﬁring (baseline Vm 60.4 ± 2.9 mV 
versus post-retigabine Vm 66.3 ± 3.6 mV, n = 11; p = 0.001, ttest). In (A) and (B), CNQX (15 mM), D-AP5 (20 
mM), bicuculline (25 mM), and strychnine (2.5 mM) were added to the external solution. (C) Dose-response 
curve for retigabine on suppression of spontaneous action potentials in MEA recording and Hill plot ﬁt of mean 
data from 39b (n = 4) and RB9d (n = 4) with EC50 1.5 ± 0.8 mM. (D) Effect of vehicle (open circles) and 1 mM 
retigabine (ﬁlled circles) treatment from days 14–28 of culture on the survival of Islet-positive, Tuj1-positive 
motor neurons measured at day 30 (total control n = 11; total ALS n = 9; F-test for effect of retigabine on all 
cells p = 3.83 X 10-4; effect of retigabine in ALS motor neurons, red, 25.3% (SD 5.6; ttest p = 6.43 X 10-5); 
effect of retigabine in control motor neurons, black, 6.1% (SD 5.1, p = 0.23). Cell counts are from individual 
wells for four separate differentiations. Error bars represent SEM. 71 
 
greater than that of SOD1
+/+ control motor neurons. Two weeks of treatment with retigabine (1 
µM) increased the number of ALS motor neurons in vitro by 25% (p<10
-4, t-test; Figure 2.13D), 
restoring the number of surviving ALS motor neurons to that of controls. 
 
Inherent ER Stress in Human Motor Neurons is Dependent on Their Physiological 
Activity.  Given  that  the  SOD1
+/A4V  human  MNs  that  we  report  here  are  hyper-excitable  in 
comparison to controls and levels of XBP1 splicing increased as MNs matured (Figure 2.11A), 
we reasoned that a relationship might exist between the inherent ER stress we found in MNs 
and  their  electrophysiological  activity.  Treatment  of  MN  cultures  with  sufficient  tetrodotoxin 
(TTX)  to  effectively  block  action  potentials,  as  measured  by  MEA  recording  (Figure  2.14A), 
significantly reduced XBP1 splicing (Figure 2.14B). Reciprocally, treatment of cultures with the 
glutamatergic agonist kainate, which depolarizes MNs, led to a significant increase in XBP1 
splicing  (Figure  2.14D).  Linopiridine,  a  compound  that  blocks  Kv7  voltage  gated  potassium 
channels
59  and  increased  MN  activity  (Figure  2.14C),  had  a  similar  effect  to  kainate,  in 
increasing XBP1 splicing (Figure 2.14D). Thus, changes in the physiological activity of human 
MN cultures correlated with their levels of ER stress, with decreased or increased firing of action 
potentials  leading  to  lower  or  higher  ER  stress  levels,  respectively.  Consistent  with  these 
findings,  in  SOD1A4V  MNs  we  also  observed  significant  alterations  in  the  transcription  of 
SCNA1 and KCNN3, which encode voltage-gated sodium and potassium channels, which could 
either be contributing or compensating for the changes in motor neuron excitability. 
The  ER  plays  an  essential  role  in  both  neuronal  proteostasis  and  physiology
62  and 
therefore  we  next  assessed  whether  manipulating  the  level  of  ER  stress  would  affect  the 
electrical activity of MNs. Reduction of ER stress levels by treatment with salubrinal, resulted in 
a relative reduction in the number of spikes per minute (Figure 2.14E). Conversely, an acute 
treatment  of  MN  cultures  with  DTT,  which  robustly  induced  XBP1  splicing  (Figure  2.14G), 
resulted in an increase in the number of spikes per minute as measured by multi-electrode array 72 
 
recordings  (Figure  2.14F).  These  two  data  sets  suggest  that  ER  stress,  the  UPR  and  the 
excitability of human MNs are interconnected and can potentially form a ‘vicious’ cycle driven by 
mutant SOD1 that may lead to apoptosis (Figure 2.14H). 
   
 
A Subset of Transcriptional Changes in SOD1
+/A4V are shared in C9orf72 MNs.  We 
have shown that MNs produced from patient-derived iPSCs harboring the SOD1
+/A4V genotype 
exhibit transcriptional changes and disturbances in mitochondrial metabolism and transport as 
well as oxidative and ER-related stress (Figures 2.9-2.11). Furthermore we demonstrated the 
Figure 2.14. ER Stress In Human Motor Neurons Is Linked to Their Physiological Activity (A) TTX reduces the 
Electrophysiological activity and decreases XPB1 splicing (B).  Conversly, Linopirdine increases action potential 
firing (C) and increases XPB1 splicing (D).  Kainate also increases XPB1 splicing.  Treatment with (E) salubrinal 
reduces, while (F) DTT increases action potential firing (n = 3, ±SEM, p < 0.05).  DTT also increases XPB1 
splicing (G). (H) ER stress, the UPR, and electrical activity of MNs are connected. 
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increased  excitability  of  MNs  generated  from  iPSCs  harboring  SOD1,  FUS,  and  C9orf72 
mutations.   This finding  begins to  address the central question  of  whether  mutations  in the 
diverse genes that cause ALS converge on shared molecular pathways. To additionally focus 
on this question, we used two iPSC lines (19, RB8) that carried GGGGCC repeat expansions in 
the C9orf72 locus. Both iPSCs were qualified via a range of assays including the Scorecard 
assay (Figure 2.15A). The presence of the hexanucleotide repeat expansion was confirmed by 
repeat prime PCR in both the parental fibroblasts as well as in multiple passages of the resulting 
iPSC  lines  (Figure  2.15B).  Having  demonstrated  the  ability  of  these  lines  to  effectively 
differentiate into ISL/TUJ1 and HB9/TUJ1 postmitotic MNs (Figure 2.15C), we next sought to 
address whether these MNs exhibited transcriptional disturbances similar to the ones that we 
identified in SOD1
+/A4V MNs. 
In order to reduce artifacts due to line variability we selected six iPSC lines originating 
from  five  different  healthy  individuals
17.  These  control  iPSCs  were  generated  via  the  same 
reprogramming strategy, had an almost identical average age at biopsy to the C9orf72 ALS 
patients  (52.4  Vs  52.5),  and  were  maintained  under  the  same  culture  conditions.  We  then 
differentiated  all  iPSC  lines  into  MNs  and  FACS-purified  Hb9::RFP+  MNs  from  healthy  and 
C9orf72 cultures in multiple biological replicates (n=8 iPSC lines, n=1-5 per line), after 15 days 
of co-culture with glial cells. 
Using  qRT-PCR  we  interrogated  a  subset  of  transcripts  pre-selected  to  be 
representative  of  pathways,  or  cellular  functions,  which  we  had  found  to  be  altered  by  the 
SOD1A4V mutation (Figure 2.15D). These transcripts were selected based on their centrality in 
the  particular  pathway  and/or  the  magnitude  of  their  change  in  transcript  abundance. 
Interestingly, in C9orf72 mutant MNs, we did not detect a significant change in the transcript 
levels of selected genes implicated in electron transport in mitochondria (COX7A2, COX7C, 
ACOT2) but we did detect a significant change in levels of the mitochondrial transporter MTX3, 
suggesting that as in SOD1A4V MNs, mitochondrial function may be affected in C9orf72 MNs. 74 
 
Further supporting this view,  we found that as in SOD1
+/A4V  MNs, C9orf72 MNs exhibited a 





To  determine  whether  intracellular  transport  might  be  impacted  in  C9orf72  MNs,  we 
examined  expression  of  the  two  most  highly  upregulated  motor  proteins  in  SOD1
+/A4V  MNs 
(KIF14  and  DNAH11).  As  in  SOD1
+/A4V  MNs,  we  found  that  expression  of  KIF14  was 
significantly induced in C9orf72 MNs. Although there was a trend towards increased DNAH11 
transcription, it did not reach significance. 
Finally, we analyzed the levels of 4 additional transcripts (DNAJC12, EIF2B3, SCN1A, 
KCNN3) modulated in SOD1
+/A4V MNs to determine whether there was evidence for an unfolded 
protein response and/or shared changes in the expression of channels that might be associated 
with  changes  in  membrane  excitability.  Of  these  transcripts,  3  of  4,  including  both  cation 
channels and the protein chaperone DNAJC12 were transcribed at significantly different levels 
between control and C9orf72 MNs, again supporting the notion that at least a subset of changes 
are shared between MNs of these two types. 
Discussion 
      Transgenic rodent models of ALS have been indispensable for developing hypotheses 
concerning  how  mutant  SOD1  proteins  induce MN  degeneration.  However,  studies  in these 
animals  have  yet  to  yield  an  effective  treatment
10,11.  We  reasoned  that  the  gulf  between 
successful animal studies and more positive clinical outcomes might be bridged with model 
systems that enable hypotheses originating from animals to be validated and extended in the 
context of human MNs bearing patient mutations. Utilizing iPSCs, genome editing and directed 
differentiation,  we  established  a  well-controlled  cell  culture  system  and  interrogated  the 
differential properties of patient-derived and healthy control MNs. Advances in gene targeting 
tools,  which  we  have  employed  here,  allowed  our  studies  of  the  SOD1A4V  variant  to  be 
Figure 2.15. (Continued) Transcriptional Changes Detected in SOD1+/A4V MNs Are Partially Conserved in MNs 
with C9orf72 Expansions (A) Scorecard analysis of pluripotency genes for iPSCs and for three germ layer 
differentiation after 16 days, the red dots indicate values for each of the two lines. (B) Genotyping of samples by 
repeat-primed PCR and allele sizing for C9orf72. Patient samples RB8 and 19 exhibited more than 50 GGGGCC 
repeats. (C) Representative images of MN cultures differentiated from C9orf72 ALS patients (scale bar = 50 
mm). (D) A subset of transcripts found to be differentially expressed in SOD1+/A4V MNs also exhibited 
significant transcriptional changes in MNs derived from C9orf72 (n = 2 lines, n = 8 replicates, ±SEM, p < 0.05) 
compared to a large number of control samples (n = 6 lines, n = 15 replicates, ±SEM, p < 0.05). 76 
 
elevated beyond correlative distinctions between ALS cases and controls
63 to the demonstration 
of  causal  connections  between  this  mutation  and  transcriptional  as  well  as  functional 
phenotypes. 
       Notably, our studies demonstrate that the SOD1A4V missense mutation is necessary to 
cause a pro-apoptotic phenotype in cultured human MNs, restricting their long-term survival. By 
employing  RNA  sequencing,  we  defined  the  transcriptional  differences  between  human 
SOD1
+/A4V  and  isogenic  control  MNs.  Curating  these  data  supported  the  view  that  patient-
specific  ALS  iPSC-derived  MNs  display  hallmarks  of  disease  found  in  both  patients  and  in 
animal models. We identified defects in mitochondrial transport and morphology, oxidative and 
ER-related stress and an activated UPR, all of which were dependent on the presence of the 
SOD1A4V mutation. Importantly, we identified an increase in electrical activity in the mutant 
MNs which could be corrected by the FDA approved drug retigabine.  The use of retigabine to 
block hyperexcitability of the SOD1
+/A4V MNs rescued the survival deficit, implicating the altered 
physiology in the apoptotic phenotype described here. 
       We also found that other cell and neural-types were relatively unaffected by the SOD1 
mutation. However, and as is observed in ALS patients, our molecular and pharmacological 
studies suggest that human MNs were more susceptible to mutant SOD1. We propose that this 
susceptibility  originates  from  a  pre-existing  burden  of  ER  stress  that  we  found  to  be 
constitutively present in normal physiologically active MNs, but absent from a variety of other 
cell-types. It has previously been proposed that combinations of stressors may converge and 
reinforce each other leading to dysfunction and eventual degeneration of vulnerable neurons
64. 
We have found that the unfolded protein response, ER stress and electrical activity of MNs are 
interconnected and could therefore form a ‘vicious cycle’ driven by disease causing mutations 
such as SOD1A4V. Therefore three distinct categories of compounds may be of substantial 
therapeutic benefit to ALS patients by disrupting the ‘vicious cycle’; those that support folding of 
proteins generally, those that specifically aid MNs in handling ER stress, and finally those that 77 
 
reduce  MN  excitability.  Our  studies  with  salubrinal  and  retigabine,  support  this  view.  It  is 
noteworthy that neither treatment with salubrinal, nor knockdown of XBP1 alone resulted in a 
complete rescue of the survival deficit, implying that perhaps ER stress in only one of many 
components that contribute to MN death in our system. 
       While the function of the C9ORF72 protein remains unknown, the mechanism by which 
the hexanucleotide repeat expansion predisposes individuals to ALS has been suggested to 
range from haploinsufficiency to toxic gain-of-function properties of the mutant RNA or protein 
6,65,66. Our studies indicate that MNs derived from patients harboring the repeat expansion are 
hyper excitable and furthermore demonstrated a partial conservation of transcriptional changes 
between SOD1
+/A4V and C9orf72 cases. Of particular note are transcripts reflecting a heightened 
oxidative  stress  response,  reduced  mitochondrial  function,  as  well  as  changes  in  cation 
channels  and  motor  proteins.  Our  discoveries  of  transcriptional  and  functional  aberrations 
particularly in relation to mitochondria and ER stress in these patient-specific iPSC MNs could 
potentially relate to the typically late clinical onset of ALS, as these pathways are known to be 
involved in natural ageing processes. Taken together our work validates the utility of iPSCs and 
genome  engineering  strategies  for  probing  relationships  between  the  genetic  variants 
responsible for ALS in the MNs that selectively degenerate in this disease. 
  
Experimental Procedures 
Cell Culture. Cell cultures were maintained at 37
C, 5% CO
2. Human fibroblasts were 
cultured  in  KO-DMEM  (Invitrogen),  supplemented  with  20%  Earl’s  salts  199  (Gibco),  10% 
Hyclone (Gibco), 1x GlutaMax, (Invitrogen), and 100 M 2-mercaptoethanol and passaged by 
trypsinization  (0.25%  trypsin  EDTA,  Invitrogen).  HuES  and  iPS  cells  were  maintained  on 
Matrigel (BD Biosciences) with mTeSR1 media (Stem Cell Technologies). Media was changed 
every 24 hours and lines were passaged by dispase (Gibco, 1mg/mL in hES media for 30min at 
37
C).  Human  primary  astrocytes  were  purchased  from  Sciencell  Research  Laboratories  and 78 
 
grown according to supplier instructions. 
Derivation of Human Fibroblasts and iPS Cell Generation. Human fibroblasts were 
generated  from  3mm  forearm  dermal  biopsies  following  informed  consent  as  described 
previously
14. Generation of iPS cells was done essentially as reported previously by retroviral 
transduction of KLF4, SOX2, OCT4 and (cMYC)
17. Retrovirus preparations were done at the 
Harvard  Gene  Therapy  Initiative  at  Harvard  Medical  School  (Boston,  MA).  For  iPS  cell 
derivation, 30,000 human fibroblasts were transduced at an MOI of 3-5 per gene, with viruses 
containing all three genes. 
Scorecard Assay. RNA samples were produced and analyzed as described previously 
(Bock et al., 2011) with minor modifications. Whole iPS and ES cell colonies were isolated by 
dispase treatment and plated in suspension in the presence of mTeSR1 media, cell aggregates 
(EBs) were allowed to form and 48hrs later EBs were switched to KOSR media without FGF 
(DMEM/F12, 10% KOSR, NEAA, Glutamax, and 100 M 2-mercaptoethanol). EBs were grown 
for a total of 16 days, at the end of which, cells were lysed and total RNA was extracted using 
Trizol  (Invitrogen).  Subsequently,  RNA  was  analyzed  on  the  NanoString  nCounter  using  a 
custom codeset. The calculation of the iPS lines’ lineage scores were performed according to 
our previously published protocol (Bock et al., 2011) using our published dataset for 20 human 
embryonic stem cell lines as a reference. 
Motor  Neuron  Differentiation.  MN  differentiation  was  carried  out  as  previously 
described
17 with modifications (see also Figure 2.2A). Briefly, pluripotent stem cell colonies were 
dissociated with accutase and single cells were plated in suspension in low-adherence dishes, 
at a 400K/ml density with 10mM ROCK inhibitor (Sigma, Y-27632) in mTeSR media for 24hrs. 
Embryoid bodies (EBs) were formed and media was gradually diluted (50% on day 3 and 100% 
on  day  4)  to  KOSR  (DMEM/F12,  10%  KOSR)  between  days  1-4  and  to  a  neural  induction 
medium  (NIM:  DMEM/F12  with  L-glutamine,  NEAA,  Heparin  (2mg/ml),  N2  supplement 
(Invitrogen) for days 5-24. From days 1-6 cells were cultured in the presence of SB431542 79 
 
(10M,  Sigma  Aldrich)  and  Dorsmorphin  (1mM,  Stemgent),  and  from  days  5-24  with  BDNF 
(10mg/ml, R&D), ascorbic acid (AA, 0.4mg/ml, Sigma), Retinoic Acid (RA, 0.1mM, Sigma) and 
Smoothened Agonist 1.3 (SAG 1.3, 1mM, Calbiochem). At day 24 EBs were dissociated to 
single cells with Papain/DNase (Worthington Bio) and plated onto poly-lysine laminin-coated 
chamber slides/plates/coverslips (BD Biosciences) for relevant experiments. 
Motor  Neuron  Survival  Assay.  After  24  days  of  differentiation,  neuronal  EBs  were 
dissociated and 20K were plated on poly-D-lysine/Laminin coated 8-well chamber slides (BD 
biosciences)  containing  a  confluent  monolayer  of  primary  cortical  mouse  glia.  Primary  glial 
preparations from P0-P2 mouse pups were generated as described previously
17. Fresh glial 
preparations (<1 month, <2 passages) were used. Co-cultures were maintained in Neurobasal 
media (NB, Invitrogen), supplemented with B27 and N2 supplement (Invitrogen), 10mg/mL each 
of BDNF, GDNF, CNTF (R&D) and ascorbic acid (AA, 0.4mg/ml, Sigma) and fed every 2-3 
days. Slides were fixed at various time points (3, 15, 20, 30 days), cultures were stained and 
cell numbers assessed. Whole-well images were quantified in a manner blinded to the genotype 
and condition of the experiment. Neuronal numbers on day 3 were set as 100% and numbers 
on subsequent time points were expressed as a percentage of day 3. To evaluate cell death, 
neuronal cultures were plated without glia on coverslips and live cells were assayed using the In 
Situ Cell Death Kit (Roche Diagnostics) according to manufacturer’s instructions. 
RNA  Preparation,  RT-PCR  and  RNA  Sequencing.  Total  RNA  was  isolated  from 
relevant cell types using Trizol LS (Invitrogen) according to manufacturer’s instructions. MNs 
were differentiated as described above, MN cultures were plated on glial monolayers, infected 
with the Hb9::RFP virus on days 5-7 and FACS was used for purification of RFP MNs on day 
15. A total of 300-1000ng was used to synthesize cDNA by reverse transcription according to 
the iSCRIPT kit (Bio-rad).Quantitative RT-PCR was then performed using SYBR green (Bio-
Rad) and the iCycler system (Bio-rad). Quantitative levels for all genes were normalized to the 
average levels of 3 housekeeping genes: GAPDH/b-Actin/YWHAZ and expressed relative to the 80 
 
relevant  control  samples  or  the  lowest  expressing  sample  in  the  experiment  (see  figure 
legends).  QPCR  for  retroviral  and  endogenous  reprogramming  genes  was  carried  out  as 
previously reported
17. All primer sequences are available upon request. Human spinal cord RNA 
was purchased from Clonetech (#636530) and total human brain RNA was purchased from 
Applied Biosystems (#AM6050). Spinal cord RNA was pooled from 22 male/female Caucasians 
aged between 22-69, while total brain RNA was pooled from 23 male/female Caucasians aged 
between 23-86. For TTX (48hrs), kainate/linopiridine (48hrs) and DTT (2hrs) treatments, co-
cultures were treated, RFP positive neurons were purified and RNA was subsequently isolated. 
For next-generation RNA sequencing, RNA integrity numbers (RIN) above 7.5, determined by 
bioAnalyzer,  were  used  for  library  preparation.  In  brief,  RNA  sequencing  libraries  were 
generated  from  ~250ng  total  RNA  using  the  illumina  TruSeq  RNA  kit  v2,  according  to  the 
manufacturer’s directions. Libraries were sequenced at the Harvard Bauer Core Sequencing 
facility on a HiSeq 2000. All FASTQ files were analyzed using FastQC software (v 0.10.1) to 
confirm that Phred scores were acceptable at all read positions (median Phred score>25 and 
lower quartile>20). The FASTQ files were aligned to the GRCh37/hg19 reference genome using 
Tophat (v 2.0.7). Duplicated reads were removed using Picard Tools MarkDuplicates (v 1.44). 
Differential  expression  testing  was  performed  independently  using  two  separate  analysis 
packages:  Cufflinks  (v  2.1.1)  and  DESeq.  The  Cufflinks  output  was  visualized  with  the 
cummeRbund R package using a false discovery rate of 0.05. For DESeq analysis, gene level 
annotation  count  files  were  first  generated  using  the  HTseq  count  Python  script  (v  0.5.4). 
DESeq  analysis  was  performed  using  the  methods  recommended  by  the  package  authors. 
Gene Ontology term enrichment was determined for significantly differentially expressed genes 
at a false discovery rate cutoff of 0.05 using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7. Gene Set Enrichment Analysis (GSEA, Broad Institute) was 
performed by first creating a pre-ranked gene list of all genes included in differential expression 
testing ordered by log2 fold change. Analysis was performed using the GSEA preranked tool 81 
 
with the REACTOME and KEGG Pathway MSigDB collections. 
Mitochondrial Transport Assays and EM Analysis. After 24 days of differentiation, 
neuronal EBs were dissociated and 20K were plated on poly-D-lysine/laminin-coated 35 mm 
glass bottom culture dishes (MatTek Corporation) or coverslips (BD-Biosciences). Cultures were 
infected with Hb9::RFP lentivirus 5 days after dissociation and MNs were selected based on 
expression of RFP. On days 23-26, MNs were stained with MitoTracker® Green FM (50nM, 
Invitrogen)  and  transferred  to  a  custom  observation  chamber  mounted  on  the  stage  of  the 
microscope. Live microscopy of mitochondrial transport was performed with a Nikon Eclipse Ti 
equipped with an automated stage and In Vivo Scientific incubator. Mitochondrial movements 
were recorded for 5 minutes with 4-second time-lapse intervals using NIS-Elements (Nikon) 
using a 63x lens. Kymographs were generated from each video using NIS-Elements Analyzing 
Software  (Nikon).  Mitochondria  were  considered  motile  if  they  traveled  faster  than  0.017 
µm/second.  The  average  distance  between  mitochondria  was  calculated  excluding  motile 
mitochondria, and the total unoccupied space was divided by total process length analyzed to 
yield the proportion of processes unoccupied by mitochondria. Average distance was measured 
using the top portion of each kymograph using NIS-Elements Analyzing Software (Nikon). For 
Electron  Microscopy  analysis,  MN  cultures  were  fixed  with  2.5%  glutaraldehyde-2% 
paraformaldehyde  in  0.1M  sodium  cacodylate  buffer  (pH  7.4)  and  maintained  at  4° C  O/N. 
Cultures were then postfixed in 1% OsO4-1.5% KFeCN6 for 30 min, washed in water 3x and 
incubated  in  1%  aqueous  uranyl  acetate  for  30mn  followed  by  2x  washes  in  water  and 
subsequent dehydration in grades of alcohol (5min each; 50%, 70%, 95%, 2x 100%). Cells were 
then embedded in plastic and ~60nm thick sections were cut, picked up onto copper grids, 
stained with lead citrate and analyzed in a JEOL 1200EX Transmission Electron Microscope. At 
least 3 independent differentiation experiments were analyzed in each case and pictures were 
taken by a technician blinded for sample IDs. 
XBP1 Splicing Assay. 300ng of RNA was used to generate cDNA. PCR reactions were 82 
 
set up using 2ml of cDNA and premixed Ampligold Taq Polymerase (Applied. Biosystems), at 
66
C annealing. PCR products were analyzed on a 2% low-melting agarose gel. The ratio of 
spliced/unspliced bands was quantified using Image J software. Primers available upon request. 
Gene Targeting. Zinc finger nucleases (ZFNs) were constructed using either the OPEN 
method as described previously
67 or a modified version of OPEN that uses antibiotic resistance 
for the selection as previously described
68. Briefly, pools of ZF pre-selected zinc finger (ZF) 
domains were ligated together to create a combinatorial library of three-3 finger proteins. A 
bacterial two-hybrid-based selection system was used to interrogate the ZF library for proteins 
that could bind the appropriate target sequences of interest. ZF proteins that bound the target 
sequence were cloned into a mammalian expression vector and fused to heterodimeric FokI 
nuclease protein domains to construct ZFNs. Active ZFNs capable of inducing a double strand 
break at the desired locus were identified by screening pairs of nucleases for the capability to 
induce characteristic indel mutations at the SOD1 target site in sequencing the locus of ZFN-
treated HEK 293s. 2.5 million iPS cells of the 39b cell line were accutased and nucleofected, 
using  Human  Stem  Cell  Kit  II  and  program  A-023,  with  1  mg  of  ZFN  plasmid  and  5mg  of 
targeting plasmid.  After nucleofection the cells were plated on matrigel with mTesr and ROCK 
inhibitor. After 48hrs puromycin selection was applied for 1 week after which surviving colonies 
were  passaged  and  gDNA  was  extractedPCR  was  used  to  confirm  proper  targeting  of  the 
cassette. To remove the puromycin cassette 2.5 million cells were nucleofected with 1mg of a 
mammalian expression plasmid containing hygromycin and 5mg of a mammalian expression 
plasmid  containing  the  FLPo  recombinase  and  plated  on  matrigel  with  mTeSR  and  ROCK 
inhibitor. Twenty four hours after nucleofection, hygromycin was added for 48 hours. Colonies 
were allowed to expand for 1 week then picked and genomic DNA was extracted. Sequencing 
of the genomic DNA was used to confirm removal of the puromycin cassette. SOD1 expression 
was verified by qPCR after RNA extraction and cDNA synthesis. PshAI digestion along with 
sequencing of the qPCR product demonstrated loss of expression of the mutant allele. Copy 83 
 
number qPCR using primer SOD1cnF and SOD1cnR was performed as described previously
69 
to rule out random integration events. Primer sequences are available upon request. 
Genome Sequencing and Analysis. DNA samples were derived from the parental 39b 
cell line and the gene corrected clone using phenol chloroform extraction.  The sequencing 
libraries were made with 50ng genomic DNA using the Illumina Nexterra DNA kit.  Deep (30×) 
WGS was performed using the Illumina HiSeq 2500 Platform (500 bp library, 101 bp reads).  All 
subsequent alignments and analysis were performed with hg19 as a reference. To investigate 
whether  there  were  changes  in  copy  number  due  to  the  cell  line  transformation,  we  used 
Genome STRiP
34 to extract and process the read depth signal from the aligned sequencing 
data.    Using  a genome  alignability  mask  of  size  101,  we  segmented the  genome  into  non-
overlapping windows each containing 100Kb of uniquely alignable base positions (based on a 
read length of 101bp). In each window, we computed normalized read depth by counting the 
read  fragments  aligned  within  that  window  with  a  minimum  mapping  quality  of  10  and 
normalized the counts based on genome-wide sequencing depth and correcting for sequencing 
coverage bias due to local G+C content.  This was done separately for the parental and derived 
cell lines. To look for regions of copy number change, we evaluated the ratio of normalized read 
depth in the derived cell line compared to the parental cell line in each window. To find rare 
coding  SNPs  in  ALS  genes,  we  annotated  coding  variants  called  by  Haplotype  caller  with 
SNPeff
70. SNPs classified as missense, silent, or nonsense were retained. We then integrated 
allele frequencies for the European population from the thousand genomes project
71. Variants 
were selected that overlapped target genes for ALS. To find variants that differed between cell 
lines,  we  compared  the  genotypes  of  both  lines  in  a  stringent  manner  similar  to  the 
methodologies used to discover de novo mutations.  For a variant to be confidently different 
between cell lines, we required a read depth of at least 2 and a likelihood score (PL) of at least 
30 across both lines. Homozygous variants were required to have no more than 5% of the reads 
observed from the alternate allele, while heterozygous variants were required to have at least 84 
 
30% of reads observed from the less frequent allele and at most 70% of the reads from the 
more frequent allele.  To examine the off target effects of the designed nuclease, variants within 
the  top  12,000  potential  off  target  nuclease  cut  sites  were  selected  from  this filtered  set of 
confident variants.   
Nanostring Karyotyping. Karyotyping was undertaken using the Nanostring nCounter 
Human  Karyotype  Panel  (Nanostring  Technologies,  USA)  and  performed  as  per  the 
manufacturer’s instructions. In brief, the protocol is as follows: 600 ng of genomic DNA was Alu1 
digested  at  37  ° C  for  2  hours,  before  being  denatur ed  at  95  ° C  for  5  minutes.  To  prevent 
renaturing samples were kept on ice. A total of 300 ng of Alu1-digested DNA per sample was 
mixed with hybridization buffer, capture and reporter codes. Following a 16 hour incubation at 
65 ° C, samples were transferred to a Nanostring Pre p station where hybridized DNA was bound 
to  an  imaging  cartridge  before  imaging.  Using  reference  samples,  a  copy  number  was 
calculated for each chromosome following normalization of the data using nSolver (Nanostring 
Technologies, USA) and Microsoft Excel. 
MEA Recording. After 24 days of differentiation, equal numbers of control and ALS 
neurons were plated on poly-D-lysine/laminin coated p515A probes (Alpha Med Scientific) or 
M768-GLx 12-well plates (Axion BioSystems) at typical densities of 40,000-80,000/ probe or 
well. Adherence to the electrodes after plating over the course of subsequent incubation was 
variable, with occasional migration of neurons off the probes. For that reason, all probes were 
visualized immediately before each recording session to confirm a full monolayer of cells. Initial 
experiments (11a, 18a, 39b, and RB9d comparison) were performed as close as possible to the 
time of patch recordings (4 weeks). However, because we wished to evaluate firing at a time 
point prior to significant motor neuron death (Kiskinis et al., cosubmission), we performed 
subsequent experiments (39b-Cor and 39b comparison and all later experiments) at day 14 
after dissociation. 
   Recordings from 64 extracellular electrodes were made using a Med64 (Alpha Med 85 
 
Scientific) or Maestro (Axion BioSystems) MEA recording amplifier with a head stage that 
maintained a temperature of 37° C. For Med64 recordi ngs, data were sampled at 20 kHz, 
digitized, and analyzed by spike clustering and spike extraction algorithms using Mobius 
software (Alpha Med Scientific) with a 2 kHz 9-pole Bessel low pass filter, 10 µV action 
threshold detection limit, and 30% cluster similarity radius. These standard settings were 
maintained for all analyses. We confirmed that we obtained similar results across a wide range 
of action potential threshold and cluster similarity radius settings. Cross-correlation analysis to 
detect and correct for clusters detected by multiple electrodes was performed using custom 
Matlab software. Total action potential firing rates and mean neuronal firing frequencies were 
then determined and plotted. In order to record in larger replicates, we used the Axion Maestro 
MEA device, in a 12-well format with 64 extracellular electrodes in each well. For Maestro 
recordings, data were sampled at 15 kHz, digitized, and analyzed using Axion Integrated Studio 
software (Axion BioSystems) with a 200 Hz high pass and 2500 kHz low pass filter and an 
adaptive spike detection threshold set at 5.5 times the standard deviation for each electrode 
with 1 second binning. These standard settings were maintained for all Axion MEA recording 
and analysis. 
   For retigabine dose response curves, action potential numbers during one minute of 
recording in each concentration of retigabine were normalized to the initial action potential 
number during one minute of recording in standard extracellular saline solution. The EC50 value 
was determined by fitting the mean normalized data values to the Hill equation, y = 1/((EC50/x)
 
nH+1) where nH is the Hill coefficient. 
   Patch Electrophysiology. Whole-cell patch recordings were performed on iPS-derived 
motor neurons identified by transduction with an HB9::RFP lentivirus. Lentiviral transduction 
was typically performed 7-10 days before recording. Two large comparisons were performed, 
one consisting of 11a, 18a, 39b, and RB9d, and the second consisting of 39b-Cor and 39b. 
Each comparison was made from pooled data from multiple separate experiments, each 86 
 
consisting of synchronous and parallel iPSC culture and differentiation, embryoid body 
dissociation, plating and maturation of control- and ALS-derived neurons. Equal numbers of 
control and ALS motor neurons were recorded from each experiment. Comparison of the 
original four lines (11a, 18a, 39b, and RB9d) was made using four separate parallel 
differentiation experiments, while comparison of the isogenic correction comparison (39b-Cor 
and 39b) was performed using three separate parallel differentiation experiments. 
   For each experiment, neurons from control and ALS lines were dissociated after 24 days 
of differentiation and plated onto poly-d-lysine/laminin coated glass coverslips (20,000-
40,000/coverslip) and allowed to mature for four weeks from start of differentiation. We chose 
four weeks as the best timepoint because this yielded the most homogeneous population of 
mature-appearing HB9::RFP-positive motor neurons (at the requisite low cell density for patch 
clamp) with the most mature electrophysiological properties. Whole-cell current-clamp and 
voltage-clamp recordings were performed using a Multiclamp 700B (Molecular Devices) at room 
temperature (21-23° C). Data were sampled at 20 kHz  and digitized with a Digidata 1440A A/D 
interface and recorded using pCLAMP 10 software (Molecular Devices). Data were low-pass 
filtered at 2 kHz. Patch pipettes were pulled from borosilicate glass capillaries on a Sutter 
Instruments P-97 puller and had resistances of 2-4 MW. The pipette capacitance was reduced 
by wrapping the shank with Parafilm and compensated for using the amplifier circuitry. Series 
resistance was typically 5-10 MW, always less than 15 MW, and compensated by at least 80%. 
Neurons were excluded from analysis if holding current at -80 mV exceeded 100 pA, input 
resistance was less than 250 or greater than 2000 MW, or spikes elicited from -65 mV had 
peaks below 0 mV. Resting membrane potential was determined by averaging for 20s of 
recording, and afterwards a small holding current (typically with amplitude less than 5 pA) was 
used to clamp the resting membrane potential as close as possible to -65 mV. Rheobase was 
measured by applying 1 s steps in increments of 2.5 pA until an action potential was generated. 
Current ramps were elicited from an initial hyperpolarizing current of 10 pA for 1 s followed by a 87 
 
210 pA/s depolarizing ramp of duration 1 s. Spikes on the ramps were counted if the peak 
voltage exceeded -10 mV. Action potential properties were determined using custom-written 
analysis software in Igor Pro (Wavemetrics) with DataAccess (Bruxton) for importing the files. 
For voltage-clamp recordings, voltages were elicited by 100-ms depolarizing steps from a 
holding potential of -80 mV to test potentials ranging from -80 mV to 50 mV in 10 mV 
increments. For the latter gene correction experiments the step length was increased to 200 ms 
to assay delayed-rectifier currents after more complete decay of transient potassium currents. 
For retigabine patch applications, resting membrane potential was recorded immediately before 
and 10 seconds after the application of 10 µM retigabine (in each case, membrane potential 
was an average of values sampled for 20 seconds).  For all patch experiments, series 
resistance was monitored by brief -5 pA hyperpolarizing steps during current clamp recordings 
and by 5 mV hyperpolarizing steps during voltage clamp recordings. Electrode drift was 
measured at the end of each recording and was typically 1-2 mV. The extracellular solution was 
sodium-based and contained 135 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 
glucose, 10 mM HEPES 10, pH 7.4. The intracellular solution was potassium-based and 
contained 150 mM KCl, 2 mM MgCl2, 10 mM HEPES, 4 mM MgATP, 0.3 mM NaGTP, 10 mM 
Na2PhosCr, 1mM EGTA, pH 7.4. For isolation of delayed-rectifier potassium channels, 300 nM 
TTX and 100 µM CdCl2 were used to block voltage-gated sodium channels and voltage- and 
calcium-activated potassium channels, respectively. For isolation of voltage-gated sodium 
currents, internal KCl was replaced by CsCl to block potassium currents and 100 µM CdCl2 was 
used to block calcium currents. 
Treatments  with  Small  Molecules  and  siRNAs.  For  ER  stress  induction,  human 
fibroblasts  and  human  astrocytes  were  treated  with  Dithiothreitol  (DTT)  (2mM)  (Bio-Rad 
Laboratories) for 2hrs washed with PBS and either fixed, stained and evaluated or trypsinized 
for RNA/protein collection. For analysis of SOD1 protein, MN cultures were treated with vehicle 
or 1mM MG132 for 48hrs. For assessing the role of XBP1 (s14913) and ATF4 (s1702) 40nM of 88 
 
siRNA  (Ambion)  was  transfected  into  MN  cultures  using  siRNA-Select  in  Optimem  on  days 
10/20 and knockdown levels and survival were assessed on day 30.   
Immunocytochemistry.  Cell  cultures  were  fixed  in  4%  PFA  for  15minutes  at  4° C, 
permeabilized with 0.2% Triton-X in PBS for 45 minutes and blocked with 10% donkey serum in 
PBS-T (Triton 0.1%). Cells were then incubated in primary antibody overnight and secondary 
antibodies for 1 hour in 2% donkey serum in PBS-T after several washes in between. DNA was 
visualized by a Hoechst stain. The following antibodies were used: Primary antibodies used in 
this study are TRA1-81 (1:500, Chemicon, MAB4381), Nanog (1:500, R&D, AF 1997),  Islet1 
(1:200,  DSHB,  40.2D6),  HB9  (1:100,  DSHB,  MNR2  81.5C10-c),  ChAT  (1:100,  Chemicon, 
AB144P),  TUJ1  (1:1000,  Sigma,  T2200),    MAP2  (1:10000,  Abcam  ab5392),  BrdU  (3H579, 
Santa  Cruz  Biotechnology,  sc-70441),  Ki67  (1:400,  Abcam,  ab833),  GFP  (1:500,  Life 
Technologies, A10262), SOD1 (1:2000, Agrisera #AS09 540), Hoxa5 and FOXP1 (courtesy of 
Susan  Morton,  Jessell  lab).  Secondary  antibodies  used  (488,  555,  594,  and  647)  were 
AlexaFluor  (1:1000,  Life  Technologies)  and  DyLight  (1:500,  Jackson  ImmunoResearch 
Laboratories). 
Chick Embryo Transplants. HUES3 Hb9::GFP+ MNs were differentiated and one EB 
was placed into the neural tube of a stage 15 chick embryo using a tungsten needle. Embryos 
were harvested after 5 days, fixed and sectioned in paraffin. Sections were immunostained with 
antibodies specific for GFP (rabbit, Abcam) and an HRP-conjugated anti-rabbit antibody (Vector 
labs) and counterstained with hematoxylin. 
Western Blots. For analysis of Phospho-eIF2a protein, cells were lysed in RIPA buffer 
(150mM Sodium Chloride; 1% Triton X-100; 0.5% sodium deoxycholate; 0.1% SDS; 50 mM Tris 
pH  8.0)  containing  protease  and  phosphatase  inhibitors  (Roche)  for  20  min  on  ice,  and 
centrifuged at high speed. Samples containing 20mg of protein were separated by SDS-PAGE 
(NuPAGE®, Life Technologies) and transferred to nitrocellulose membranes. Membranes were 
probed  with  anti-Phospho-eIF2a  antibody  (#3597,  Cell  Signaling  Technology),  and  anti-a-89 
 
Tubulin (abcam, ab4074) and anti-eIF2a (Cell Signaling Technology, #9722) antibodies were 
used as loading and normalizing controls, respectively. For analysis of SOD1 protein, detergent-
soluble  fractions  were  prepared  using  RIPA  buffer  and  detergent-insoluble  fractions  were 
obtained  using  UREA  buffer  (8M  UREA;  4%  CHAPS;  40  mM  Tris;  0.2%  Bio-Lyte®  3/10 
ampholyte).  5mg of detergent-soluble and equivalent volumes of detergent-insoluble protein 
samples  were  separated  by  SDS-PAGE  (Bio  Rad  Laboratories),  transferred  to  PDVF 
membranes  and  probed  with  anti-SOD1  antibody  (Agrisera  #AS09  540)  and  anti-a-Tubulin 
(Sigma  Aldrich  #  T6199).    For  mitochondrial  biogenesis  analysis,  6ug  of  detergent  soluble 
protein samples were analyzed using the MitoBiogenesis
TM Western Blot Cocktail (ab123545). 
Statistical analysis. Statistical significance was assessed by a standard Students T test 
(1 tail & 2 tail); P<0.05 was considered significant. Two-tailed, unpaired tests were used except 
to confirm specific hypotheses, in which case one-tailed, unpaired tests were used. Error bars 
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  For decades, the study and development of novel therapeutics for neurodegenerative 
diseases  have  been  stymied  by  difficulties  accessing  the  specific  types  of  neuronal  tissues 
which degenerate in these conditions
1. Pluripotent stem cell technology holds great promise for 
ameliorating this problem, theoretically allowing for the production of an unlimited supply of the 
affected  cell  type,  as  well  as  patient-specific  cell  lines  containing  mutations  which  may 
predispose an individual toward the development of neurodegenerative pathology
1. 
  Amyotrophic  Lateral  Sclerosis  (ALS)  is  the  most  common  adult  motor  neuron  (MN) 
neurodegenerative  disorder
2.  Spinal  and  cortical  MNs  are  the  primary  cell  types  which 
degenerate  during  ALS  disease  progression,  leading  to  paralysis  and  eventually  death
2.  To 
date, mutations  in  over  20  genes  have  been  identified  which  can  result  in  familial  forms of 
ALS
2,3, the first of which was found in SUPEROXIDE DISMUTASE 1 (SOD1). SOD1 is a free 
radical scavenger expressed widely throughout the body
3. A mouse model overexpressing a 
mutated version of human SOD1 displays many of the pathologies found in patients, and has 
been  used  extensively  to  understand  the  disorder
4.  This  mouse  model  has  been  extremely 
valuable for studying ALS, resulting in several novel insights about the disease
5,6. However, the 
mutant protein must be expressed well above normal physiological levels for phenotypes to 
develop
7. Furthermore, drugs found to be efficacious in the animal model have failed in human 
clinical trials
8, suggesting an incomplete concordance between the mouse model and human 
patients, and motivating the development of ALS models using human cell lines.  To address 
this concern, we and others have demonstrated the application of human pluripotent stem cell 
technology for modeling ALS, providing an in vitro human system in which to discover disease 
relevant phenotypes and test possible therapeutics
9. 
  Our earlier studies reported on the establishment of many in vitro phenotypes which 
were dependent on the SOD1 A4V mutation
9. Specifically, we used gene targeting to correct the 
mutation, and demonstrated the requirement of mutated SOD1 for the development of several in 98 
 
vitro phenotypes including malformed mitochondria, reduced MN survival, increased neuronal 
excitability, and increased ER stress
9.  We wanted to delve deeper into the in vitro phenotypes 
we previously described by working toward improved understanding of two specific areas. 
 First, while gene correction was used to determine the necessity of the A4V mutation for 
the development of the phenotypes described in Chapter 2
9, a single cell line was corrected, 
leaving open the possibility that the patient-specific iPSC line used for gene correction had other 
unknown modifying mutations which led to more dramatic phenotypes in vitro. To determine 
which phenotypes may have broader penetrance and therefore may be more clinically relevant, 
we aimed to further probe the effect of the SOD1 A4V mutation on stem cell-derived MNs, 
specifically  determining  the  sufficiency  of  this  mutation  for  the  development  of  the  in  vitro 
phenotypes by introducing the mutation into a control ES cell genetic background. Because the 
hES  cell  line  was  not  derived  from  patient  tissue  with  any  clinical  history  of  ALS,  it  should 
provide an unaffected control genetic background in which to induce the SOD1 A4V mutation
10.   
Second, while the degeneration of MNs is the primary cause of patient death, other cells 
types have been implicated in ALS disease progression
11,12. This non-cell autonomous aspect of 
the disorder can lead to complications when studying the disease with pluripotent stem cell 
technology,  as  current  in  vitro  differentiation  protocols  produce  a  panoply  of  cell  types  in 
addition  to  the  specific  cell  type  of  interest
13.  When  purely  cell-autonomous  aspects  of  the 
disease are to be studied, it would be ideal to isolate the MNs away from any other neuronal 
byproducts which could be expressing the mutation being studied, and therefore could have a 
non-cell  autonomous  role  in  degeneration  of  the  MNs
1.  To  address  this  limitation,  we  used 
nuclease assisted gene targeting to induce the SOD1 A4V mutation in a previously described 
reporter  hES  cell  line  (Hues3  HB9:GFP)
14.    This  cell  line  harbors  a  transgenic  construct 
(HB9:GFP) enabling the transcription of GFP to be controlled by the motor neuron specific HB9 
promotor
14.  Using gene targeting to introduce the A4V mutations into the Hues3 HB9:GFP cell 
line allowed for the purification of MNs from heterogeneous neuronal differentiations of isogenic 99 
 
control and SOD1
A4V/WT pluripotent cell lines. 
  The  current  chapter  will  describe  the  use  of  a  combination  of  gene  targeting  and  a 
reporter  hES  cell  line  to  address  the  questions  described  above,  and  demonstrate  the 
sufficiency of the SOD1 A4V variant to drive the accumulation of abnormal mitochondria and 
increased  neuronal  excitability.  Furthermore,  we  used  transcriptional  profiling  by  RNA 
sequencing to probe the MN transcripts for proximal targets which may be responsible for the 
increase in neuronal excitability observed in MNs expressing the SOD1 A4V variant. Lastly, 
using  transcriptional  profiling,  we  made  initial  attempts  at  discovering  specific  target  genes 
which, when modulated by siRNA, can result in increased neuronal excitability. 
Results 
Induction of SOD1 A4V mutation in control hES cell line. To introduce the SOD1 
A4V mutation into the previously validated Hues3 HB9::GFP SOD1
WT/WT reporter cell line
14, we 
used  similar  techniques  and  reagents  as  described  previously  in  Chapter  2  of  this  thesis
9.  
Briefly,  a  targeting  plasmid  was  constructed  containing  a  FRT  flanked  puromycin  cassette 
surrounded by 700 bp homology arms for the SOD1 locus (Figure 3.1A). This targeting plasmid 
was introduced into the HuES3 HB9:GFP cell line, along with a plasmid encoding a previously 
described  zinc  finger  nuclease  capable  of  introducing  a  DSB  at  the  SOD1  locus.  The 
introduction of a DSB at the SOD1 locus stimulated homologous recombination between the 
genomic and plasmid DNA, resulting in the incorporation of the SOD1 A4V variant along with 
the puromycin cassette under the control of the PGK promotor to identify successful targeting 
events by antibiotic selection. This gene targeting strategy resulted in the production of several 
puromycin-resistant stem cell colonies which were picked and allowed to expand.  PCR followed 
by  sequencing  and  restriction  fragment  length  polymorphism  (RFLP)  analysis  for  a  unique 
PshAI site were used to identify properly targeted colonies (Figure 3.1B and C).  Two correctly 
targeted stem cell lines from independent targeting experiments were chosen for excision of the 
puromycin cassette which from here out will be described as Hues3 SOD1
KO/WT ZFN_1 and 100 
 
Hues3  SOD1
KO/WT  ZFN_2.    Separate  expression  plasmids  containing  the  site  specific 
recombinase FLPo and Hygromycin expression cassettes were co-transfected into the positive 
stem  cell  lines  and  hygromycin  was  applied  to  select  for  cells  which  were  successfully 
transfected. Resistant colonies were picked and expanded, and PCR followed by RFLP analysis 
was used to confirm the removal of the puromycin cassette (Figure 3.1B and C). Single colonies 
derived  from  Hues3  SOD1
KO/WT  ZFN_1  and  Hues3  SOD1
KO/WT  ZFN_2  which  had  their 
puromycin cassettes removed were named Hues3 SOD1
A4V/WT ZFN_1 and Hues3 SOD1
A4V/WT 
ZFN_2 respectively. Because the puromycin cassette was integrated into the first intron of the 
SOD1 locus during the first step of the gene targeting, transcription and translation of the full 
length SOD1 mRNA and protein were inhibited in the SOD1
KO/WT cell lines.  Western blotting 
and qPCR of the parental Hues3 SOD1
WT/WT, Hues3 SOD1
KO/WT ZFN_1, and Hues3 SOD1
A4V/WT 
ZFN_1  confirmed  the  reduction  in  SOD1  expression  when  the  puromycin  cassette  was 
introduced into the SOD1 locus and the subsequent re-establishment of SOD1 transcript and 




While the fidelity of the ZFNs used in this experiment have been previously validated by 
whole genome sequencing
9, we decided to generate additional stem cell lines which could be 
used to demonstrate the sufficiency of the A4V mutation and alleviate the concern of off target 
mutations introducing modifying mutations elsewhere in the genome.  To derive these important 
controls cell lines we took two strategies. First, using a very similar gene targeting strategy as 
described previously we corrected the A4V mutation from Hues3 SOD1
A4V/WT ZFN_1, effectively 
Figure 3.1. The SOD1 A4V mutation was introduced into a control hES cell line. (A) Diagram of gene targeting 
strategy. (B) Sequencing of SOD1 locus and RFLP analysis for a unique PshAI restriction site (C) confirmed 
correct targeting of SOD1. (D) qPCR of the gene  targeted stem cell lines demonstrated reduced levels of the 
SOD1 transcript and protein (E) in the intermediate Hues3 SOD1KO/WT ZFN_1 cell line which are restored in 
the Hues3 SOD1A4V/WT  ZFN_1 cell line. 102 
 
reverting the cell line to the original SOD1 WT genotype and establishing a second control cell 
line, from here on referred to as Hues3 SOD1
WT/WT ZFNcorr_1 which can be used to determine 
the  impact  of  any  off  target  mutations  introduced  during  the  gene  targeting  process  by 
comparing Hues3 SOD1
WT/WT ZFNcorr_1 to the original untargeted Hues3 SOD1
WT/WT cell line 
(Figure  3.2A).    This  time,  for  the  editing  of  the  SOD1
A4V  allele  we  used  the  Dre/ROX 
recombination system to remove the puromycin resistant cassette rather than the FLPo/FRT 
system used previously due to difficulties in re targeting SOD1 when the FRT site is already 
integrated at the genomic locus (data not shown).   
Our second strategy was to generate an additional cell line in which the SOD1 A4V 
mutation was introduced using a different site specific nuclease technology. Recently, the use of 
the  bacterially  derived  CRISPR/Cas9  system  has  been  employed  to  generate  site  specific 
DSBs
15,16. This nuclease technology is directed to the chosen genomic loci by co-introducing a 
guide  RNA  (gRNA)  construct  which  is  loaded  into  the  Cas9  protein
16.    The  Cas9/gRNA 
riboprotein complex is then directed to the genomic loci which is complementary to a 20 base 
pair region of the gRNA
16.  The Cas9 protein then introduces a DSB through its endogenous 
nuclease activity
16.  By altering the 20 bp sequence of the gRNA which directs the Cas9 protein 
to genomic DNA it is possible to target virtually any loci within the genome
16,17.  Furthermore, by 
using a semi-catalytically inactive Cas9 protein it is possible to introduce a single stranded nick 
at a chosen genomic loci
17.  The use of the Cas9 nickase allows for efficient gene targeting 
while  also  limiting  the  possibility  of  introducing DSB  at  off target  sites within  the  genome
17. 
Using ZFN and Cas9/CRISPR nuclease technologies to generate separate clones harboring the 
same introduced mutation should reduce the possibility of common off target mutations driving 
any phenotypes.  We designed gRNAs that would allow for the introduction of a DSB near the 5’ 
of  the  SOD1  locus  using  CRISPR/Cas9  technology.    The  same  gene  targeting  strategy 
described above was used to induce the A4V mutation with CRISPR/Cas9 technology except 
the Cas9 nickase was introduced in the cells to stimulate HR rather than the previously used 103 
 
ZFN. Several puromycin resistant colonies were established using the Cas9 nickase technology 
and  one  was  chosen  for  puromycin  cassette  removal.  After  isolation  of  colonies  no  longer 
containing the puromycin cassette a single cell line was chosen for further experiments, here on 
referred to as Hues3 SOD1
A4V/WT Cas9n_1.  PCR followed by sequencing and RFLP analysis 
were used to confirm correct targeting of the SOD1 locus (Figure 3.2B and C).  The transcript 
levels of SOD1 in the gene targeted cell lines were queried by qPCR to demonstrate expression 
from the targeted SOD1 locus (Figure 3.2D). 
 
 
Currently  we  are  using  whole  genome  sequencing  to  identify  potential  off-target 
mutations and determine the stability of the genomes in the parental Hues3 SOD1
WT/WT, Hues3 
SOD1
KO/WT ZFN_1, Hues3 SOD1
A4V/WT ZFN_1, Hues3 SOD1
A4V/WT ZFN_2, Hues3 SOD1
WT/WT 
ZFNcorr_1, and Hues3 SOD1
A4V/WT Cas9n_1 cell lines (Figure 3.3). 
Figure 3.2. Gene targeting of additional cell lines for isogenic controls. (A) Diagram of the targeting strategy. 
Sequencing (B) and RFLP (C) analysis was used to confirm correct targeting of the SOD1 locus.  The SOD1 






Purification of Functional MNs from Isogenic hES Cell Lines. To generate MNs from 
the parental Hues3 SOD1
WT/WT and Hues3 SOD1
A4V/WT ZFN_1 gene targeted stem cell lines, we 
subjected them to a previously described
9,18 24 day EB MN differentiation protocol based on six 
days of dual SMAD inhibition to convert the stem cells to neural progenitors
19 and the addition of 
RA and SAG for MN specification (Figure 3.4A).  On day 24, the cultures were dissociated and 
FACS was used to analyze the cultures for GFP fluorescence. As described previously
14, when 
compared to cultures where RA and SAG were omitted from the differentiation protocol, we 
found a population of cells which exhibited a clear increase in GFP fluorescence (Figure 3.4B). 
Figure 3.3. Outline of parental and gene targeted hES cells which have been sequenced to over 30X coverage.  
To the left of the dotted line indicates the cells lines which have been sequenced.  To the right of the dotted line 
indicates the targeting steps which were taken to generate the cell lines.  Nuclease = step whereby ZFN or 
Cas9n was used to modify A4V allele, Recombinase = step whereby FLPo or Dre was used to excise Puromycin 
cassette from SOD1 locus.  Each step required clonal isolation. 
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We used qPCR and Western blotting to confirm the expression and translation of SOD1 in the 
differentiated cultures (Figure 3.4C and D).  As shown previously
14, the cells which expressed 
GFP were found to also express Islet1 when queried by immunostaining (Figure 3.4E).  We 
found it was possible to plate the MNs down on poly-d-Lysine and Laminin coated tissue culture 
plates after purification, allowing for the establishment of cultures composed entirely of MNs, 




Figure 3.4. Parental and gene targetd hES cell lines can be differentiated into MNs and purified by FACS.  (A) 
Schematic of EB differenitation protocol with FACS isolation of MNs. There is a clear population of cells which 
express GFP as determined by FACS (B).  The neurons generated from this protocol express the SOD1 
transcript (C) and protein (D).  The GFP-positive cells co stain for ISLET indicating MN identity (E).  The MNs can 
be plated after FACS isolation and maintained as purified MN cultures (F) as determined by live imaging of MN 
cultures stained with a live dye at sequential time points. 
 
b.  c. 
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SOD1  Aggregation.  Aggregation  of  SOD1  is  a  common  pathological  finding  in  ALS 
patients with familial SOD1 mutations
2.  While the clinical significance of these aggregates is 
controversial,  they  are nonetheless  an  important  demonstration  of  the  altered  processing  of 
SOD1 mutant proteins
2.  Our previous findings demonstrated large scale aggregates were not 
necessary for the degeneration of MNs in our culture system however, insoluble SOD1 could be 
observed after treatment with the proteasome inhibitor MG132
9. To determine the sufficiency of 
the SOD1 A4V mutation to alter the solubility of SOD1 within in vitro derived MNs, we generated 
MNs from the Hues3 SOD1
WT/WT and Hues3 SOD1
A4V/WT ZFN_1 cell lines using the 24 day EB 
protocol.  Because it was difficult to generate and FACS purify the required number of MNs 
needed  for  biochemical  studies,  the  unpurified  differentiated  cultures  were  plated  after 
dissociation and allowed to mature for 10 days in vitro. On day 10, the cultures were treated 
with the proteasome inhibitor, MG132, or DMSO as a control.  After 5 days of treatment, soluble 
protein was extracted from the cultures using RIPA lysis and solubilization buffer (Figure 3.5A). 
The cell lysate was then centrifuged and the supernatant was transferred into a separate tube. 
The remaining insoluble protein was washed with PBS, then centrifuged to pellet the protein. 
Urea buffer was then used to solubilize the remaining protein pellet. When western blotting was 
used to probe for SOD1 in the soluble and insoluble protein fractions, we found insoluble SOD1 
was only observed in cultures which were both expressing the SOD1 A4V protein and treated 
with the proteasome inhibitor (Figure 3.5B). While we cannot rule out low levels of insoluble 
SOD1 which could not be detected using our methods, this finding suggests that large-scale 
SOD1 aggregates do not develop in the Hues3 stem cell-derived MNs under normal conditions, 
even when expressing a mutant form of the protein.  This result demonstrated the sufficiency of 
the SOD1 A4V mutation to alter the processing of the SOD1 protein in a similar manner to our 
previous findings using MNs derived from patient specific iPSCs.  Because of the concordance 
of our results from the previous study using patient specific iPSCs
9 and the current study using 





Survival of MNs expressing the SOD1 A4V variant. We previously found that MNs 
derived from patient specific iPSCs harboring the SOD1 A4V mutation exhibited higher levels of 
apoptosis than control MNs
9. Importantly, the reduced survival was rescued upon correction of 
the A4V mutation demonstrating the necessity of the mutation for the diminished survival
9. We 
were interested in determining the impact of the induced SOD1 A4V mutation on the survival of 
MNs derived from the gene targeted hES cell line. We used the parental Hues3 SOD1
WT/WT and 
HuES3 SOD1
A4V/WT ZFN_1 cell lines to generate MNs which were then purified by FACS (Figure 
3.6A).    Removing  all  non-MNs  expressing  the  SOD1  A4V  protein  from  the  cultures  should 
reduce the chances of non-cell autonomous toxicity impacting MN survival. The isolated MNs 
were plated on a monolayer of primary glia and the cultures were fixed and stained for human 
Figure 3.5. Solubility status of SOD1WT/WT and SOD1A4V/WT in neuronal cultures. (A) Diagram of experiment. 
SOD1 accumulates in the insolube protein fraction (B) when neuronal cultures are expressing the SOD1 A4V 
variant and are treated with the proteosome inhibitor MG132. 
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nuclei and TUJ1 on days 3 and 30 (Figure 3.6B). Whole well imaging and automated counting 
was used to determine the number of MNs remaining after 3 and 30 days of culture. A trend for 
reduced survival was found in MNs expressing the SOD1 A4V protein when compared to the 
survival of MNs derived from the control cell line (Figure 3.6C n=4, p=0.09).   
 
 
It is currently unclear why the reduced survival of MNs expressing the SOD1 A4V allele 
was  not  as  prominent  in  this  experiment  when  compared  with  our  previous  findings.    It  is 
possible the initial FACS purification of the MNs sub selects for particularly hardy MNs, as they 
must survive the stressful experience of dissociation and subsequent exposure to high pressure 
in the FACS machine.  Additionally, the use of FACS purified MNs eliminated other cell types 
which could be expressing the SOD1 A4V protein.  In the original MN survival experiments
9, 
other  non-MN  cell  types  expressing  the  SOD1  A4V  protein  may  have  induced  non  cell 
Figure 3.6. There is a trend for reduced survival in MNs expressing the SOD1 A4V variant when compared to 
controls.  (A) Schematic of experiment. (B) Representative images of Human Nuclei and TUJ1 staining at days 3 
and 30.  (C) A non-significant reduction in MN survival is found in the SOD1A4V/WT MNs when compared to WT 
controls. (p = 0.09, n= 4) 110 
 
autonomous toxicity in the MNs, resulting in the observed survival deficit
9. Another explanation 
could be the presence of modifying mutations in the Hues3 genetic background, which confer 
partial  resistance  to  the  apoptotic  effects  of  the  SOD1  A4V  variant
2.  To  address  these 
possibilities, we are currently performing the MN survival assay described in Chapter 2
9 with the 
Hues3  isogenic  cell  lines,  in  which  the  MNs  are  not  FACS  purified  but  instead  the  entire 
differentiated mixture is plated on murine glia and MNs are identified and counted by Tuj1 and 
Islet co-staining.  
RNA Sequencing of EB Derived and Purified MNs Expressing WT or A4V SOD1. 
The  previous  study  using  patient-specific  iPSCs  used  transcriptional  profiling  by  RNA 
sequencing to uncover pathways modulated by expression of the SOD1 A4V protein
9. These 
experiments proved enlightening, but were performed on MNs which had been cultured in the 
presence  of  other  cell  types  which  expressed  the  SOD1  A4V  protein,  leaving  open  the 
possibility that non-MN cell types in the culture could have induced transcriptional changes in a 
non-cell  autonomous  manner
14.  To  eliminate  the  confounding  influence  of  other  cell  types 
expressing the mutant protein in differentiated cultures, we used the parental Hues3 SOD1
WT/WT 
and Hues3 SOD1
A4V/WT ZFN_1 hES cell lines to generate MNs which were then isolated by 
FACS and plated as pure MN cultures on poly-d-lysine and laminin. After 15 days of in vitro 
culture with MN media which had been conditioned in the presence of murine glial cells, RNA 
was extracted from the MN cultures and used to generate libraries which were subjected to next 
generation  sequencing  (Figure  3.7A).  The  sequenced  reads  were  aligned  to  the  human 
genome, and differentially expressed genes were identified by the tuxedo suite of bioinformatics 
tools.  Unsupervised hierarchical clustering segregated the samples based on expression of the 
SOD1  WT  or  A4V  proteins,  demonstrating  that  the  mutant  protein  was  capable  of  driving 




A major question we wanted to answer was how similar the transcriptional differences 
found in the current study would be to our previous RNA sequencing experiments
9.  We found 
the  transcriptional  differences  found  in  the  current  study  were  not  in  concordance  with  the 
altered transcripts found in our previous transcriptional profiling experiments using MNs derived 
from the patient-specific iPSC and its gene corrected control.  While there was no clear overlap 
between  the  two  data  sets  in  regards  to gene by  gene  comparisons, there  were  signals of 
degenerative processes being underway in the current data set when analyzed by Gene Set 
Enrichment Analysis (GSEA)
20.  For example, genes involved in apoptosis and the heat shock 
response were found to be significantly up regulated (Figure 3.7C FDR q-value < 0.01).  As 
stated in regards to the MN survival data, in which there was a nonsignificant trend for reduced 
Figure 3.7. Transcriptional profiling of purified parental Hues3 SOD1WT/WT and Hues3 SOD1A4V/WT MNs. 
(A) Diagram of experiment.  Unsupervised hierarchical clustering separates the samples based on genotypes 
(B).  Gene Set Analysis Enrichment identifies the Apoptosis pathway and Heat Shock Proteins as being 
significantly upregulated (C) (FDR q-value < 0.01). 112 
 
survival of MNs generated from the Hues3 SOD1
A4V/WT ZFN_1 hES cell line when compared to 
the parental Hues3 HB9:GFP cell line, there are several reasons this may have occurred. First, 
the different genetic backgrounds may influence the impact of the SOD1 A4V protein in different 
ways
2. Second, the current study used glial-conditioned MN media rather than plating in the 
presence of glial cell types to facilitate the isolation of human MN RNA without murine glial 
contamination.  It  is  possible  that  direct  contact  with  glial  cell  types  alters  the  maturation  of 
synaptic networks of MNs, and results in large differences in the transcriptional profiles of MNs 
in  the  presence  vs.  absence  of  glial  cells.  To  come  to  a  more  uniform  understanding  of 
transcriptional  changes  driven  by  the  SOD1  A4V  variant,  we  are  currently  performing 
transcriptional profiling on the parental Hues3 SOD1
WT/WT and Hues3 SOD1
A4V/WT ZFN_1 as well 
as the previously described 39b SOD1
A4V/WT and gene corrected 39b SOD
1A4V/WT cell lines in the 
exact manner described in Chapter 2.  Additionally, we recently generated a third set of isogenic 
SOD1
WT/WT  and  SOD1
A4V/WT  pairs  by  correcting the  SOD1  A4V  mutation from  the  previously 
described Rb9d iPSC cell lines
9.  These iPSCs will also be used for transcriptional profiling as 
described in Chapter 2.  We hope that by using 3 different sets of cell lines, each of which have 
undergone  gene  targeting  to  generate  genetically  controlled  comparison  cell  lines,  we  can 
identify  robust  and  meaningful  gene  expression  differences.  Furthermore,  due  to  technical 
difficulties in the implementation of the EB protocol for the production of large numbers of MNs, 
which are necessary for RNA sequencing experiments, we adopted an alternative MN directed 
differentiation protocol, based on approaches recently described by Lorenz Studer’s research 
group
21. The bulk production and purification of MNs allows for testing many more conditions 
than were previously possible, which holds promise for clarifying previous conflicting results. 
Bulk Preparation of ES Cell Derived MNs. To facilitate bulk preparations of purified 
MNs, we used an adherent MN differentiation protocol. The adherent protocol reflects similar 
developmental pathways as the EB protocol, including dual SMAD inhibition to differentiate the 
stem cells to neural progenitors
19, along with the addition of RA and SAG to caudalize and 113 
 
ventralize  the  neurons  into  a  MN  identity.  However,  after  day  5  of  differentiation  we  also 
included  the  small  molecule  DAPT,  a  notch  inhibitor,  and  SU5402,  an  FGF  inhibitor.  This 
modification was based on a recent study demonstrating an increased efficiency of neuronal 
differentiation and decreased time to neurogenesis when these small molecules are included in 
a directed differentiation
21.  The inclusion of DAPT and SU5402 allowed for a dramatic decrease 
in the time required for MNs to develop (Figure 3.8A). This allowed for robust production of MNs 
in 14 days, a 10 day decrease in protocol length when compared to the original EB protocol. 
When FACS purification was used to monitor GFP fluorescence, a clear population of GFP 
positive cells could be identified when compared to cultures where RA and SAG were omitted 
from the differentiation protocol (Figure 3.8B). When plated after FACS purification, a majority of 
the isolated GFP positive cells were found to be immunopositive for ISLET1 (Figure 3.8C and 
D). A significant difference in differentiation efficiency was not found between the parental and 
genome edited stem cell lines, indicating the absence of developmental complications driven by 




Mitochondrial Swelling in Purified MNs Harboring the SOD1 A4V Allele. We had 
previously found malformed mitochondria within cells expressing the SOD1 A4V variant when 
investigated by electron microscopy (EM)
9. In that study, we found the mitochondrial defect was 
removed upon genetic correction of the SOD1 A4V mutation, demonstrating the necessity of the 
mutation for the phenotype
9. To demonstrate the sufficiency of the A4V mutation to drive this 
mitochondrial defect, we used the adherent differentiation protocol to generate MNs from 1) the 
parental HuES3 SOD1
WT/WT, 2) Hues3 SOD1
A4V/WT ZFN_1, 3) Hues3 SOD1
A4V/WT Cas9n_1n, and 
4) Hues3 SOD1
WT/WT ZFNcorr_1, then FACS purified MNs based on GFP fluorescence. Twenty 
Figure 3.8. Bulk purification of MNs. (A) Protocol for the adherent differentiation of MNs. A clear GFP-positive 
population of cells is present after 14 days of differenitation as determined by FACS (B). The purified GFP-
positive cells co-stain for Islet1 (C and D) indicating MN identity (n = 100 neurons for each genotype, GFP and 
Islet1 overlap = 96% for the parental Hues3  SOD1WT/WT and 98% for Hues3 SOD1A4V/WT  ZFN_1). 115 
 
thousand MNs were plated on coverslips and cultured with glia-conditioned MN media (Figure 
3.9A). On days 20 and 30, the MNs were fixed and processed for EM. There were no apparent 
differences between SOD1 WT and SOD1 A4V in the shape of mitochondria from MNs cultured 
for  20  days  (data  not  shown).  However,  swollen  mitochondria  were  found  in  MNs  which 
expressed the SOD1 A4V variants and had been cultured for 30 days (Figure 3.9B). This finding 
demonstrates  the  sufficiency  of  the  A4V  mutation  for  mitochondrial  swelling  as  well  as  the 
degenerative nature of this defect, as it was seen in MNs cultured for 30 days but not 20. This 
finding also importantly depicted mitochondrial swelling within purified MNs in the absence of 
other cell types which could be influencing the phenotype, which was technically impossible to 




Hyperexcitability in Purified MNs Expressing the SOD1 A4V Protein. To investigate 
the excitability of the purified MNs from the parental and gene targeted stem cell lines, the 
adherent  differentiation  protocol  was  used  to  derive  MNs  from  1)  the  parental  HuES3 
SOD1
WT/WT, 2) Hues3 SOD1
A4V/WT ZFN_1, and 3) Hues3 SOD1
A4V/WT Cas9n_1 hES. FACS was 
used to isolate GFP+ cells, which were then plated on 12-well MEA plates with murine glia. The 
Figure 3.9. Malformed mitochondria are found in MNs derived from gene targeted Hues3 cell lines harboring 
the SOD1 A4V mutation. (A) Diagram of the experiment.  (B) Only MNs which are expressing the A4V variant 
contain swollen mitochondria (scale bar = 500nm). 117 
 
purified MNs were allowed to mature in culture while MEA recordings were taken every 3 days 
(Figure 3.10A). The cultures of MNs expressing the SOD1 A4V protein exhibited heightened 
spike  rates  after  three  weeks  of  culture,  mirroring  our  previous  findings  with  unsorted 
MNs
9,22(Figure  3.10B).  This  result  supports  our  previous  interpretation  that  the  increased 
excitability in MNs expressing the mutant SOD1 protein was not derived from synaptic inputs of 
other inhibitory or excitatory neurons on the MNs
22, as the MNs in the current experiment were 
purified and plated in the absence of other neuronal subtypes. Furthermore, the current study 
demonstrates the sufficiency of the induced A4V mutation to drive the heightened excitability in 
purified MNs. Lastly, the absence of other cell types expressing the SOD1 A4V protein indicates 
that  the  increased  firing  rate  results  from  the  impact  of  the  mutant  protein  in  the  MNs 




When investigating neuron excitability using the MEA, we observed that the neurons 
began to fire synchronously after approximately 10 days in culture (Figure 3.10C). Though this 
“bursting” activity was common to all genotypes we are currently analyzing the impact of the 
SOD1 A4V protein on this network activity 
Figure 3.10. MNs derived from the gene targeted Hues3 cell lines which express the SOD1 A4V transcript 
show increased excitability. (A) Diagram of experiment.  (B) Longitudinal MEA recordings demonstrate 
hyper-excitability of Hues3 SOD1A4V/WT ZFN_1 and Hues3 SOD1A4V/WT Cas9n_1 derived MNs (p < 
0.05). (C) Raster plots demonstrating synchronized “bursting” activity in mature cultures. 
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RNA Sequencing of Purified MNs from Sequential Time Points. Longitudinal MEA 
recordings demonstrated dramatic changes in physiology as the MNs matured in culture. We 
were interested in acquiring a global perspective of the dynamics of MN maturation in vitro, and 
how this process may impact disease-relevant transcriptional signatures. To this end, we used 
RNA sequencing after multiple sequential durations of culture to develop a time course of in 
vitro MN maturation and SOD1 A4V genotypic deviation. To acquire the large number of MNs 
needed for harvesting RNA at multiple time points, we used the adherent differentiation protocol 
described above to generate MNs from the parental Hues3 SOD1
WT/WT and Hues3 SOD1
A4V/WT 
ZFN_1 lines, which were purified using FACS based on GFP expression. The purified MNs 
were plated on poly-d-lysine/laminin coated plates and cultured with glia conditioned MN media. 
Every other day from day 2 onward, RNA was extracted by adding trizol directly to the culture 
wells, thus preserving any axonally transported mRNA which may be eliminated if neuronal 
cultures were dissociated before the isolation of RNA (Figure 3.11A). Sequencing libraries were 
prepared from the isolated RNA using the TruSeq sequencing library preparation kit and 
sequenced on an Illumina HiSeq 2500. Tuxedo suite bioinformatics tools were used to align the 
sequencing reads and identify significantly differentially expressed transcripts. 
Unsupervised hierarchical clustering revealed grouping based on chronological age of 
the MNs as well as the SOD1 genotype (Figure 3.11B). This confirmed our assumption that the 
amount of time spent in culture has a major impact on the gene expression profile of the MNs. 
The time point exhibiting the largest number of genotypically altered transcripts was day 4 
(Figure 3.11C). Furthermore, the time point at which the most unique gene expression changes, 
meaning these genes were not differentially regulated between SOD1
WT/WT and SOD1
A4V/WT MNs 
at any other time point was day 4 followed by day 2.  This finding was at first surprising, as we 
had predicted that genotypic differences would increase over time due to the degenerative 
nature of the SOD1 A4V mutant protein. However, it is possible that the increase in the 
genotypic differences at the early time points is partially driven by the dynamic nature of gene 120 
 
expression found during this period. In support of this hypothesis, we also found that when 
investigating sequential time points for differentially expressed transcripts, days 2 to 4 had the 
highest number of altered expression levels, followed by days 4 to 6 (Figure 3.11D).  This 
finding highlights the importance of carefully considering the time points for transcriptional 
investigation, as considerable variability can be introduced from stochastic differences in 
neuronal maturation, which may be independent of genotype.  Furthermore, more biological 
replicates will be necessary to confirm any genotypically differentially expressed transcripts, if 




Figure 3.11. RNA sequencing of MNs at sequencial time points.  (A) Diagram of experiment.  (B) 
Unsupervised  hierarchical clustering segregates the  MNs by chronological time and genotype.  (C) The time 
point which contained the most unique genotypically altered transcripts was day four and the time point with 
the least was day 20.  (D) The number of significantly altered transcripts between sequential timepoints in 
SOD1WT/WT MNs is from day four to six and in SOD1A4V/WT MNs is from day two to four indicating the 
initial days in culture are transcriptionally dynamic. 122 
 
When investigating sets of genes with common cellular function, genes involved in 
synaptic transmission were found to be upregulated over time in both genotypes, likely 
representing the maturation of the neurons in our cultures. Specifically, transcripts of the 
synaptotagmin and voltage gated ion channel families were significantly and continuously 
increased throughout the time course, indicating the establishment of synapses and 
development of electrophysiological capacity in MNs within the cultures (Figure 3.12A FDR q-
value < 0.01). Previously, we had found gene sets associated with ER stress and mitochondria 
to be misregulated in MNs expressing the SOD1 A4V protein
9. In the currently described data 
set, these pathways were not found when GSEA weas used to query the RNA sequencing 
information. While widespread increases in ER stress were not found, when we investigated the 
ratio of spliced to unspliced XBP1, an initial step in the initiation of the unfolded protein 
response
23, there was a non-significant trend for an increase in this ratio on day 20 when MNs 




Several factors can explain why the same gene expression signatures were not found 
when RNA sequencing was used to identify differentially expressed genes in MNs derived from 
SOD1 WT and SOD1 A4V pluripotent cell lines. First, in the previous experiments using patient 
derived iPSCs, the entire differentiated culture was plated on glia and cultured for 15 days 
before FACS purification of the MNs. This allows for the possibility of many other cell types to 
Figure 3.12. Analysis of sequential RNA sequencing experiment reveals maturation of MN cultures.  (A) Gene 
set enrichment analysis found pathways involved in electrophysiological and synaptic maturity to be up 
regulated in Hues3 SOD1WT/WT MNs between days 2 and 20 (FDR q-value < 0.01) (B) A trend for increased 
XBP1 splicing in Hues3 SOD1A4V/WT ZFN_1 derived MNs when compared to parental Hues3 SOD1WT/WT 
MNs was found only at day 20. (C) Bioinformatic analysis of multiple RNA sequencing data sets demonstrates 
the influence of  culture conditions and differentiation method on the maturation of MNs in vitro. 
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interact with the MNs during their time in culture, which may facilitate increased maturation of 
the MNs or cause more rapid degeneration due to non-cell autonomous toxicity of other cells 
expressing the SOD1 A4V protein in culture
12. Furthermore, the EB protocol was used to 
generate MNs for the previously described RNA sequencing experiment, which is 10 days 
longer and thus may produce more mature MNs which exhibit signs of degeneration earlier than 
MNs produced from the adherent protocol. To test these possibilities, we used the 
bioinformatics tool MONOCLE to compare several MN RNA sequencing data sets generated by 
different members of our group. Results indicated that the MNs used in the currently described 
RNA sequencing experiment, which were purified at day 0 and cultured in the absence of all 
other cell types, were bioinformatically less mature than the MNs used in the previously 
described RNA sequencing experiments which were purified after being cultured with murine 
glia for 15 days
9 (Figure 3.12C). Additionally, transcriptional signatures derived from expression 
of the SOD1 A4V variant may be confounded by differences in genetic modifiers between the 
cell lines used
1.  Currently, we are producing RNA sequencing libraries from MNs which were 
cultured for longer durations of time than used in this study in the hopes that more mature 
degenerative signatures can be revealed. 
While the current RNA sequencing data are not entirely consistent with our previous 
data, the results were informative, and served to shift our focus for next step experiments.  We 
decided to focus on the genes which were most likely to alter the physiological properties of the 
neurons. To operationally define these genes, we first used 5 FPKM as a cutoff for expression, 
based on an earlier finding that genes expressed below these levels are often difficult to detect 
and therefore reproduce (unpublished finding). Transcripts which had previously been shown to 
encode delayed rectifying potassium channels were prioritized even if not found to be 
differentially expressed, as we previously found deficits in delayed rectifying potassium currents 
in SOD1
A4V/WT MNs
22. Because the dynamic nature of neuronal maturation in the initial time 
points can lead to irreproducible expression differences, we eliminated genes which were not 125 
 
significantly altered between the SOD1 WT and SOD1 A4V MNs at the day 20 time point. 
Considering that the MNs did not show increased excitability until day 20, we believe that the 
differences directly preceding this event are likely the most important. Other transcripts which 
did not encode voltage-gated channels but were differentially expressed between the two 
genotypes and had some implication in excitability or neurodegeneration were also chosen as 
interesting targets (Figure 3.13A). We performed qPCR on multiple biological replicates 
generated in the exact same manner as the material used for RNA sequencing, to determine 
the reproducibility of gene expression differences in the initial list of chosen targets (Figure 
3.13B). We used the qPCR results to further eliminate genes which did not produce robust 
alteration in gene expression when compared to the RNA sequencing data.  We confirmed the 




Electrophysiological Measurements after Knockdown of Target Genes in Stem 
Cell-Derived MNs. As the next step in our analysis, we investigated the impact of reducing the 
levels of several genes found to be expressed in the stem cell-derived MNs from our RNA 
sequencing data. To this end, we planned to use an siRNA approach to down regulate the 
individual genes within MNs on MEA plates, and monitor the neuronal excitability. To validate 
the effectiveness of this approach, we cultured purified MNs from the parental Hues3 
SOD1
WT/WT hES cell line with murine glia for 15 days, then used Lipofectamine RNAiMax to 
transfect the mature cultures with either a scramble siRNA, a scramble red fluorescentl 
(conjugated to Alexa Fluor 555 molecule) control siRNA, or an siRNA targeting KCNQ3 (Figure 
3.14A).  We chose KCNQ3 because it is a direct target of retigabine and was found to be 
expressed in our MNs. Three days after the treatment, we dissociated the cultures and used an 
NCAM antibody which was conjugated to a 647 fluorophore to purify the MNs away from the 
murine glia. FACS analysis confirmed the absence of NCAM labeling in a culture in which 
murine glia were plated without the addition of MNs, whereas cultures containing both glia and 
MNs had an NCAM positive fraction (Figure 3.14A). This result demonstrated the ability of 
NCAM labeling to identify MNs when previously purified from other neuronal cell types. FACS 
analysis revealed that over 95% of the NCAM-positive cells were co-labeled with the control red 
fluorescent siRNA, demonstrating the ability of the siRNAs to enter MNs in the mixed cultures. 
Furthermore, when qPCR was performed on the RNA isolated from the NCAM-positive fraction 
of the cultures which were treated with the KCNQ3 siRNA, the levels of KCNQ3 were found to 
be reduced to below 15% when compared to the scramble control (Figure 3.14B). 
After confirming the efficiency of siRNA knockdown in our cultures, we designed an 
initial pilot study in which we would reduce the levels of KCNQ3 and SLC10A4, each gene 
Figure 3.13. (Continued) A group of target genes was identified which could be modulators of phenotypic 
differences between parental Hues3 SOD1WT/WT and Hues3 SOD1A4V/WT derived MNs.  (A) A list of 
genes was generated based on differential gene expression or being implicated in physiological activity.  (B) 
qPCR was used to confirm differential expression of the target genes (n = 2, genes which we could not obtain 
qPCR data are not shown). 127 
 
having been found to be expressed in our MNs and implicated in MN excitability. We generated 
MNs from the parental Hues3 SOD1
WT/WT cell line using the adherent differentiation protocol, 
and used FACS to isolate MNs based on GFP fluorescence.  After FACS purification we plated 
50,000 MNs with 50,000 murine gla on a 12 well MEA plate. After 18 days of culture, we treated 
the cultures with a KCNQ3, SLC10A4, or scramble siRNA. To determine the impact of the 
transfection on spike rate, we withheld treatment of some wells for comparison with the 
scramble siRNA. We found that the application of the scramble siRNA resulted in a significant 
decrease in spike rate 10 days after transfection (Figure 3.14C). However, the considerable 
variability between wells suggested that many wells per treatment would be necessary for 
reliable results to be obtained. Unfortunately, this finding limited the utility of the 12-well MEA 
plates for future experiments, given the time and labor necessary to treat multiple wells across 
several plates, as would be required to investigate a large number of the transcripts identified as 
possible modulators of MN excitability. Thus, in order to optimize siRNA transfection during 
MEA experiments while maintaining many treated wells per condition, we established MN 




First, we performed a pilot experiment aimed at determining the appropriate number of 
cells required for robust spike rates in 48- and 96-well MEA plates. For both the 48- and 96-well 
MEA plates, we added 20K, 35K, or 50K MNs per well. At the same time as the MNs were 
plated, we also added 60K murine glia for the 48-well plate and 40K murine glia for the 96-well 
plate. To determine the spike rates in our cultures, we took MEA recordings every 3 days for 3 
weeks. As a cutoff criterion for reliable measurements, we only used recordings from which 75% 
Figure 3.14. MEA recordings after reduction of target transcripts.  (A) Diagram of experiment.  (B) FACS 
analysis confirmed the transfection of NCAM-positive MNs with a flourescently conjugated oligonucleotide. (C) 
KCNQ3 levels could be dramatically reduced by siRNA transfection. (D) siRNA transfection causes a change in 
physiological activity when compared to unstransfected controls. (E) 96-well MEA plates provide reliable spike 
rate recordings. (F) Co-culture with murine glial cells has a dramatic impact on the physiology of MN cultures. 
 
  a129 
 
of the electrodes had a spike activity above background. Using this criteria, we found a large 
number of sub-threshold wells in the 48-well plate when 20K, 35K, or 50K MNs were plated with 
60K murine glia (Data not shown). We therefore eliminated the 48 well plate from further 
experiments. The 96 well MEA plate performed reliably with all conditions tested (Figure 3.14D). 
After confirming the functionality of the 96-well MEA plates, we decided to use the larger 
format to address a question which had previously been difficult due to the lack of a larger 
multiwell MEA platform. We were concerned that variability in the percentage of MNs produced 
across differentiations would substantially influence the total number of MNs on the MEA plates, 
thereby creating noise and reducing the reproducibility of our findings. In order to determine the 
impact of varying plated MN numbers on MEA recordings, we first used the adherent 
differentiation protocol to generate MNs from the previously described 39b patient-specific iPSC 
cell line
9. We then plated 1K, 5K, 15K, 45K and 135K unsorted cells per well in a 96-well MEA 
plate in the presence or absence of murine glia, and monitored the excitability of each well after 
20 days. For the wells which contained murine glia we found very little difference in spike rate in 
wells which contained 1K or 5K cells per well (Figure 3.14E). However, the spike rate 
dramatically increased when the number of cells was increased to 15K per well. Thereafter, the 
spike rate remained fairly constant in wells containing between 15K and 135K cells per well. 
While these results were surprising, they demonstrated that the spike rate was not majorly 
impacted by the cell number within a range of 15K and 135K. Given this information, we 
decided to plate 50K cells per well in future experiments, to minimize the likelihood that cell 
number would drive differences in spike rates. Another interesting observation from these 
experiments was the dramatic increase in spike rates observed when the MNs were cultured 
with murine glial support. This observation demonstrates the importance of glial support, and 
sheds light on the transcriptional differences between the RNA sequencing experiments 
described in the current chapter and the previous study (described in chapter 2) using patient-
specific iPSCs
9. Ideally, MEA recordings from purified MNs in the absence of glia would 130 
 
facilitate further exploration of the relationship between physiological activity and glial support. 
Unfortunately, we have not been able to obtain reliable recordings from purified MNs on the 
MEA plates without the addition of murine glia. We believe that this is due to the clumping of 
purified MNs in the absence of glia, which leads to heterogeneous coverage of the electrodes 
within a well, and therefore variable recordings when comparing multiple wells. Currently, we 
are testing multiple surface conditions to find a coating which will allow the MNs to mature in 
culture without clumping. We will then be able to determine the electrophysiological properties 
of the MNs in the absence of murine glial cell types.  
Currently we are using the 96 well MEA plates to optimize siRNA transfection conditions.  
After optimal conditions are found we will proceed with knocking down the transcript levels of 
our chosen targets and assessing the impact on spike rate. 
Discussion 
  Our previous findings established robust phenotypic differences in MNs expressing the 
SOD1 A4V variant when compared to controls
9. Findings from gene editing experiments 
confirmed the necessity of the mutation for the modulation of pathways observed in culture and 
transcriptional analysis
9. The aims of the current study were to determine the sufficiency of the 
SOD1 A4V mutation to drive phenotypic changes when introduced into a control hES genetic 
background, as well as to investigate the cell autonomous nature of the previously described 
phenotypes by performing experiments on cultures containing purified MNs. We were able to 
confirm a number of our previously demonstrated phenotypes using the purified MN cultures, 
and are currently working towards understanding discrepancies between these and previous 
results. Importantly, we have improved upon the methodologies used in previous experiments to 
develop more robust and high throughput assays. 
  The RNA sequencing experiment described here is, to our knowledge, the first attempt 
at discovering transcriptional changes which develop as stem cell derived MNs develop in 
culture. While our main goal was to uncover maturation-dependent genotypic differences, this 131 
 
data set has also provided incredible insights into the impact of in vitro culture on MN 
development. It may be possible to use this data set to determine signaling pathways capable of 
driving MNs to more mature states in vitro, without the need for murine glial support. While our 
current data sets generated with purified MNs derived from the parental and gene target Hues3 
cell lines do not show enrichment in mitochondrial dysfunction or ER stress, we do find some 
indications that these pathways are modulated in the cells. First, using EM we observed 
malformed mitochondria in MNs when analyzed at day 30. Second, increased XBP1 splicing 
was found in the SOD1
A4V/WT MNs at later time points. These results indicate that the 
degenerative process is underway in the purified MNs, but that the timing may be delayed, 
possibly due to the absence of direct interaction with murine glial support. In sum, the current 
data set provided unique methodological advances and new information about the processes 
which influence the output of neurodegenerative disease modeling experiments, which promise 
to shape the future of stem cell disease modeling in important ways.  
Our finding of increased excitability in purified MNs expressing the SOD1 A4V mutation 
confirms this pathway as a novel, therapeutically relevant phenotype. Using gene targeting and 
reporter cell lines, we established a well-controlled system amenable to high throughput 
screens. This will benefit future experiments by reducing the chance of indirect effects of small 
molecules on non-MNs in the culture and increases the chances of finding drugs which act 
directly on the MNs to alter physiological properties. After determining appropriate conditions for 
siRNA knockdown within MEA wells, we are now poised to uncover the impact of reducing 
several interesting candidates found in our RNA sequencing experiments. We are hopeful that 
these findings will lead to more therapeutically relevant targets, which can then be screened 





Cell Culture. Cell were cultured at 37C in the presence of 5% CO2. All pluripotent stem 
cell culture was performed with mTesr media with the use of matrigel coatings.  hES and iPSCs 
were allowed to expand for 4-5 days and then passaged by incubation with 1mM EDTA for 5 
minutes.  The EDTA was then removed and 1 mL of mTesr was used to dislodge the cells from 
the plate.  The cells were then passaged 1:10 into a freshly coated matrigel coated dish.  All 
neurons were cultured with MN media (Neurobasal, Glutamax, NEAA, N2, and B27) with ROCK 
inhibitor, GDNF, BDNF, and CNTF.  For glial conditioned media, MN media was conditioned in 
the presence of glia for 72 hours.  The media was then filtered with a 0.45um filter and frozen at 
-80C.  The glial conditioned media was then thawed and diluted 1:! with fresh MN media.  
BDNF, GDNF, and CNTF (10mg/mL each) were added fresh to the 1:1 mixture the day of 
feedings. 
Gene Targeting. Zinc finger nucleases (ZFNs) were constructed using either the OPEN 
method as described previously (Maeder et al., 2008) or a modified version of OPEN that uses 
antibiotic resistance for the selection as previously described (Sander et al., 2011). Briefly, pools 
of ZF pre-selected zinc finger (ZF) domains were ligated together to create a combinatorial 
library of three-3 finger proteins. A bacterial two-hybrid-based selection system was used to 
interrogate the ZF library for proteins that could bind the appropriate target sequences of 
interest. ZF proteins that bound the target sequence were cloned into a mammalian expression 
vector and fused to heterodimeric FokI nuclease protein domains to construct ZFNs. Active 
ZFNs capable of inducing a double strand break at the desired locus were identified by 
screening pairs of nucleases for the capability to induce characteristic indel mutations at the 
SOD1 target site in sequencing the locus of ZFN-treated HEK 293s. 2.5 million iPS cells of the 
39b cell line were accutased and nucleofected using Human Stem Cell Kit II and program A-
023, with 1 mg of ZFN plasmid and 5mg of targeting plasmid. After nucleofection, the cells were 
plated on matrigel with mTesr and ROCK inhibitor. After 48 hours, puromycin selection was 
applied for 1 week, after which surviving colonies were passaged and gDNA was extracted. 133 
 
PCR was used to confirm proper targeting of the cassette. To remove the puromycin cassette, 
2.5 million cells were nucleofected with 1mg of a mammalian expression plasmid containing 
hygromycin and 5mg of a mammalian expression plasmid containing the FLPo recombinase. 
The cells were then plated on matrigel with mTeSR and ROCK inhibitor. Twenty four hours after 
nucleofection, hygromycin was added for 48 hours. Colonies were allowed to expand for 1 
week, after which time they were picked and genomic DNA was extracted. Sequencing of the 
genomic DNA was used to confirm removal of the puromycin cassette. SOD1 expression was 
verified by qPCR after RNA extraction and cDNA synthesis. PshAI digestion along with 
sequencing of the qPCR product demonstrated loss of expression of the mutant allele.  For 
CRISPR targeting, a gRNA targeting the SOD1 locus was cloned into plasmid pX335 
(Addgene). This plasmid was substituted for the ZFN plasmid and all other steps were 
replicated as described above. 
MN differentiation and purification 
Genome Sequencing. Pluripotent stem cells were washed once with PBS, then 
scraped off the plates, resuspended in PBS, and spun down. The PBS was then aspirated off 
and the pellet was resuspended in cell lysis buffer. DNA was extracted using standard phenol 
chloroform methods. DNA sequencing libraries were generated using the Illumina Nextera DNA 
sample preparation kit. The libraries were sequenced on an Illumina HighSeq 2500. 
MN Differentiation. EB motor neuron differentiation was carried at as previously 
described by our lab.  Briefly, pluripotent stem cell colonies were dissociated with accutase and 
single cells were plated in suspension in low-adherence dishes, at a 400K/ml density with 10mM 
ROCK inhibitor (Sigma, Y-27632) in mTeSR media for 24hrs. Embryoid bodies (EBs) were 
formed and media was gradually diluted (50% on day 3 and 100% on day 4) to KOSR 
(DMEM/F12, 10% KOSR) between days 1-4 and to a neural induction medium (NIM: 
DMEM/F12 with L-glutamine, NEAA, Heparin (2mg/ml), N2 supplement (Invitrogen) for days 5-
24. From days 1-6 cells were cultured in the presence of SB431542 (10mM, Sigma Aldrich) and 134 
 
Dorsmorphin (1mM, Stemgent), and from days 5-24 with BDNF (10mg/ml, R&D), ascorbic acid 
(AA, 0.4mg/ml, Sigma), Retinoic Acid (RA, 0.1mM, Sigma) and Smoothened Agonist 1.3 (SAG 
1.3, 1mM, Calbiochem). At day 24 EBs were dissociated to single cells with Papain/DNase 
(Worthington Bio) and plated onto poly-lysine laminin-coated chamber slides/plates/coverslips 
(BD Biosciences) for relevant experiments.  For adherent differentiation of MNs the 
pluripotenent stem cells were dissociated to single cell with accutase and then 1,000,000 cells 
were plated in mTesr with ROCK inhibitor in one well of a 6-well plate.  The cells were fed with 
mTesr until they reached confluency (typically 2 days) then the media was changed to 2D-Diff 
media (1:1 Neurobasal:DMEM,F12 with Glutamax, NEAA, N2, and B27 supplements) with the 
addition of SB431542 (10mM), LDN (100nM), RA (0.1mM), and SAG 1.3 (1mM) for days 0-5. 
On day 6 the media was changed to 2D-Diff media with RA (0.1mM), SAG 1.3 (1mM), DAPT 
(5mM), and SU4312 (5mM).  On day 14 the cultures were dissociated with Accutase and plated 
in MN media (Neurobasal, Glutamax, NEAA, N2, and B27) with ROCK inhibitor, GDNF, BDNF, 
and CNTF.  The next day the media was changed to MN media with GDNF, BDNF, and CNTF.  
The media was then refreshed every 3 days. 
FACS Analysis. Day 24 EB differentations were dissociated with Pappain or day 14 
Adherent differenations were dissociated with Accutase for forty five minutes.  The cultures 
were then pipetted until the cells were single cells and spun down.  The neurons were 
resuspended in MN media with ROCK inhibitor, GDNF, BDNF, and CNTF.  The Neurons were 
then passed through a 0.45 um filter and then MN media was added (4 mLs for every well of 
dissociated cultures).  The cells were then sorted for GFP fluorescence at the Bauer core.  MNs 
were collected and plated in MN media with Rock inhibitor, GDNF, BDNF, and CNTF.  The next 
day the MNs were fed with MN media containing GDNF, BDNF, and CNTF. 
Immunocytochemistry. Cell cultures were fixed in 4% PFA for 15minutes at 4° C, 
permeabilized with 0.2% Triton-X in PBS for 45 minutes and blocked with 10% donkey serum in 
PBS-T (Triton 0.1%). Cells were then incubated in primary antibody overnight and secondary 135 
 
antibodies for 1 hour in 2% donkey serum in PBS-T after several washes in between. DNA was 
visualized by a Hoechst stain. The following antibodies were used: Primary antibodies used in 
this study are Islet1 (1:200, DSHB, 40.2D6), TUJ1 (1:1000, Sigma, T2200),  SOD1 (1:2000, 
Agrisera #AS09 540). Secondary antibodies used (488, 555, 594, and 647) were AlexaFluor 
(1:1000, Life Technologies) and DyLight (1:500, Jackson ImmunoResearch Laboratories). 
Motor Neuron Survival Assay. After 24 days of differentiation, neuronal EBs were 
dissociated and FACS purified.  20K MNs were plated on poly-D-lysine/Laminin coated 8-well 
chamber slides (BD biosciences) containing a confluent monolayer of primary cortical mouse 
glia. Primary glial preparations from P0-P2 mouse pups were generated as described previously 
(Boulting et al., 2011; Di Giorgio et al., 2008). Fresh glial preparations (<1 month, <2 passages) 
were used. Co-cultures were maintained in Neurobasal media (NB, Invitrogen), supplemented 
with B27 and N2 supplement (Invitrogen), 10mg/mL each of BDNF, GDNF, CNTF (R&D) and 
fed every 3 days. Slides were fixed on days 3 and 30. Cultures were stained for TUJ! And 
Human Nuclei and cell numbers assessed. Whole-well images were quantified using imageJ. 
Neuronal numbers on day 3 were set as 100% and numbers day 30 were expressed as a 
percentage of day 3.  
Mitochondrial EM Analysis. After 14 days of adherent differentiation, neuronal cultures 
were dissociated and FACS purified. 20K MNs were plated on poly-D-lysine/laminin-coated 35 
mm glass coverslips (BD-Biosciences). MN cultures were fixed with 2.5% glutaraldehyde-2% 
paraformaldehyde in 0.1M sodium cacodylate buffer (pH 7.4) and maintained at 4° C O/N. 
Cultures were then postfixed in 1% OsO4-1.5% KFeCN6 for 30 min, washed in water 3x and 
incubated in 1% aqueous uranyl acetate for 30mn followed by 2x washes in water and 
subsequent dehydration in grades of alcohol (5min each; 50%, 70%, 95%, 2x 100%). Cells were 
then embedded in plastic and ~60nm thick sections were cut, picked up onto copper grids, 
stained with lead citrate and analyzed in a JEOL 1200EX Transmission Electron Microscope. 
Pictures were taken by a technician blinded for sample IDs. 136 
 
SOD1 Solubility. After 24 days of differentiation, neuronal EBs were dissociated and 
500k cells were plated on poly-d-lysine and laminin coated 6-well plates. After 10 days of culture 
the wells were treated with 0.5 uM MG132 or DMSO control for 5 days. For analysis of SOD1 
protein, detergent-soluble fractions were prepared using RIPA buffer and detergent-insoluble 
fractions were obtained using UREA buffer (8M UREA; 4% CHAPS; 40 mM Tris; 0.2% Bio-
Lyte® 3/10 ampholyte).  5mg of detergent-soluble and equivalent volumes of detergent-
insoluble protein samples were separated by SDS-PAGE (Bio Rad Laboratories), transferred to 
PDVF membranes and probed with anti-SOD1 antibody (Agrisera #AS09 540) and anti-a-
Tubulin (Sigma Aldrich # T6199).   
Sequential Time Point RNA Sequencing and Analysis. MNs were produced with the 
adherent differentiation protocol.  On day 14 the differentiations were dissociated and MNs were 
purifed  by  FACS  and  200,000  were  plated  in  a  24-well  plate  coated  with  poly-d-lysine  and 
laminin. The MNs were cultured in glia-conditioned MN media. Every other day from days 2 
through 20, two wells of WT and two wells of SOD1 A4V MNs were washed once with PBS and 
then 250ul of Trizol was added to the wells. RNA was then extracted using standard purification 
methods.  For  next-generation  RNA  sequencing,  RNA  integrity  numbers  (RIN)  above  7.5, 
determined by bioAnalyzer, were used for library preparation. In brief, RNA sequencing libraries 
were generated from ~250ng total RNA using the illumina TruSeq RNA kit v2, according to the 
manufacturer’s directions. Libraries were sequenced at the Harvard Bauer Core Sequencing 
facility on a HiSeq 2000. All FASTQ files were analyzed using FastQC software (v 0.10.1) to 
confirm that Phred scores were acceptable at all read positions (median Phred score>25 and 
lower quartile>20). The FASTQ files were aligned to the GRCh37/hg19 reference genome using 
Tophat (v 2.0.7). Duplicated reads were removed using Picard Tools MarkDuplicates (v 1.44). 
Differential  expression  testing  was  performed  independently  using  two  separate  analysis 
packages:  Cufflinks  (v  2.1.1)  and  DESeq.  The  Cufflinks  output  was  visualized  with  the 
cummeRbund R package using a false discovery rate of 0.05.  Gene Set Enrichment Analysis 137 
 
(GSEA,  Broad  Institute)  was  performed  by first  creating  a  pre-ranked gene  list  of  all genes 
included in differential expression testing ordered by log2 fold change. Analysis was performed 
using the GSEA preranked tool with the REACTOME and KEGG Pathway MSigDB collections. 
XBP1 Splicing Assay. 300ng of RNA was used to generate cDNA. PCR reactions were 
set up using 2ul of cDNA and premixed Ampligold Taq Polymerase (Applied. Biosystems), at 
66
C annealing. PCR products were analyzed on a Tapestation 2200 and analyzed with the 
Tapestation software. 
RT-PCR. On day 14, adherent MN differentiation cultures were dissociated and purified 
by FACS. 200,000 sorted MNs were plated in poly-d-lysine and laminin coated plates. On day 
20, RNA was isolated from the MNs using Trizol. Iscript cDNA synthesis kit was used to 
generate cDNA from the purified RNA. qPCR was performed using SYBER green. 
MEA  Recording.  Differentiated  MN  cultures  were  dissociated  and  50,000  sorted  or 
unsorted MNs were combined with 50,000 murine glia. The MN and glia cells were spotted onto 
the 12 well MEA plates and allowed to attach for 30 minutes. After 30 minutes, media was 
added to all wells of the MEA plate. For MEA recording, the AXION MEA system was heated to 
37 degrees. Subsequently, the MEA plate which was to be recorded was taken from the tissue 
culture incubator and placed in the AXION device for 1 minute. Recordings were then taken for 
2  minutes.    For  48-well  and  96-well  MEA  experiments  the  cells  were  not  spotted  onto  the 
electrodes.  Instead, 200ul or 100ul of cells and glia mixture was added to the 48-well or 96-well 
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The studies included in this thesis have demonstrated the capability of modeling ALS 
with neurons derived from pluripotent stem cells. In addition to the studies described herein, 
several reports of disease modeling experiments for other late onset neurodegenerative 
disorders have been published
1,2. These successful experiments have proven the utility of 
pluripotent stem cell technology for disease modeling, and the potential of this technology for 
the development of promising therapeutic compounds. While the sophistication of disease 
modeling experiments has improved vastly in recent years, there remain some important and 
concrete next steps toward a more complete understanding of disease mechanisms. This 
chapter will describe methodological “best practices” which I believe should be employed in 
future disease modeling experiments as well as future experiments which could address of the 
questions which arise from the results presented in the previous sections.  
Minimizing the Presence and Impact of Off-Target Mutations 
The  inherent  genomic  variation  of  each  pluripotent  stem  cell  line,  and  the  potential 
confounding  element  it  presents,  is  a  major  source  of  concern  in  any  disease  modeling 
experiment
3. Initial disease modeling experiments were performed without proper controls for 
this variability
2, likely due to technical limitations in the generation of ideal controls. However, 
advances  in  gene  targeting  technology  have  now  routinized  the  generation  of  genetically 
corrected cell lines, thus eliminating much of the variability derived from individual differences in 
genetic  backgrounds,  and  allowing  for  the  illustration  of  causative  relationships  between 
mutations and phenotypes
4,5. While these advances have been transformative, as with any new 
methodological advancement, care must be taken to ensure that the conclusions drawn from 
experiments  using  genetically  manipulated  cell  lines  are  as  accurate  and  free  from  bias  as 
possible.  Specific  methodological  concerns  should  be  considered  when  planning  such 
experiments, which will be described in detail below.   
The primary consideration which must be deliberated when initiating a gene targeting 
experiment is which technology should be used to drive homologous recombination (HR) at the 142 
 
chosen genomic loci. The uniquely troublesome nature of gene targeting in human pluripotent 
stem cells has resulted in the advent of many approaches aimed at introducing and removing 
nucleotides in ES or iPS cells. This thesis has described two such technique, one of which was 
the use of zinc finger nuclease (ZFN) technology to introduce a double strand break to drive 
HR
6. However, developing functional ZFNs is technically challenging and laborious
7. Recently, 
the CRISPR/Cas9 system has been shown to introduce site-specific double strand breaks with 
high accuracy and precision
8. Because of the relative ease of use of the CRISPR/Cas9 system, 
it has become rapidly adopted. Thus, future gene targeting experiments will likely benefit from 
the less technically challenging CRISPR/Cas9 system.  
While the fidelity  of  site  specific  nucleases  has  been  shown  to  be  remarkably  high
9, 
using nuclease techniques will always carry the worry of unintentional mutations driven by non-
specific  activity
10.  The  current  thesis  has  described  specific  steps  which  may  be  used  to 
overcome this problem. Firstly, off-target mutations have been shown to occur at sites which 
harbor some sequence similarity to the intended on-target site
10. Therefore, mutations induced 
by  nucleases  which  target  different  genomic  sequences  should  have  different  off-target 
possibilities
10.  This  non-random  pattern  of  inducing  off-target  mutations  indirectly  provides  a 
means for addressing the potential variability such mutations present. Specifically, by employing 
at least two independent nucleases to target sequences sharing little homology, scientists can 
generate  independent  gene-targeted  clones  which  should  not  share  any  off-target  sites.  By 
confirming that the phenotype of interest is present in each clone, one can be sure that an off-
target mutation is not driving the main finding. Second, mutations which have been corrected 
with gene targeting can subsequently be reverted to the parental genotype using another round 
of nuclease-driven HR.  Any off-target mutations which were induced in the initial round of gene 
targeting should remain in the reverted cell line, and in this way, the reverted cell line can be 
used  to  confirm  that  the  other  off-target  sites  are  not  driving  any  phenotypes  found.  Third, 
whole-genome sequencing can be utilized to reveal any major aberrations within cell lines, in 143 
 
order to exclude such lines from gene targeting experiments
9. Lastly, the confirmation of results 
using non-isogenic patient-specific iPSCs, but which harbor the disease mutations, will provide 
more  evidence  that  the  results  in  question  are  not  driven  by-off  site  mutations
5.  Carefully 
employing the techniques described above should greatly reduce the likelihood of conclusions 
about disease mechanisms being driven by unintentional off-target mutations.  
Addressing Culture-induced Mutations 
In addition to off-site mutations introduced by gene targeting, additional sources of 
variation should be considered and addressed when conducting any experiment which requires 
the clonal isolation and subsequent propagation of a pluripotent stem cell line. For example, 
recent publications using whole-genome sequencing have demonstrated unavoidable 
accumulation of mutations as a result of in vitro culture
5,9.  Consistent with these findings, we 
too found the accumulation of SNVs in our gene targeted cell lines when compared with the 
parental cell line’s genome
5.  These SNVs were likely spontaneously induced during in vitro 
culture, as they were not found near sequences which contained any homology to the intended 
nuclease site
5.  Unfortunately, current gene targeting technology necessitates clonal isolation 
steps which consistently result in a cell line not wholly isogenic to the parental line. As 
pluripotent stem cells are mitotically active, mutations will naturally accrue through various 
mechanisms
9. Thus, a population of pluripotent stem cells which are descendants of a single 
cell derived from an embryo (for hESCs) or fibroblast (for iPSCs) will be a heterogenous mixture 
of cells with random SNVs derived from cell culture. Therefore, any cell isolated from the 
heterogeneous population will go through a genetic bottleneck, and necessarily the resulting cell 
line will have a slightly different genetic background when compared to the bulk parental 
population
9. There are several steps, described in detail below, which can be taken to reduce 
the effects of culture-incurred mutations propagated by clonal isolation steps.  First, the use of 
parental cell lines which are low passage or recently clonally isolated will reduce the genetic 
heterogeneity within the cells to be targeted
11.  Second, recent advances in gene targeting 144 
 
technology have allowed for efficient single-step targeting using oligos
8. This technique 
eliminates a second clonal isolation step, and will therefore reduce the number of culture-
induced mutations between the parental and final gene targeted cell line. When oligo-based 
targeting is not possible and the use of an antibiotic selection cassette is necessary (e.g., when 
adding larger cassettes such as disease-associated expansions or fluorescent proteins for 
reporter cell line generation), it will be important to limit the number of passages before the 
selection cassette is excised from the intermediate cell line.  This can be achieved by optimizing 
the selection cassette removal step so that very few cells are necessary for the removal step, 
and therefore fewer cell divisions are required. Finally, if multiple genomic sites are to be 
modified in a single cell line, advances in CRISPR/Cas9 technology now make possible multi-
site targeting, allowing for multiple targeted modifications in a single gene targeting 
experiment
12. In sum, these techniques serve to minimize culture-induced mutations by 
reducing the number of clonal isolation steps as much as possible without compromising the 
integrity of the experiment. Keeping this strategy in mind as a priority in future gene targeting 
experiments should serve to minimize deviations from isogenic cell lines, and thus maximize 
precision of results.  
Identifying and Addressing Epigenetic Changes 
While the majority of concerns about gene targeting technology have focused on off-site 
and culture-induced mutations
10, an often-overlooked but potentially as concerning product of 
gene targeting may be epigenetic variability. Studies in yeast have demonstrated the capacity 
for mammalian cells to retain small populations of epigenetically distinct progeny, which arise 
spontaneously and can be stably propagated after clonal isolation
13. Ostensibly, a similar 
mechanism could result in the isolation of a gene-targeted cell line in which certain loci have 
been epigenetically silenced, or are more accessible than in the parental cell line from which it 
was derived. This could present a considerable problem for disease modeling experiments, if 
the altered loci had any bearing on disease phenotypes. Using existing technology, it is 145 
 
conceivable to confirm the presence of or absence of epigenetic variability between parental 
and gene-targeted cell lines. For example, the same cell lines used for whole-genome 
sequencing in the current thesis could be used to acquire whole methylome data and examine 
the possibility of any variation in methylation sites. If any variation was identified, it may be 
possible to remove the epigenetic variability by exposing the parental and gene targeted 
progeny to epigenetic modifying small molecules.  For example, treating aberrantly methylated 
cell lines with the DNA methyltransferase inhibitor 5-aza-cytidine (AZA) could remove the 
altered methylation and “reset” the cells lines to a common basal state of methylation
14. 
Furthermore, the same “best practices” described above to minimize culture-induced genetic 
mutations should also reduce epigenetic variability in gene-targeted cell lines. 
Modifying Mutations in Genetic Background 
While ensuring that off-site mutations do not have an impact on results is a critical step 
for disease modeling experiments, there are other steps which should be taken in order to 
ensure robust and disease-relevant results. Most diseases, ALS included, have variable times 
of onset and rates of progression, even amongst patients harboring the same predisposing 
mutation
15. While this variability likely has a large environmental component, studies have 
demonstrated that other modifying mutations are major drivers of variable onset and 
progression
15. To circumnavigate this potential problem we used gene targeting to ensure an 
identical genetic background between the cell lines harboring the control and familial 
mutations
5.  In doing so, it is possible our results are biased if strong modifying mutations were 
present in the individual from whom the cell lines were drawn. We induced a familial ALS 
mutation into a control genetic background in the hopes we could identify robust phenotypes 
which did not require other modifying mutations for their identification.  While we made an initial 
attempt at resolving this issue, it will likely require the use of many cell lines which have gene 
targeted counterparts from which to identify the impact of modifying mutations on a phenotype 
of interest.  This approach would ensure any results driven by strong modifying mutations in a 146 
 
single individual will be tempered by other parental and gene targeted pairs which lack the 
modifying mutations.   
The use of large cohorts of parental and gene targeted pairs may also be helpful for 
grouping patients into meaningful phenotypically distinct populations as well as discovering 
single nucleotide variants (SNVs) which strongly influence disease progression in human cells. 
As described in the introduction, ALS has a considerable amount of phenotypic heterogeneity
15. 
Utilization of whole genome sequencing technologies along with phenotyping large cohorts of 
patient-specific iPSCs and their gene corrected progeny could allow for the sub categorization 
of patients based on the performance of their iPSC derived MNs in disease modeling 
experiments as well as identify modifying mutations influencing cellular performance. For 
example, establishing a cohort of a hundred iPSC lines from patients harboring the same SOD1 
A4V mutation, correcting the mutation in each cell line, and examining associations between the 
resulting phenotypes and the different modifying mutations present in each line may allow for 
improved understanding of the precise impact of specific mutations on disease progression. In 
addition, by simultaneously following the clinical outcome of each patient from whom the iPSCs 
were derived, it would be possible to make associations between in-vitro phenotypes and 
clinical outcomes. However, automation of the entire disease modeling process, from pluripotent 
stem cell derivation and culture to neural differentiation and phenotyping, will likely be 
necessary before a large enough cohort could be analyzed to yield convincing information about 
modifying loci. One approach which may minimize the number of cell lines needed to obtain 
such information may be to select iPSC lines derived from individuals with extreme clinical 
outcomes, thus increasing the likelihood of obtaining lines containing substantially influential 
modifying SNVs. If, in these cases, clinical progression of the patient was mirrored by 
performance in in-vitro experiments, this would represent strong evidence for the presence of 
modifying SNVs.  
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Gene targeting provides a unique tool for isolating and understanding the impact of 
single disease variants, by generating nearly isogenic cell lines except for the single variant 
being studied
5. While this kind of knowledge will provide important pieces of the puzzle in our 
quest to more fully understand the etiology and pathophysiology of neurodegenerative diseases, 
a broader approach will be needed in order to understand how these puzzle pieces come 
together in a larger picture. This broader approach will likely require examination of cells derived 
from a large number of patients harboring different disease-causing mutations. For example, 
there are over 20 known familial mutations for ALS, which comprise almost the entirety of 
familial cases
15.  Taking a gene targeting approach to each of these mutations will allow for the 
generation of patient-specific iPSCs harboring each mutation, and their subsequent corrected 
control cell line. Transcriptional profiling and phenotyping of such genetically controlled pairs will 
illuminate any pathways which show signs of degeneration and are shared amongst the 
different familial mutations. These pathways may be more therapeutically advantageous, as 
they would likely be efficacious in a larger number of patients. Furthermore, as most of the ALS 
cases are idiopathic in nature, understanding the common pathways in a majority of the familial 
cases will likely be the most promising path toward developing therapies for sporadic cases
15. 
The current thesis has described initial efforts in this vein, by using qPCR to identify common 
transcriptional changes between SOD1 and C9orf72 mutant MNs and MEA recordings to 
demonstrate increased excitability in SOD1, FUS and C9orf72 mutant MNs. Future studies 
should aim to continue identifying such common disease pathways, and work toward the 
development of therapeutics to normalize these disease phenotypes.  
  One specific approach to this goal may be to utilize gene targeting to introduce each 
familial mutation into a control ES cell background. Using this methodology, a single parental 
cell line would provide a control for the larger mutant cohort, eliminating the confounding 
influence of background variability between pairs of isogenic cell lines. Common molecular 
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avenue toward understanding common mechanisms of ALS progression across disease-
causing mutations.  Additionally, to gain further insight into ALS pathology one could introduce 
familial mutations found in Parkinson’s or Alzheimer’s cases into the control cell line. Common 
molecular and cellular pathways found to be perturbed from the parental control cell line only 
amongst the cells harboring familial ALS mutations, and not Parkinson’s or Alzheimer’s 
mutations, would be most interesting to pursue.  
How Best to Generate Meaningful RNA Sequencing Data 
The  overarching  goal  of  the  studies  described  in  this  thesis  was  to  find  genes  or 
pathways necessary for ALS disease progression. We successfully identified multiple pathways 
which were altered by a familial SOD1 mutation, leading to the identification of retigabine as a 
novel possible therapeutic drug
16. Still, we  were unable to identify single genes which  were 
modifiers of the disease. While we did find a large number of genes which were differentially 
expressed between disease and control MNs, we found it complicated to filter out transcriptional 
changes which are important for disease pathology. This complication resulted in a change of 
direction within the current project, our focus shifted increasingly onto the pathways which were 
identified, rather than specific genes.  
If future studies are to build on our findings, it will be important to carefully select controls 
which can be transcriptionally profiled, and employ these to filter out transcriptional changes not 
likely necessary for disease manifestation. One possible such method is to utilize cell types 
known to be disease-resistant in vivo. As described in the introduction, sensory neurons are 
resistant to ALS, and importantly protocols exist to generate these neurons from pluripotent 
stem cells
17. Future studies using isogenic lower MN and sensory neurons harboring the WT or 
A4V SOD1 allele for transcriptional profiling would allow for removal of many genes not relevant 
to disease pathology, and highlight clinically relevant disease mechanisms. Another interesting 
means for generating meaningful transcriptional data may be to treat MNs with small molecules 
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gene expression differences which are markedly increased when the MNs are treated with the 
exacerbating drugs, and significantly decreased when small molecules known to rescue in vitro 
phenotypes are applied, specific genes relevant to disease progression may be highlighted. For 
example, we found that retigabine could rescue the hyper excitability and cell survival 
phenotypes found in MNs derived from the 39b iPSC line. Treating these MNs with retigabine, 
and then comparing their transcriptional signature with MNs derived from the 39b iPSC cell line 
which have not been treated with retigabine as well as the genetically corrected control MN 
treated with retigabine, could identify important transcripts which are modulated and lead to 
rescue of the survival deficit. 
The expression profiling experiments described in this thesis provided a panoramic view 
of the in vitro disease course. A major disadvantage of our approach was the population-level 
transcriptome we obtained. While we undertook strategies aimed at obtaining a more 
homogeneous cell population, the use of a single gene is often not rigorous enough for creating 
a completely identical cell cohort
17. Therefore, some of the changes observed in our 
transcriptional data may reflect an alteration in the various MN subtypes found within the 
population of cells being studies, rather than the up- or down-regulation of a gene across all 
cells in the dish. This issue is particularly important for the study of neurodegenerative 
disorders, since cell subtype specificity is often a key pathological finding
17.  Development of 
more sophisticated reporter cell lines which can parse MN subpopulations more finely is one 
promising avenue for addressing this issue. Additionally, recent advances in single-cell RNA 
sequencing technology may allow for identification of MN subtypes and determination of 
possible disease signatures simultaneously
18. As the molecular underpinnings of MN subtype 
identity become better understood, this transcriptional code will allow for the prescribing of 
single MNs into the correct subtype class after sequencing
18. After sub-categorizing the bulk MN 
population, it will be possible to identify signatures indicative of increased susceptibility. 
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determine the dynamic nature of a purified MN population, and possibly identify susceptible 
subpopulations based on the loss of cell-type signatures
18. 
Generating Mature Neurons for Disease Modeling Experiments   
  Possibly the most important complication of modeling late onset neurodegenerative 
disorders is the unknown factor of in vitro maturation and aging. Traditionally, chronological age 
has been used to describe the maturation state of neuronal cultures. The studies described 
herein used a range of time points from days 2 to 30. Other studies have used time points as 
late as day 75
19. Highlighting the centrality of this issue, the results of the experiments described 
in Chapters two and three of the current thesis implicate the maturation state of the MNs as 
potential drivers of phenotypic inconsistencies between experiments. Specifically, when 
comparing the RNA sequencing experiments from Chapters two and three, there was very little 
overlap between significantly altered genes. While we present multiple rationales to explain 
these inconsistencies, I believe the presence of direct contact between the purified MNs and 
murine glial cell types in one data set (see Chapter 2) but not the other (see Chapter 3) is the 
most likely cause of the discrepant results. Two main findings have led me to this hypothesis. 
First, we have demonstrated through MEA recordings that a dramatic increase in 
electrophysiological activity occurs when neuronal cultures are plated on glial monolayers. 
Second, we have established a correspondence between neuronal firing rates and ER stress. 
These findings indicate that the MNs which were cultured in the absence of a glial monolayer 
likely had lower levels of physiological activity. In turn, this may have led to a reduced level of 
ER stress, which is known to cause widespread transcriptional and translational alterations
20. It 
would therefore be no surprise to find differences in the significant genes identified between 
experiments, if the cells being analyzed had considerable differences in their ER stress levels 
due to culture conditions. Currently, we are investigating this hypothesis by performing the 
transcriptional profiling experiment with the parental Hues3 SOD1
WT/WT and Hues3 SOD1
A4V/WT 
ZFN_1 in with the same methodology described in Chapter 2. An alternate approach would be 151 
 
to integrate an expression construct carrying an epitope-tagged ribosomal subunit into the 
genome of the parental Hues3 SOD1
WT/WT and Hues3 SOD1
A4V/WT ZFN_1
21. The MNs could then 
be purified by FACS directly after differentiation and plated down on a glial monolayer. After 15 
days of culture, the cells could be lysed and transcripts which are actively being translated could 
be pulled down by immunoprecipitating the epitope-tagged ribosomal subunit
21. This would 
allow for purification of the human MN RNA for RNA sequencing libraries, but not necessitate 
culturing MNs in isolation.   
Data from RNA sequencing experiments performed at multiple sequential time points 
may also serve as a resource for future experiments aimed at artificially increasing the 
maturation state of neurons. With this data at our disposal, it may be possible to introduce 
genetic factors necessary for neuronal maturation, to reduce the time necessary to produce the 
mature cells most vulnerable to disease processes. We found the Inhibitor of DNA binding (ID) 
class of transcriptional repressors to be dramatically reduced during the first 10 days of MN 
culture (Figure 4.1). It is possible that using siRNA to reduce the levels of the ID transcripts 
could hasten MN differentiation. Furthermore, the transcript levels of the POU3 class of 
transcription factors increased during the first two weeks of MN culture, implicating these 
transcription factors in the maturation of the MNs in vitro (Figure 4.2). Future studies which 
overexpress or reduce the levels of the factors found to be differentially expressed as the MNs 
mature may uncover factors which can decrease the time necessary for the production of 






How can Culture Conditions Develop a Broader Insight to ALS? 
  The experiments described in this thesis have focused on the cell-autonomous impact of 
Figure 4.2. POU3F1 and POU3F2 were found to be upregulated in MNs over time. 
 




familial ALS mutations. Understanding of the molecular changes driven by the mutant SOD1 
protein in MNs alone is an important step in uncovering the underpinnings of degeneration in 
ALS.  However  it  has  been  previously  shown  that many  other  cell  types  are  involved  in  the 
disease  course
22,23.  Use  of  stem  cell-derived  cell  types  for  modeling  complex  cell  to  cell 
interactions could enable dissection of the complex interplay between the various cell types 
involved in ALS.   
  Many  reports  have  demonstrated  that  astrocytes  and  microglia  expressing  familial 
mutations are toxic to MNs
23,24. Most of these studies have involved primary rodent tissue and 
have focused on SOD1 mutations, as rodent models overexpressing various SOD1 alleles are 
readily available
24. These studies of toxic non-cell autonomous astrocytes and microglia have 
implicated  many  possible  therapeutic  pathways,  such  as  inflammation  and  the  immune 
response
25.  However,  many  of  these  models  suffer  from  the  use  of  higher-than-normal 
expression of the mutant protein, as well as being from rodent models, which have not provided 
good  predictive  therapeutic  value  when  compared  to  human  trials  in  the  past
26. The  use of 
pluripotent  stem  cell-derived  astrocytes  and  microglia  to  explore  the  non-cell  autonomous 
impact of familial ALS mutations on MNs would be an important next step for disease modeling 
of ALS. Currently, this avenue of research is limited by several factors. First, there are far fewer 
protocols  for  the  differentiation  of  astrocytes,  and  fewer  still  for  microglia
27,28.  Many  of  the 
current astrocyte differentiation protocols require a prohibitively long period of time and have not 
been widely used
27,28, leaving their replicability in question. Second, while the molecular road 
map of MN development has been intensely studied for many years
29,30, the transcription factors 
and other cellular markers leading to the establishment of astrocytes are less well-studied. This 
creates  complications  in  generating  astrocytes  from  stem  cells,  as  there  is  not  a  widely-
accepted marker which can be used to delineate astrocytes. Third, the maturation of astrocytes 
in vitro may be more complicated than that of MNs, and may in fact require other cell types, 
leading to an even more complex in vitro system
31. These problems will need to be overcome 154 
 
before more complex disease modeling experiments, combining MNs, astrocytes, and microglia, 
can be conducted. 
The  interaction  between  MNs  and  other  glial  cell  types  is  important  and  will  provide 
valuable insight into disease mechanisms. However, perhaps the most important interaction to 
model in vitro is the interplay between MNs and muscle. The breakdown of the motor unit has 
been shown to be one of the first pathologies evident in rodent ALS models
32,33.  Additionally, 
experiments which increase the re-innervation of muscle by surviving MNs have been found to 
increase  the  lifespan  of  the  ALS  mouse  model
33.  These  findings  indicate  that  the  MN  and 
muscle interaction could be a very therapeutically valuable system to model in vitro. Our lab and 
others have used primary mouse muscle to demonstrate the ability of our stem cell-derived MNs 
to innervate and form neuromuscular junctions (NMJs) in vitro
34,35. However, these experiments 
have proven extremely laborious, and their results have been variable. A major impediment to 
routine  MN/muscle  co-culture  systems  is  the  need  to  derive  muscle  from  primary  tissue. 
Recently,  stem  cell  differentiation  protocols  for  generating  muscle  have  been  described, 
possibly providing an alternative to the use of primary cells
36. Ultimately the reconstruction of 
the NMJ may be the most important in vitro model which can be established for diseases in 
which spinal MNs are involved. 
While this report has focused on the impact of familial ALS mutations on spinal MNs, the 
disease is not exclusive to these neurons. Upper MNs also degenerate during ALS disease 
progression, and should be taken into consideration when establishing ALS disease models
15. 
The  major  obstacle  impeding  widespread  interrogation  of  upper  motor  neurons  in  stem  cell 
disease modeling experiments has been the lack of available differentiation protocols. However, 
protocols  for  the  generation  of  cortical  MNs  are  readily  being  produced,  and  will  hopefully 
provide this much needed cell type. 
In light of the bright future unfolding with respect to stem cell differentiation protocols, it 
may one day be possible to recapitulate the entire in vivo cellular environment from stem cells. 155 
 
This could allow for intricate studies involving the mixing and matching of patient and gene-
corrected cell types, which could provide a window into what cell types are causing the different 
pathologies commonly seen in patients.  Furthermore, the establishment of the complex circuit 
between cortical MN, lower MN, muscle, and possibly sensory neurons will allow for very 
informative physiological experiments to be conducted. It is likely that this complex culture may 
require advances not only in current differentiation protocols, but also in tissue culture 
techniques. In addition, it is important to remember that plating all the necessary ingredients 
down into a dish is not equivalent to establishing the connections and interactions which are 
important in vivo. Most likely, the use of microfluidic devices will be needed to facilitate the 
establishment of the correct circuits and also to provide a more convenient way to monitor these 
interactions. For example, astrocytes, microglia, and upper MNs could be plated in one 
chamber, which would allow the axons of the upper MNs to pass into a chamber containing 
astrocytes, microglia and lower MNs, which in turn would provide an avenue for the lower MN 
axons to access a chamber containing muscle. Various tracing dyes or viruses could be used to 
follow the connections made in the device, and more importantly, study the degeneration of 
these connections as disease processes progress. 
Translation of Findings to Clinical Trials 
  Previous studies employing mouse models of ALS have thus far failed to produce 
efficacious therapeutic compounds
37. This thesis has described the use of pluripotent stem cells 
to establish human models of the disorder, and importantly, discovered the FDA approved drug 
retigabine as a potential modifier of disease pathology. The utility of human stem cell-based 
models will ultimately be decided in the clinic, as therapeutic compounds discovered using 
these techniques are tested in human trials. In addition to the discovery of therapeutic 
compounds, use of patient-derived stem cells will also shed light on the most effective methods 
for undertaking human trials. As described earlier, segregating patients based on in vitro 
phenotypes may allow for the re-classification of patients into subgroups, which may have 156 
 
different manifestations of the disorder
15. This data could, in turn, provide a path for the 
establishment of more efficient and predictive clinical trials. For example, if small molecules are 
found which only rescue phenotypes only in patient-derived iPSCs which harbor SOD1 fALS 
mutations and not C9orf72 or TDP43, then clinicians could design a trial including only patients 
with SOD1 mutations, rather than including all ALS patients in the trial and thus diluting sub-
group therapeutic benefits.  
Conclusions 
In this chapter, I have described my suggestions for next-step studies in the area of stem 
cell modeling of neurodegenerative diseases. While not comprehensive, each step may be a 
promising avenue toward improved understanding of disease etiology and the development of 
therapeutics, particularly given the rapidly advancing technology and protocols available today.  
More importantly, they can provide evidence for or against the limits of in vitro disease modeling 
with stem cell derived neurons. The use of a common genetic background in which to introduce 
known  familial  mutations  will  allow  for  comprehensive  insight  into  the  genetic  influence  of 
neurodegenerative  disease,  which  could  not  be  obtained  using  other  currently  available 
methods. Furthermore, comparing gene targeted cell lines from large cohorts of individuals with 
the same mutations may help to explain the heterogeneity in clinical presentations observed 
amongst  patients.  Additionally,  carefully  conducting  transcriptional  profiling  experiments  with 
well thought out controls, thereby highlighting clinically relevant alterations, will point toward 
genes for which overexpression or reduction may modify disease course. In sum, these next-
step  experiments  will  contribute  to  improved  understanding  of  ALS  and  the  use  of  human 
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